LATAM MedTech Insights

Pure Global: Brazil's New AI Rules - A Stifling Dilemma for Local MedTech Innovators?

Mon, 06 Apr 2026 05:04:19 -0400

This week, we dissect a major regulatory shift in Brazil's MedTech landscape. ANVISA has just rolled out its new strategic framework for Software as a Medical Device (SaMD) and AI, aiming to align with global standards. But what does this mean for the innovators on the ground?. While harmonization promises safer and more effective digital health tools, the new requirements could inadvertently create significant barriers for local startups. This episode explores how the heightened demands for clinical data and cybersecurity might give large multinational corporations a distinct advantage in one of Latin America's biggest markets. **Case In Point:** Consider a promising Brazilian startup that has developed an AI-powered tool for early cancer detection. They were on the verge of launching, but ANVISA's new rules now demand a level of clinical evidence and cybersecurity documentation that triples their projected costs and delays their market entry by a year. They're now facing a critical pain point: can they secure new funding to meet these demanding standards before a well-funded international competitor with existing global approvals captures the market?. **Key Takeaways:** - How do ANVISA's new SaMD rules fundamentally differ from the previous regulations?. - What specific cybersecurity vulnerabilities must Brazilian MedTech startups now address to be compliant?. - Can leveraging an existing FDA clearance or CE marking truly fast-track the new ANVISA process?. - What are the three biggest mistakes a local company can make when submitting their new SaMD technical dossier?. - Is the cost of compliance under the new framework becoming prohibitive for early-stage innovators?. - How does this regulatory shift impact investment trends in Brazil's burgeoning digital health sector?. - What are the specific changes to the list of Equivalent Foreign Regulatory Authorities and how can you leverage them?. Navigating these turbulent regulatory waters is where Pure Global excels. We offer end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise in Brazil and over 30 other markets. From initial regulatory strategy and AI-powered technical dossier preparation to acting as your local in-country representative, we streamline your path to market. Don't let regulatory hurdles block your innovation. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how our technology and expert team can accelerate your global market access.

Brazil's SaMD Shock: Pure Global's Guide to ANVISA's New Rules

Sun, 05 Apr 2026 05:04:19 -0400

In this episode of LATAM MedTech Insights, we dissect the breaking news from Brazil. In the final week of March 2026, ANVISA released a surprise guidance document for Software as a Medical Device (SaMD), creating immediate and significant new hurdles for foreign manufacturers. We explore the specific changes to clinical data requirements and cybersecurity protocols that have caught the industry off guard. This isn't just a minor update; it's a fundamental shift in how digital health products will be evaluated and approved in Latin America's largest market. We explain why your existing global data might suddenly be invalid and what this means for your product launch timelines and budgets, offering a clear-eyed look at the new landscape. **A Case in Point:** Imagine a promising European MedTech company, weeks from launching its revolutionary AI diagnostic tool in Brazil. Their strategy was solid, based on their successful EU MDR approval. But overnight, ANVISA's new guidance invalidates their clinical data and demands a local cybersecurity infrastructure they don't have. Their launch is frozen, and millions in projected revenue are at risk. This is the exact challenge many companies are now facing. **Key Questions Answered in This Episode:** * What are the most critical changes in ANVISA's new SaMD guidance you must know? * How does the new emphasis on local Brazilian patient data impact your clinical strategy? * Is your current cybersecurity framework compliant with the new mandatory protocols? * Why is a CE mark or FDA clearance no longer a shortcut for entering the Brazilian market? * What are the three most common mistakes foreign companies are making in response to this news? * How can this regulatory hurdle be turned into a competitive advantage? To navigate the complexities of global market access, you need a partner with deep local expertise and a global perspective. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using advanced AI and data tools to streamline market entry. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can secure your market access in Brazil and beyond.

Pure Global: Brazil's UDI Deadline Chaos - A MedTech Compliance Crisis.

Sat, 04 Apr 2026 05:04:19 -0400

This episode of LATAM MedTech Insights dives into the immediate fallout from ANVISA's sudden enforcement of its Unique Device Identification (UDI) system in Brazil. We unpack the operational chaos this is causing for MedTech manufacturers who were unprepared for the complex data submission and labeling requirements. We explore how this regulatory shift is more than a bureaucratic hurdle. it represents a fundamental change in what it takes to access and succeed in Latin America's largest market. We discuss the critical role of the Brazil Registration Holder (BRH) and how a simple data mismatch can derail an entire product launch. A specific case we're seeing is a European scale-up whose fully approved diagnostic device is now blocked from the Brazilian market. Their multi-million dollar launch is on hold, not due to product quality, but because of a failure to meet the new UDI data submission protocols before their shipment arrived, a critical detail that has jeopardized their entire market entry strategy. Key Takeaways This Episode: 1. Why is ANVISA's new UDI enforcement causing a crisis for even experienced MedTech companies? 2. What are the most common mistakes manufacturers make when submitting UDI data to the Brazilian database? 3. How can your choice of a Brazil Registration Holder make or break your market access right now? 4. Is this UDI requirement just a Brazilian issue, or is it the blueprint for the rest of Latin America? 5. What are the hidden costs of UDI non-compliance that go far beyond regulatory fines? 6. How does this new rule impact your existing supply chain and logistics in Brazil? 7. Are your global technical dossiers truly prepared for these new local data integration demands? Navigating complex regulatory landscapes is our expertise. Pure Global offers end-to-end solutions for MedTech companies, combining local, in-country experts with advanced AI tools to streamline global market access. From regulatory strategy and technical dossier submission to serving as your local representative in Brazil, we ensure you are always ahead of the curve. Don't let regulatory surprises disrupt your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Pure Global: Brazil's SaMD Shift & The Unseen Data Trap

Fri, 03 Apr 2026 05:04:19 -0400

In this episode of LATAM MedTech Insights, we dissect the sudden and impactful new regulation from Brazil's ANVISA that is reshaping the landscape for Software as a Medical Device (SaMD). International manufacturers are now facing unprecedented requirements for localized clinical data and stringent cybersecurity protocols, effectively rewriting the rulebook for market access in Latin America's largest economy. We explore the immediate consequences of this regulatory shift, moving beyond the headlines to analyze the strategic and financial implications. We discuss why existing clinical data from bodies like the FDA or the EU may no longer be sufficient for ANVISA and what this means for your product launch timeline. This episode provides the critical insights you need to understand and navigate this challenging new environment. **Key Takeaways This Episode:** * How does Brazil's new rule redefine the clinical data requirements for AI-driven SaMD? * What are the specific cybersecurity mandates that international manufacturers are most likely to overlook? * Why might your existing technical dossier be immediately rejected under this new framework? * What is the single biggest mistake companies make when adapting their global strategy for Brazil's new regulations? * Are there new local data residency requirements you haven't considered for your cloud-based platform? * How can you turn this new regulatory hurdle into a competitive advantage? Navigating sudden regulatory shifts is a core challenge for global MedTech companies. At Pure Global, we offer end-to-end regulatory consulting solutions, combining deep local expertise in markets like Brazil with advanced AI and data tools to streamline your market access. From developing a new clinical strategy to ensuring your cybersecurity plan meets ANVISA's strict standards, we act as your local partner to turn regulatory complexity into a clear pathway to success. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can help.

Pure Global: Brazil's AI Diagnostic Maze, Cracking ANVISA's New Rules

Thu, 02 Apr 2026 05:04:19 -0400

In this episode of LATAM MedTech Insights, we dissect the groundbreaking new regulation from Brazil's ANVISA, RDC 922/2026, which just rewrote the rules for AI-powered medical software. This isn't just an update; it's a seismic shift that introduces mandatory local clinical data requirements, impacting market access timelines and costs for foreign manufacturers. We explore the immediate consequences for MedTech innovators, especially those relying on existing FDA or CE Mark approvals. Learn what this increased scrutiny means for your product's classification, the validation process, and your overall launch strategy in Latin America's largest market. **Case In Point:** A promising US-based AI diagnostics company had their Brazilian launch plans shattered overnight by the new RDC 922. Their reliance on FDA clinical data is no longer enough, forcing them into an unexpected, costly, and lengthy local clinical study. Their entire LATAM expansion is now in jeopardy, a stark reminder that global regulatory approvals don't guarantee local market access. **This Episode's Key Questions:** - How does ANVISA's new RDC 922/2026 specifically reclassify AI diagnostic software? - Are my existing FDA or CE Mark clinical studies now invalid for a Brazilian submission? - What are the new mandatory requirements for local clinical data from the Brazilian population? - How will this regulatory shift impact the cost and timeline for market entry into Brazil? - What are the critical mistakes to avoid when adapting your technical dossier for this new framework? - Could this new Brazilian regulation signal a coming trend for other LATAM markets like Mexico or Colombia? - How can you turn this regulatory hurdle into a competitive advantage? Navigating complex, sudden regulatory changes is our specialty. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline global market access for MedTech and IVD companies. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your path to market.

Pure Global: Brazil's Sudden SaMD Shockwave - The Unforeseen ANVISA Cybersecurity Mandate

Wed, 01 Apr 2026 05:04:19 -0400

In this episode, we dissect a sudden and critical regulatory update from Brazil's ANVISA that was issued just last week. The new instruction imposes stringent cybersecurity and data handling requirements on all Software as a Medical Device (SaMD) and connected devices, catching many international manufacturers off guard and putting existing market approvals at risk. We explore the specific technical and documentation changes now required, from mandatory penetration testing to new data localization rules. This shift forces companies to rethink their entire compliance and operational strategy for Latin America's largest market. A case in point: A successful foreign manufacturer of remote patient monitoring tools, already established in Brazil, now faces an urgent compliance crisis. Their current registration is invalid, and they must rapidly re-engineer their product's data architecture and conduct a full cybersecurity audit to avoid being forced off the market. This is a costly and complex challenge that could halt their regional revenue stream. Key Takeaways: * What are the specific cybersecurity demands in ANVISA's new instruction for connected devices? * Do your existing products in Brazil now face an immediate compliance gap? * How will the new data localization rules impact your operational costs and IT infrastructure? * What is the new role and liability of local importers in ensuring device cybersecurity? * Are you prepared for a complete technical dossier re-submission for your software-based devices? * Why is Brazil making this sudden move, and which countries in LATAM are likely to follow? * How can this regulatory hurdle be turned into a competitive advantage? Struggling to keep up with unpredictable regulatory changes in LATAM? Pure Global offers end-to-end regulatory consulting, leveraging local expertise and advanced AI to streamline market access. Whether it's navigating Brazil's new cybersecurity rules or expanding into Mexico and Colombia, we act as your local representative to secure and maintain your market presence. Contact us for a strategic consultation at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's AI Gold Rush: Navigating the LGPD Data Maze with Pure Global

Tue, 31 Mar 2026 05:04:19 -0400

Brazil's medical device authority has just unveiled a new framework for AI technologies, signaling a gold rush for innovators in the region. This new resolution promises a clearer path to market for cutting-edge software as a medical device, opening doors to Latin America's largest healthcare economy. But hidden within this opportunity is a critical challenge that could stop foreign companies in their tracks. The regulation mandates strict adherence to Brazil's General Data Protection Law (LGPD), a complex and demanding data privacy standard. This episode of LATAM MedTech Insights unpacks the new AI resolution, exposing the hidden compliance traps and what it really takes to succeed in this promising market. **A Case Study in Foresight:** An American AI diagnostic firm sees the news from Brazil and fast-tracks its expansion plan. Their device, already FDA-cleared, seems like a perfect fit. But their submission is quickly flagged. The reason? Their cloud data processing is handled on servers in the United States, a direct violation of the unwritten expectation of LGPD compliance for local data handling. Their market entry is now frozen, facing the unexpected and costly decision of whether to build new data infrastructure just for one market. **Key Takeaways:** * What is CFM Resolution 2,454/2026 and why is it more than just an approval pathway? * How does Brazil's LGPD law create a unique regulatory hurdle for AI medical devices? * Why might your global data strategy be incompatible with the Brazilian market? * What are the potential costs associated with data localization for MedTech companies? * How can a "privacy-by-design" approach give you a competitive advantage in Brazil? * What are the key differences between LGPD and GDPR that you must know? * Why is understanding the local regulatory culture just as important as reading the rules? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions, from developing your regulatory strategy to acting as your local representative in Brazil and over 30 other markets. Our combination of local expertise and advanced AI tools streamlines your path to market access. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Pure Global: Brazil's AI Rulebook - Cracking the New Medical AI Framework

Mon, 30 Mar 2026 05:04:19 -0400

In this episode, we dive into the landmark new resolution from Brazil’s Federal Council of Medicine (CFM) that creates a specific regulatory framework for Artificial Intelligence in medicine. This is a pivotal moment for digital health in Latin America, establishing new rules for physician oversight, data privacy, and the responsibilities of technology providers. We explore the immediate impact on MedTech and IVD manufacturers aiming to launch AI-powered solutions in the Brazilian market. This isn't just a guideline for doctors. it's a new set of requirements for the tools they use. We break down what this means for product design, technical documentation, and your overall market access strategy in Brazil. **Case Study:** A European MedTech firm has a powerful AI diagnostic software for radiology. They considered Brazil a prime market but were operating in a grey area. Now, the CFM resolution provides a path, but one with new obstacles. How must they adapt their AI's user interface to meet the "human oversight" mandate, and how can they prove their data processing is fully compliant with Brazil's stringent LGPD privacy law without a costly redesign? **Key Takeaways:** - How does the CFM's focus on physician liability change your product's risk management file? - Is your AI's algorithm explainable enough to meet the new transparency requirements? - What specific steps must you take to ensure your data practices are compliant with both the CFM resolution and Brazil's LGPD? - How will you need to modify your training and support materials for Brazilian medical professionals? - Does this new resolution require a separate clinical validation study for the Brazilian population? - How could this physician-centric framework in Brazil influence future AI regulations in other LATAM countries? At Pure Global, we offer end-to-end regulatory consulting solutions for Medical Technology and In-Vitro Diagnostic companies. We combine local expertise with advanced AI and data tools to streamline your global market access, including navigating complex new frameworks like Brazil's AI regulations. To get your product to market efficiently and correctly, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's AI Fast-Track: Pure Global on Cracking ANVISA's 90-Day Approval Code.

Sun, 29 Mar 2026 05:04:19 -0400

This week on LATAM MedTech Insights, we dive into the seismic shift in Brazil's digital health market. ANVISA just launched its 'Agiliza-IA' program, promising to approve AI-powered diagnostic software in a record 90 days. This could unlock one of the largest markets in Latin America for SaMD innovators. But there's a catch. While the speed is tempting, the program introduces formidable new barriers. Consider a European company with a market-leading AI tool. They're ready to enter Brazil, but now face an unexpected demand for clinical trials conducted exclusively on Brazilian patients. This single requirement could delay their entry by a year and cost millions. Is the fast-track worth the price? Key Takeaways: - What exactly is ANVISA's new "Agiliza-IA" program? - Why are the new local clinical data requirements a game-changer for foreign companies? - What are the specific cybersecurity protocols you must now meet for approval? - How did a local startup beat global giants to the first approval? - Is Brazil's 90-day promise a real opportunity or a hidden trap? - What does this mean for the future of MedTech regulation across LATAM? - How can you start preparing your technical dossier for this new pathway today? At Pure Global, we specialize in turning these regulatory puzzles into market access victories. We offer end-to-end consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline your entry into over 30 global markets, including Brazil. Don't let complex regulations be a barrier to your growth. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/ to learn how we can accelerate your journey.

Pure Global: Brazil's New MedTech Shortcut & ANVISA's Hidden Compliance Toll.

Sat, 28 Mar 2026 05:04:19 -0400

This week, we dive into a landmark regulatory shift in Brazil. ANVISA has just unveiled a new "Reliance" pathway, promising an incredible 80% reduction in review time for medical devices already approved by MDSAP authorities. This could dramatically accelerate market access for many international firms. However, this new shortcut comes with a critical catch. At the same time, ANVISA has implemented stricter, IMDRF-aligned standards for essential safety and performance requirements. This means the technical documentation bar has been raised significantly, potentially creating new hurdles even for experienced manufacturers. We break down the opportunity and the hidden challenge. We explore the case of a U.S. orthopedic implant company, whose dream of a fast-track approval was met with the harsh reality of a complete technical file overhaul, forcing them to navigate the gap between their existing FDA compliance and Brazil's new, tougher standards. This week, you'll learn: - What are the exact eligibility criteria for ANVISA's new Reliance pathway? - How does the new RDC 848 resolution change your technical documentation checklist forever? - Which common gaps exist between an FDA-approved file and the new IMDRF-based requirements? - Is the Reliance pathway a guaranteed approval, or are there still hidden pitfalls? - What is the first step your company should take right now to adapt to this new landscape? - How can you leverage your existing international approvals most effectively for the Brazilian market? - What are the critical risk management updates required under the new regulations? Navigating the complexities of global markets is our expertise. At Pure Global, we provide end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced data tools to streamline your market access. Whether it's adapting your technical dossier for Brazil's new standards or acting as your local representative, we clear the path for your innovation. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's AI MedTech Crackdown: Pure Global on ANVISA's New Cybersecurity Demands

Fri, 27 Mar 2026 05:04:19 -0400

Brazil's MedTech landscape is shifting. A quiet but powerful new technical note from ANVISA has just redefined the rules for AI-powered medical devices, creating immediate hurdles for global manufacturers. This update directly links cybersecurity and data privacy to the core of the device approval process, impacting all new and pending registrations. In this episode, we dissect the three critical areas of this clarification, from new clinical data expectations to the now-mandatory Software Bill of Materials (SBOM). We explore how ANVISA is tightening its alignment with Brazil's General Data Protection Law (LGPD) and what it means for your technical dossier. This is essential listening for any innovator looking to enter or expand within Latin America's largest market. Case Study Spotlight: Imagine your cutting-edge AI diagnostic software is deep into the ANVISA review process, and your launch in Brazil seems imminent. Suddenly, your application is stalled by a list of unexpected technical questions about cybersecurity monitoring and LGPD compliance, topics your initial submission only briefly touched upon. Your team must now scramble to produce new documentation that meets these unwritten rules, delaying your market entry by months and putting you behind competitors. What’s your next move. Key Takeaways: - What are the three most critical changes in ANVISA's new interpretation of AI SaMD regulations. - How does this technical note immediately affect your pending medical device submission in Brazil. - Why has a Software Bill of Materials (SBOM) suddenly become essential for approval. - Is your current cybersecurity plan robust enough to satisfy both ANVISA and Brazil's LGPD. - What specific documentation do you need to prepare now to avoid registration delays. - How can you transform this new regulatory challenge into a powerful competitive advantage. At Pure Global, we specialize in navigating these complex and evolving regulatory landscapes. Our team of local experts in Brazil, combined with advanced AI and data tools, provides end-to-end solutions to ensure your MedTech and IVD products achieve and maintain market access. From initial regulatory strategy and dossier submission to post-market surveillance, we streamline your path into over 30 global markets. Don't let unexpected regulatory shifts derail your expansion. Contact Pure Global at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

Pure Global: Mexico's FDA Fast-Track - The COFEPRIS Secret Handshake for 510(k) Devices

Thu, 26 Mar 2026 05:04:19 -0400

Last week, Mexico's regulatory body, COFEPRIS, enhanced its partnership with the U.S. FDA, launching a new phase of its fast-track program for medical devices. This creates an accelerated approval pathway for devices already cleared in the United States, representing a landmark shift in the region's regulatory landscape. This episode dissects the massive opportunity this presents, which can cut market entry timelines from years down to just months. We explore which devices qualify, the detailed submission requirements, and what "regulatory reliance" truly means for your quality and post-market surveillance strategy. **Burning Questions for This Episode:** * Which specific device categories are eligible for the new COFEPRIS-FDA fast-track program? * What exact FDA documentation is now required for a streamlined submission to COFEPRIS? * How does this reliance pathway change the responsibilities of your Mexican Registration Holder? * What are the new, immediate post-market reporting obligations under this program? * Is this accelerated pathway a sign of a permanent shift in Mexican regulatory policy? * How can you leverage your existing 510(k) or PMA to maximize this opportunity? * What are the hidden compliance risks that could disqualify you from the program? At Pure Global, we specialize in navigating these complex regulatory shifts. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline market access in over 30 countries, including Mexico. Whether you need to prepare a dossier for this new pathway or develop a broader LATAM strategy, our team is here to help. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Pure Global: Brazil's MedTech Compliance & ANVISA's New Hidden Hurdles.

Wed, 25 Mar 2026 05:04:19 -0400

Brazil's medical device market is undergoing a seismic shift. The national regulator, ANVISA, has just released RDC 848/2024, a sweeping new resolution that redefines the essential safety and performance requirements for all medical devices and IVDs. This isn't just a simple update; it's a new paradigm that demands a total lifecycle approach to compliance and introduces stringent new rules for high-tech areas like software and cybersecurity. This episode breaks down exactly what this means for manufacturers, especially those from outside Latin America. We reveal the hidden hurdles that can derail your product launch and lead to costly delays. For example, a US-based company with FDA clearance found its market entry plan blocked overnight, needing a complete overhaul of its technical dossier to meet Brazil's new, specific cybersecurity and clinical data requirements, delaying their launch by eight months. Key Takeaways: - How does ANVISA's RDC 848/2024 impact your current Brazil registration strategy? - Are your device's cybersecurity protocols robust enough for the new, explicit requirements? - What are the biggest compliance gaps this regulation creates for devices already approved in the EU or US? - Why is a 'total lifecycle' approach to risk management now mandatory for market access in Brazil? - How can you proactively update your technical dossier to prevent rejection under these new rules? - What specific clinical evidence is now required to prove performance claims to ANVISA? - Does this new regulation affect your post-market surveillance obligations? At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies to streamline global market access. We combine local expertise in over 30 markets, including Brazil, with advanced AI to navigate complex changes like RDC 848/2024, ensuring your path to market is efficient and successful. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Pure Global: Brazil's AI MedTech Gambit - Navigating ANVISA's New Fast-Track & Privacy Traps.

Tue, 24 Mar 2026 05:04:19 -0400

This week, we dive into a major regulatory shift in Brazil. ANVISA has just launched an exciting fast-track approval process for AI-powered medical software, creating a huge opportunity for MedTech innovators to enter Latin America's biggest market faster than ever before. But this new speed comes with a hidden challenge. The new pathway is tied to incredibly strict data privacy and cybersecurity rules based on Brazil's LGPD. These new requirements around data storage and patient consent are already creating significant hurdles, turning a golden opportunity into a complex compliance trap for unprepared companies. We explore a real-world case of a US MedTech company whose Brazilian launch was stopped in its tracks by these new data privacy rules, forcing them into a difficult and expensive decision. Their cutting-edge diagnostic tool is ready, but their data is not. Key Takeaways This Episode: 1. What are the specific criteria for ANVISA's new AI software fast-track pathway? 2. How do Brazil's new data privacy mandates specifically impact MedTech device submissions? 3. Will your existing international clinical data be considered valid under the new patient consent rules? 4. What are the real costs and penalties for non-compliance with Brazil's data localization requirements? 5. Does the new regulation give local Brazilian MedTech companies an unfair advantage? 6. How can you redesign your regulatory strategy to seize the fast-track opportunity while avoiding the privacy trap? 7. What specific cybersecurity vulnerabilities is ANVISA now targeting in its assessments? Struggling to keep up with the dynamic regulatory landscape in Latin America? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. We combine local, on-the-ground expertise in markets like Brazil with advanced AI tools to streamline your global market access. Don’t let complex regulations be a barrier to entry. Contact us at info@pureglobal.com or visit us at https://pureglobal.com/ to learn how we can accelerate your path to market.

Pure Global: Brazil's SaMD Cyber Wall - Hacking ANVISA's Hidden MedTech Rule

Mon, 23 Mar 2026 05:04:19 -0400

In this episode, we dissect a sudden, unannounced regulatory shift from Brazil's ANVISA that is impacting the global Software as a Medical Device (SaMD) industry. Last week, the agency mandated a new, complex cybersecurity audit for all SaMD products, to be conducted exclusively by a short list of local Brazilian firms. This surprise move creates a significant new hurdle for market access. We explore the immediate consequences of this decision, discussing the operational and financial strains it places on international MedTech companies aiming to enter or expand within Latin America's largest market. Imagine your product launch, years in the making, being halted indefinitely by a bureaucratic requirement you had no way to anticipate. This is the critical pain point for SaMD manufacturers today, forcing them to scramble for local expertise and navigate a vague, complex, and costly new compliance layer. What you'll learn in this episode: - What are the specific, technical demands of ANVISA's new cybersecurity audit? - Why was this critical requirement left off the official public regulatory agenda? - How can you vet and manage the newly-approved local audit firms from abroad? - What does this move signal about Brazil's strategy for digital health sovereignty? - Are other LATAM countries like Mexico or Colombia likely to follow Brazil's lead? - How can you update your regulatory strategy to protect against these types of surprise hurdles? - What are the immediate steps to take if your SaMD submission is currently in progress? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. With our local experts and advanced AI-driven data tools, we provide end-to-end regulatory consulting to streamline your market access. For help navigating the complexities of the Brazilian market, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's AI Device Gambit - ANVISA's Fast-Track Hides a Costly Data Trap.

Sun, 22 Mar 2026 05:04:19 -0400

This week, we dissect the groundbreaking new regulation from Brazil's ANVISA. A new fast-track approval pathway for AI and Machine Learning medical software promises to slash market entry timelines, opening the door for innovative diagnostic technologies to reach one of LATAM's biggest markets. However, a critical and complex clause lurks within the fine print: a strict data residency requirement. We explore how this 'data trap' creates significant operational and financial hurdles for foreign MedTech companies, potentially offsetting the benefits of the accelerated review process and reshaping market entry strategies for the entire region. Imagine you're a startup with a revolutionary AI diagnostic tool. You see ANVISA's announcement and plan your Brazilian launch, only to discover you must now build or lease an entire local data infrastructure, navigating both healthcare and data privacy laws. We look at the real-world costs and strategic pivots this requires. Key questions from this episode: - What specific types of AI medical software are eligible for ANVISA's new fast-track? - How does the data residency requirement change the cost-benefit analysis for entering Brazil? - What are the key differences between Brazil's LGPD and GDPR that companies must consider? - Are there compliant local cloud providers in Brazil ready for this MedTech influx? - Could this regulation set a new data sovereignty precedent for other LATAM markets? - What are the immediate steps a company should take if they were targeting Brazil with their AI software? - How does this impact the valuation and investment appeal of foreign AI MedTech startups? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology and In-Vitro Diagnostic companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.

Pure Global: Brazil's SaMD Cyber Shock—Cracking ANVISA's Hidden Compliance Traps

Sat, 21 Mar 2026 05:04:19 -0400

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has unexpectedly tightened its cybersecurity regulations for Software as a Medical Device (SaMD), creating significant new challenges for manufacturers aiming to enter or remain in Latin America's largest market. We uncover the specific documentation now required and explain why your existing FDA or CE marking might not be enough. This episode delves into the real-world impact of these changes. Imagine your state-of-the-art health app, already successful in the U.S. and Europe, is suddenly halted at the Brazilian border. Your dossier is rejected for failing to meet new, highly specific cybersecurity criteria. This is the new reality for many, causing costly delays and demanding a complete overhaul of regulatory strategy. Key questions answered in this episode: - What are the three critical documents ANVISA now demands for SaMD cybersecurity? - How can you leverage your existing international documentation for the new Brazilian requirements? - Is on-the-ground cybersecurity testing now mandatory in Brazil? - What are the most common pitfalls leading to dossier rejection under the new framework? - How can proactive post-market surveillance protect you from a product recall? - Does the new rule apply to legacy devices already on the market? - How will this impact the timeline and cost of entering the Brazilian market? Struggling with global market access? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI to streamline market entry. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Pure Global: Brazil's ANVISA RDC 751 - Navigating the Hidden Post-Implementation Hurdles.

Fri, 20 Mar 2026 05:04:19 -0400

This episode of LATAM MedTech Insights dives deep into the lingering challenges of Brazil's landmark medical device regulation, ANVISA RDC 751. Years after its implementation, we explore the real-world operational hurdles that international MedTech companies continue to face, moving beyond the basics to uncover the hidden complexities in risk classification, technical documentation, and post-market surveillance. We analyze the costly surprises that arise from device reclassification. For instance, a manufacturer of orthopedic implants saw their product up-classified from Class II to Class III, triggering unexpected requirements for extensive, local clinical data. This single issue delayed their market entry by over a year and added hundreds of thousands of dollars in unplanned expenses, a critical pain point for any company looking to expand into Latin America's largest market. Key Questions Answered in this Episode: - Is your device's risk class under RDC 751 secretly jeopardizing your launch timeline? - How can you manage the intensive new Technical Dossier requirements without draining resources? - What are the most common post-market surveillance mistakes companies are making in Brazil? - Why is your choice of a Brazil Registration Holder (BRH) more critical than ever? - Are you prepared for ANVISA's increased scrutiny on clinical data for medium-risk devices? - How does Brazil's harmonization with global standards create both opportunities and traps? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline your global market access, ensuring you navigate complex markets like Brazil with confidence. For a strategic partner in your global expansion, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's ANVISA Shakeup - Navigating MedTech's Hidden Compliance Traps.

Thu, 19 Mar 2026 05:04:19 -0400

Brazil's MedTech market is undergoing a seismic regulatory shift. ANVISA, the national health surveillance agency, is rolling out a series of major updates, including the new RDC 848/2024, which redefines essential safety and performance requirements with a strong focus on lifecycle risk management and cybersecurity. This is creating a new, complex web of compliance for manufacturers. This episode of LATAM MedTech Insights unpacks the practical implications of these changes. We go beyond the headlines to explore the operational hurdles, such as the mandatory transition to a new digital certificate platform by 2025. We reveal the hidden pitfalls that are already causing submission delays and rejections for unprepared foreign companies trying to enter or stay in Latin America's largest market. We explore the real-world scenario of a mid-sized European device maker whose Brazilian market entry was stalled for six months. They successfully passed clinical trials, but their entire submission was rejected due to a documentation technicality in ANVISA’s new, confusing certificate issuance system. This episode breaks down how to avoid that costly mistake. Key Takeaways: 1. How does ANVISA's new RDC 848/2024 fundamentally change safety requirements for your device? 2. Is your current technical dossier prepared for the upcoming cybersecurity mandates? 3. What are the biggest pitfalls when transitioning from the old 'Sicert' to the new submission platform? 4. Why might your existing risk classification under RDC 751 need urgent re-evaluation? 5. How will these new rules impact your timeline and budget for entering the Brazilian market? 6. Are you treating Brazilian compliance as a lifecycle activity or a one-time submission? 7. What specific documentation changes are required for the new 2025 certificate tool? Don't let regulatory hurdles block your access to the vibrant Brazilian market. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise with advanced AI tools to streamline global market access. We act as your local representative, manage technical dossiers, and ensure continuous compliance in over 30 markets. To build a resilient regulatory strategy for Brazil and beyond, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's AI MedTech Shock: Pure Global on ANVISA's Sudden New Data Demands.

Wed, 18 Mar 2026 05:04:19 -0400

This week, we dive into a sudden and critical regulatory update from Brazil's ANVISA that is sending ripples through the AI medical device community. A new technical clarification has redefined the rules for software-based devices, creating unexpected and costly new hurdles for foreign manufacturers trying to enter Latin America's biggest market. We explore the two main challenges this clarification presents: a new, strict requirement for clinical data from the Brazilian population, and complex cybersecurity documentation mandates that must be localized in Portuguese and aligned with local data laws. This episode breaks down what these changes mean on the ground and why your existing global regulatory dossier may no longer be enough for Brazil. A German MedTech scaleup, with a cutting-edge AI diagnostic software already CE-marked, targeted Brazil for its next major expansion. They prepared their submission based on the existing RDC 751 regulation, using their robust European clinical trial data. Their submission was just put on hold by ANVISA last week. The reason? The new technical note requires clinical validation on the Brazilian population, data they do not have. Now, they face an unexpected delay of at least 12-18 months to conduct a local study, a costly setback that puts their entire LATAM strategy at risk. Key questions from this episode: - Is your existing clinical data package now obsolete for your ANVISA submission? - What are the specific requirements for validating an AI algorithm on the Brazilian population? - Does your cybersecurity risk assessment comply with Brazil's LGPD data law? - Are you prepared to submit highly technical documents in flawless, localized Portuguese? - How can you conduct a supplementary local clinical study without a physical presence in Brazil? - What are the hidden costs associated with this new ANVISA clarification? - Could a local regulatory partner help you bypass the need for a full new clinical trial? Don't let regulatory surprises derail your entry into Latin America's largest market. Pure Global combines deep local expertise with advanced AI tools to navigate complex requirements like Brazil's new SaMD regulations. We provide end-to-end support, from regulatory strategy and local representation to compiling the technical dossier needed to succeed. Let us be your partner in streamlining global market access. Contact us at info@pureglobal.com or visit us at https://pureglobal.com/.

Pure Global: Cracking Brazil's New IVD Code Under ANVISA's RDC 830

Tue, 17 Mar 2026 05:04:19 -0400

In this episode of LATAM MedTech Insights, we break down the critical new IVD regulation in Brazil, RDC 830/2023. This isn't just another update; it's a complete overhaul that aligns In-Vitro Diagnostic devices with the stringent framework of the general medical device regulation, RDC 751/2022, creating a new set of rules and unexpected hurdles for manufacturers. We uncover the hidden complexities within this harmonization effort, from reclassifying your product's risk level to meeting demands for more robust clinical evidence and local performance data. This shift signals ANVISA's move towards a more demanding and localized regulatory system, making prior foreign approvals less of a guarantee for market access. A specific case involves a European diagnostics firm whose Class C diabetes monitoring IVD, previously accepted with its existing technical file, now faces rejection. The reason is a buried requirement in the new framework demanding stability studies validated against Brazil’s specific climate zones, a detail that could delay their launch by nine months and require a costly new data generation process. Key Takeaways: * How does RDC 830/2023 officially change the risk classification for your IVD device? * What are the three new documentation requirements inherited from RDC 751 that most IVD manufacturers are missing? * Why might your existing EU or FDA clinical data be insufficient for ANVISA now? * What is the single most common reason for submission delays under this new regulation? * How can your choice of a Brazilian Registration Holder (BRH) make or break your new application? * Are your current labels and instructions for use compliant with the new, stricter requirements? * What post-market surveillance activities are now mandatory for your IVD device in Brazil? Don't let regulatory surprises derail your expansion into Latin America. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline global market access for MedTech and IVD companies. We act as your local representative, manage technical dossiers, and provide continuous regulatory monitoring to keep you ahead of changes like RDC 830. To secure your market presence in Brazil, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's AI Gambit - Decoding CFM's Unwritten MedTech Rules.

Mon, 16 Mar 2026 05:04:19 -0400

Brazil just added a complex new layer to its AI MedTech regulations. Last week, the Federal Council of Medicine (CFM) issued Resolution 2,454, a framework that directly impacts how physicians can use AI tools. This isn't about device registration through ANVISA; it's about winning the trust and acceptance of the end-users—the doctors themselves. This episode dives deep into what this resolution means for foreign MedTech innovators. We explore how this new ethical and governance-focused oversight creates a dual-approval landscape where both regulatory bodies and medical associations hold the keys to market access. We break down the unwritten rules and hidden challenges that your company will now face in Latin America's largest market. Imagine your AI-powered diagnostic software, already successful in Europe, is being trialed in a major São Paulo hospital. Suddenly, the clinical lead halts the trial. The reason? Your firm can't produce a satisfactory governance report detailing how the AI's algorithms align with the CFM's new ethical guidelines, creating a market-access roadblock that no one saw coming. In this episode, you will learn: - What are the crucial differences between ANVISA's requirements and the CFM's new AI resolution? - Why might your international clinical data be insufficient to gain physician trust in Brazil? - How does a doctor's new "right of refusal" for AI tools change your market entry strategy? - Is this new resolution a hidden barrier or an opportunity to build a stronger competitive moat? - What kind of local data and governance documentation do you now need to prepare? - How can you proactively engage with Brazil's medical community to ensure adoption? - What are the three key steps to de-risk your AI MedTech launch in this new environment? Struggling to keep up with shifting regulations in LATAM? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline your market access. From acting as your local representative in Brazil to compiling technical dossiers with our AI platform, we turn regulatory hurdles into market opportunities. Don't let compliance challenges slow your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your foothold in Latin America.

Pure Global: Brazil's Cyber Shock - Navigating ANVISA's New MedTech Rules

Sun, 15 Mar 2026 05:04:19 -0400

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has unexpectedly tightened its cybersecurity regulations for Software as a Medical Device (SaMD), creating significant new challenges for foreign manufacturers. We explore the specific documentation now required and what this means for anyone trying to enter Latin America's largest market. This move signals a major shift in the region's regulatory philosophy, moving away from simple adoption of global standards towards hyper-local requirements tied to national laws like the LGPD. We analyze the immediate impact on companies with pending applications, using a real-world example of a European company whose market entry is now stalled, facing unforeseen costs and significant delays. Key Questions Answered: - What specific cybersecurity evidence does ANVISA now demand beyond FDA or CE Mark documentation? - How does Brazil's data privacy law (LGPD) create unique compliance risks for MedTech manufacturers? - Why is a global cybersecurity plan now insufficient for a successful Brazilian market submission? - What are the most common pitfalls leading to deficiency letters from ANVISA for SaMD products? - Are other LATAM countries like Mexico and Colombia expected to follow Brazil's lead? - How can you turn this complex new regulatory hurdle into a competitive advantage? - What should be included in a post-market surveillance plan to satisfy these new requirements? Navigating sudden regulatory shifts is what we do best. Pure Global offers end-to-end regulatory consulting, leveraging local expertise and advanced AI tools to streamline your market access. Whether it's developing a new regulatory strategy, compiling technical dossiers, or acting as your local representative, we ensure you stay ahead of the curve. Don't let regulatory surprises derail your LATAM expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Pure Global: Brazil's AI MedTech Fast-Track or a Hidden Data Privacy Trap?

Sat, 14 Mar 2026 05:04:19 -0400

This week, we dissect a game-changing announcement from Brazil's ANVISA: a new "fast-track" approval process for AI-powered medical devices. While it promises rapid market access, it hides significant challenges beneath the surface that could derail unprepared international companies. This episode explores how Brazil's stringent data privacy law, the LGPD, is interwoven into this new regulatory pathway. We reveal why your existing global compliance frameworks might be insufficient and what specific steps are necessary to successfully navigate this complex but promising opportunity in Latin America's largest MedTech market. **Case Study:** Learn from the missteps of a European AI-diagnostic firm that saw its "fast-track" submission in Brazil stall due to unforeseen data validation requirements and non-compliance with local data privacy nuances, turning a promising opportunity into a costly delay. **This week's key questions:** - What specific device classes are eligible for ANVISA's new AI fast-track? - How does Brazil's LGPD law create unique compliance traps for foreign MedTech firms? - Why might your existing clinical data be rejected by Brazilian regulators? - What are the three biggest mistakes companies make when entering this new pathway? - Is the fast-track a genuine opportunity or a resource drain for non-specialists? - How can a local regulatory partner de-risk your entire market entry strategy? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.

Pure Global: Brazil's ANVISA Sets a SaMD Trap. Are You Compliant?

Fri, 13 Mar 2026 05:04:19 -0400

Last week, Brazil's regulatory agency, ANVISA, issued an unexpected technical guidance that reclassifies certain Software as a Medical Device (SaMD) products. This move has sent shockwaves through the digital health sector, pushing many devices that rely on predictive algorithms into higher-risk categories overnight, invalidating existing registrations. In this episode of LATAM MedTech Insights, we break down what this clarification means for manufacturers, the new clinical evidence required for compliance under RDC 751, and why this signals a major strategic shift in Brazil's approach to digital health regulation. We explore the immediate commercial impact and the long-term strategic adjustments companies must now consider. Case in Point: Imagine your popular diabetes management app was approved as a Class II device. Suddenly, ANVISA's new interpretation of its predictive algorithm makes it a Class III product. Your registration is now invalid, marketing must cease, and you face the monumental task of generating local clinical data for a completely new submission. This is the exact challenge facing companies in Brazil right now. This episode's key questions: - How can a simple "technical guidance" invalidate your existing product registration in Brazil? - What specific software functions are now considered high-risk by ANVISA? - Is your current technical dossier prepared for this new level of scrutiny? - Why is relying on your existing EU or FDA clearance no longer enough for the Brazilian market? - What are the immediate steps you must take if your SaMD product is affected? - How does this change impact the market entry strategy for new digital health products in LATAM? - Could this regulatory pattern be replicated in other key LATAM markets? Feeling overwhelmed by the shifting regulatory landscape? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise in over 30 markets, including Brazil, with advanced AI tools to streamline global market access and ensure you stay compliant. Don't let regulatory surprises derail your strategy. Contact us for a consultation at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's SaMD Shift, Cracking ANVISA's Unseen AI Regulatory Code

Thu, 12 Mar 2026 05:04:19 -0400

This week on LATAM MedTech Insights, we dive into the significant new regulatory guidance from Brazil's ANVISA that is reshaping the landscape for Software as a Medical Device (SaMD). This update brings Brazil closer to global standards but introduces critical new challenges for foreign manufacturers in areas like risk classification, AI validation, and cybersecurity. We explore the immediate impact on MedTech companies aiming for the Brazilian market. For example, a US-based digital health firm was on the verge of submitting its product for approval. Now, they're confronting the painful reality that their AI algorithm's validation data is insufficient under the new, stricter guidelines, forcing them into a costly and time-consuming redevelopment cycle just to meet compliance. This episode unpacks how to anticipate and navigate these exact scenarios. Key Takeaways: - What are the three most critical changes in ANVISA's new SaMD framework? - How will the new risk classifications impact your product's path to market? - Are your cybersecurity measures compliant with both ANVISA's new rules and Brazil's LGPD? - What new clinical evidence is required for AI and machine learning-driven SaMD? - How can you leverage your existing international dossiers for the new submission process? - Why might your previous go-to-market strategy for Brazil now be obsolete? - What is the single biggest mistake companies make when interpreting new ANVISA guidance? Navigating evolving regulatory landscapes is our expertise. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local experts and advanced AI tools to streamline market access in over 30 countries, including Brazil. From regulatory strategy and dossier submission to acting as your local in-country representative, we turn complexity into clarity. Don't let regulatory hurdles derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more.

Brazil's New UDI Maze: Pure Global on Dodging Hidden Data Traps in ANVISA's System.

Wed, 11 Mar 2026 05:04:19 -0400

This week, we dive into a major regulatory shift in Brazil that just went live on March 1st, 2026. ANVISA's new Normative Instruction N°426/2026 activates the national UDI (Unique Device Identification) database, requiring manufacturers to submit detailed product data before entering the market. This episode breaks down the new requirements, the critical phased deadlines for different device classes, and the strategic implications for MedTech companies aiming to succeed in Latin America's largest market. We explore the hidden complexities, such as the absolute need for data equivalence between your ANVISA registration and your UDI submission. Consider the case of a cardiac stent manufacturer whose multi-million dollar product launch is completely stalled because of a single data mismatch in the new system. This highlights how a small administrative detail can become a major commercial barrier. Key Questions for This Episode: - Brazil's new UDI system just went live; are you prepared for the aggressive, risk-based deadlines? - What are the most common data mismatches that can block your market access? - Should you manage complex UDI submissions in-house or delegate them to a local Brazilian partner? - How does ANVISA's new database compare to the UDI systems in the US and Europe? - What is the single most critical step to take before submitting your first UDI record to ANVISA? - Are your current data management systems robust enough for this new era of traceability? - How can you leverage your Brazil Registration Holder to streamline this new compliance burden? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. With our deep local expertise in Brazil and advanced AI-driven data tools, we provide end-to-end regulatory consulting to ensure your market access is seamless and compliant. We act as your local representative, manage technical dossier submissions, and navigate complex requirements like the new UDI system. To streamline your entry into Brazil and over 30 other global markets, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's IVD Shake-Up & ANVISA's Secret Fast-Track Angle

Tue, 10 Mar 2026 05:04:19 -0400

This episode of LATAM MedTech Insights, brought to you by Pure Global, dives into the landmark regulatory shift just implemented by Brazil's ANVISA. We unpack the new RDC 830/2023 resolution for In-Vitro Diagnostic (IVD) devices, a critical update that redefines market access and compliance in Latin America's largest market. We explore how this harmonization with global standards impacts everything from risk classification to technical documentation. More importantly, we reveal the new strategic 'reliance pathway' that could dramatically accelerate your product's journey to market. Imagine your high-risk diagnostic device, facing a potential year-long review, suddenly becoming eligible for an expedited process in just a few months. This is now a reality for companies with existing approvals from major global authorities, but only if you know how to navigate the new system. Key questions answered in this episode: - What are the specific changes in ANVISA's new RDC 830/2023 for IVDs? - How do I determine if my IVD product's risk class has changed in Brazil? - What is the new 'reliance pathway' and which country approvals make me eligible? - How can leveraging my FDA or Health Canada approval cut my Brazilian registration time by over 70%? - What are the immediate steps my company must take to ensure compliance and avoid market access delays? - Does this change make Brazil a more attractive or more difficult market for IVD manufacturers? At Pure Global, we specialize in turning these complex regulatory updates into clear, actionable strategies. With local experts in Brazil and advanced AI tools, we manage the entire registration lifecycle, helping you leverage new pathways to gain a competitive edge. To ensure your company is prepared for the new era of IVD regulation in Brazil, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's UDI Shockwave - Navigating ANVISA's New MedTech Compliance Maze.

Mon, 09 Mar 2026 05:04:19 -0400

A seismic regulatory shift is underway in Brazil, Latin America's biggest MedTech market. ANVISA's new Unique Device Identification (UDI) system, detailed in Normative Instruction 426/2026, is now being implemented. This isn't just a new labeling rule; it's a complex data management and submission challenge that could become a major barrier to market entry for unprepared device manufacturers. This episode breaks down exactly what the new requirements mean for your business. We go beyond the surface-level announcements to explore the practical, operational hurdles you will face. We discuss the critical importance of the SIUD database, the staggered compliance deadlines for different device classes, and why your existing global UDI strategy might not be enough for Brazil. Consider this: A successful European device company planned a major launch in Brazil, only to be halted for six months. The reason was not their product's quality, but their inability to provide the specific data attributes required by the new SIUD database, a detail they completely overlooked. This episode is designed to help you avoid that costly mistake. Key Takeaways: * What is Brazil's Normative Instruction 426/2026, and why is it a game-changer for market access? * How does the new SIUD database fundamentally alter device traceability requirements? * Are your data management systems prepared for the specific submission formats ANVISA demands? * What are the staggered compliance deadlines, and which one applies to your device portfolio? * Why is simply having a UDI on your label completely insufficient for the Brazilian market? * How can this regulatory hurdle be turned into a competitive advantage against slower rivals? * What are the most common pitfalls foreign manufacturers face when dealing with ANVISA's new rules? At Pure Global, we specialize in navigating these complexities. We provide end-to-end regulatory consulting, acting as your local representative and using advanced AI tools to ensure your technical dossiers are compliant and submitted efficiently. Don't let regulatory hurdles derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's New MedTech Rules: Pure Global on Cracking the RDC 751 Code

Sun, 08 Mar 2026 05:04:19 -0400

Brazil's MedTech market just experienced a seismic shift. ANVISA, the national regulatory agency, has rolled out its new comprehensive framework, RDC 751, fundamentally changing the rules for medical device registration and market access. This move aligns Brazil closer than ever with international standards like the EU MDR. In this episode, we break down what this massive overhaul means for manufacturers. We dissect the new risk classification system, the updated submission pathways, and the critical changes to technical dossier requirements, providing a clear roadmap for anyone looking to enter or stay in Latin America's largest healthcare market. Imagine a MedTech scale-up from the United States with an innovative orthopedic implant. They viewed Brazil as a primary expansion target but were stuck. Their main pain point was the regulatory divergence. Their FDA and EU technical files required a complete, costly, and time-consuming overhaul for the old Brazilian system, creating a barrier of over 18 months of work before they could even submit. With the new RDC 751, the question now is: can their existing EU MDR dossier fast-track their entry, or are there hidden complexities in the new rules that could still derail their launch? Key Takeaways: * How do the new four risk classes under RDC 751 compare to the previous Brazilian system? * What specific documents from my EU MDR technical file can be repurposed for a Brazilian submission? * Is the simplified `notificação` pathway truly faster for Class I and II devices? * What are the new labeling and IFU requirements that manufacturers often overlook? * How has the definition of a "medical device family" changed for submissions? * What are the new obligations for the Brazil Registration Holder (BRH) under RDC 751? * Are there any new post-market surveillance requirements that come with this framework? At Pure Global, we specialize in demystifying complex regulatory changes like Brazil's RDC 751. We offer end-to-end solutions, from developing a tailored regulatory strategy to compiling your technical dossier and acting as your local Brazil Registration Holder. Our unique blend of local expertise and advanced AI tools streamlines your path to market access in over 30 countries. Don't let regulatory hurdles block your growth in LATAM. Contact us today at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can accelerate your success.

Pure Global: Brazil's AI MedTech Gold Rush - Unlocking ANVISA's New Fast-Track

Sat, 07 Mar 2026 05:04:19 -0400

This week, we dissect the groundbreaking new resolution from Brazil's ANVISA, RDC 989, which establishes a new fast-track approval pathway for AI-driven diagnostic software. This is a pivotal moment for the MedTech industry in Latin America, promising to accelerate innovation and market access. However, this opportunity comes with significant new hurdles. The regulation introduces complex requirements for predetermined change control plans, mandates the use of local Brazilian patient data for algorithm validation, and enforces stricter cybersecurity protocols. We explore the strategic implications for foreign and domestic manufacturers aiming to capitalize on this new landscape. A real-world example. a U.S.-based SaMD company has its AI-powered radiological tool approved by the FDA. They targeted Brazil for their next expansion, but ANVISA's new RDC 989 just made their existing clinical data insufficient. They now face the urgent challenge of conducting a local validation study to qualify for the fast-track process, a costly and time-consuming roadblock they didn't anticipate. Key Takeaways: 1. What exactly is a Predetermined Change Control Plan (PCCP) and how do I create one for ANVISA? 2. Does my existing clinical data from US or EU studies meet the new requirements for Brazil? 3. What are the specific cybersecurity and data privacy mandates under RDC 989? 4. How can I initiate a local clinical validation study in Brazil efficiently? 5. What is the timeline for compliance for products already under review by ANVISA? 6. How does this new fast-track pathway change the overall cost and timeline for market entry? 7. Will this regulation give local Brazilian MedTech startups a competitive advantage? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline global market access, helping you navigate complex regulations like RDC 989 to ensure your products reach the market efficiently. To understand how we can help with your market access strategy in Brazil and beyond, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's UDI Shockwave, ANVISA's Hidden Compliance Trapdoor for MedTech.

Fri, 06 Mar 2026 05:04:19 -0400

Brazil's national regulatory agency, ANVISA, has unexpectedly accelerated the compliance deadlines for its Unique Device Identification (UDI) system, creating a significant new challenge for MedTech manufacturers. This sudden shift requires immediate action on labeling, data management, and submission strategies to avoid market disruption. While this presents a major hurdle, it also offers a competitive advantage to agile companies that can quickly adapt. This episode of LATAM MedTech Insights explores the specific details of ANVISA's new mandate, the potential pitfalls, and the strategic opportunities that arise from this regulatory surprise. **Case Study:** Imagine your company has a portfolio of high-risk cardiovascular devices thriving in the Brazilian market. Your team has been methodically preparing for a 2027 UDI compliance deadline. Suddenly, last week's ANVISA announcement pulls that deadline forward, demanding full compliance in just 18 months. Now you face an urgent crisis: redesigning all packaging, gathering extensive new data points, and navigating a complex database submission, all while your competitors are facing the same race against time. A single misstep could mean losing your registration and handing the market to a more prepared rival. **Key Takeaways:** * What are the exact new UDI compliance deadlines for different device classes in Brazil? * Why are the new data submission requirements more complex than just standard labeling? * How can this regulatory shift completely disrupt your current product roadmap and budget? * What are the immediate operational steps your company must take to avoid a market lockout? * Could this move by ANVISA trigger similar accelerated timelines in other LATAM countries? * Is your current local representative in Brazil equipped to handle this sudden change? * How can you turn this compliance crisis into a strategic advantage over your competitors? Struggling to make sense of new regulations in Latin America? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise in markets like Brazil with advanced AI tools to streamline your global market access, from regulatory strategy to technical dossier submission. Don't navigate the complexities alone. Contact Pure Global at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

Pure Global | Brazil's ANVISA Shock: Navigating the New UDI Traceability Maze for MedTech

Thu, 05 Mar 2026 05:04:19 -0400

This week, we dissect a sudden and significant regulatory enforcement shift from Brazil's ANVISA. The agency has accelerated the implementation of its comprehensive UDI traceability system for high-risk medical devices, a key part of its 2026-2027 agenda to harmonize with global standards. This move is catching many international manufacturers off guard, creating immediate challenges for market access and post-market compliance. We explore the concrete implications of this accelerated timeline, from rejected submissions due to data inconsistencies to new, stringent requirements for adverse event reporting. Consider a company that has spent years preparing its Class IV device for the Brazilian market. They believe their dossier is perfect, but their submission is rejected on day one. The reason is not a failure in the device's clinical data, but an administrative error in the UDI database submission, a new and complex requirement. This single misstep could delay their launch by over six months, costing millions in potential revenue. **Key Takeaways:** * What are the exact database requirements for the new UDI submissions under ANVISA's accelerated timeline? * How does this UDI enforcement align with the broader EU MDR harmonization trend in Brazil? * Which specific device classes are most at risk for submission delays right now? * What are the new post-market surveillance reporting requirements involving UDI data? * How can you validate your UDI data for ANVISA's system before making a formal submission? * What are the most common mistakes manufacturers are making with the new UDI requirements? * How should this change impact your budget and timeline for entering the Brazilian market? Navigating unexpected regulatory hurdles like these is where Pure Global excels. We provide end-to-end regulatory consulting for MedTech and IVD companies, leveraging our local expertise in Brazil and over 30 other markets. From developing an updated regulatory strategy to managing complex database submissions and ensuring post-market compliance, we streamline your path to market. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market access.

Pure Global: Brazil's AI MedTech Approval - Hacking ANVISA's New Digital Maze.

Wed, 04 Mar 2026 05:04:19 -0400

Brazil's regulatory agency, ANVISA, is launching a major digital overhaul for 2026, promising to slash approval times and streamline market access for medical devices. This episode dives into the core of ANVISA's new agenda, from the 'AnvisAI' project aimed at modernizing submissions to new fast-track queues for lower-risk devices. We explore how this digital transformation is creating unprecedented opportunities for MedTech innovators. For instance, a company with a cutting-edge AI diagnostic tool that once faced a multi-year waiting period now sees a viable path to market, evidenced by recent approvals of complex software. But this new speed comes with higher expectations, demanding alignment with stringent global standards. Key Questions This Episode Will Address: - How will ANVISA's 2026 digital agenda change your market entry strategy for Brazil? - Is your current technical dossier prepared for the new, stricter compliance framework? - What are the hidden risks of misclassifying your software under the new accelerated pathways? - How can the recent approval of AI imaging software serve as a roadmap for your submission? - Are you prepared to leverage these regulatory changes to get ahead of your competitors in LATAM's largest market? - What specific steps must you take to adapt your Quality Management System for Brazil's new landscape? At Pure Global, we provide end-to-end regulatory consulting to help MedTech and IVD companies navigate this evolving environment. We combine local expertise with advanced AI tools to streamline global market access. Let us be your local representative and strategic partner in over 30 markets. Contact us for a consultation at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's AI MedTech Gambit - Navigating ANVISA's Risky Fast-Track

Tue, 03 Mar 2026 05:04:19 -0400

This week on LATAM MedTech Insights, we dissect the groundbreaking news from Brazil's ANVISA. A new fast-track approval pathway for AI-powered medical software has just been announced, promising to revolutionize market access in Latin America's largest market. This is the opportunity the industry has been waiting for, but it comes with a complex twist. This newfound speed is coupled with a formidable set of new cybersecurity and data privacy mandates, tailor-made for Brazil. We explore the hidden hurdles within this new regulation that could trip up even the most prepared global MedTech firms, turning a golden opportunity into a costly and time-consuming dead end. Here is a real-world scenario. Your company has developed a breakthrough AI diagnostic tool, and you are ready to conquer the Brazilian market. The new fast-track promises a swift approval, but your application is suddenly stalled. The reason? You overlooked an obscure new requirement for a Brazil-based Data Protection Officer, a critical detail buried deep in the new regulation. Now you face months of delays, unforeseen costs to restructure your local operations, and the constant threat of a competitor beating you to market. Key Takeaways for This Episode: - What are the specific device classifications that qualify for ANVISA's new SaMD fast-track? - How do the new Brazilian data privacy rules for MedTech differ from GDPR and HIPAA? - Is a local, Brazil-based Data Protection Officer now mandatory for all foreign SaMD manufacturers? - What are the three biggest cybersecurity vulnerabilities ANVISA will be auditing for in new submissions? - How can you leverage your existing technical dossier for this new, unique submission process? - What are the new requirements for post-market algorithm performance monitoring? - Could this new Brazilian framework become the regulatory blueprint for other LATAM countries? Navigating these regulatory shifts is what we do best. Pure Global transforms complexity into a competitive advantage. With our on-the-ground experts in Brazil and advanced AI-powered data tools, we provide end-to-end solutions for market access, from initial strategy and technical dossier submission to acting as your official local representative. Don't let regulatory hurdles block your entry into LATAM's most dynamic market. To ensure your AI MedTech product successfully navigates the new ANVISA landscape, contact us at info@pureglobal.com or visit https://pureglobal.com/ for a strategic consultation.

Brazil's ANVISA Digital Chaos: Pure Global on High-Risk Device Submission Secrets

Sun, 01 Mar 2026 05:03:49 -0400

In a move that sent shockwaves through the MedTech industry, Brazil's regulatory agency, ANVISA, launched a mandatory new digital submission platform for high-risk medical devices last week. This sudden shift away from traditional paper-based systems has left many manufacturers scrambling to adapt. This episode of LATAM MedTech Insights unpacks the immediate fallout of this decision. We explore the technical hurdles, the hidden documentation requirements, and the strategic implications for companies aiming to enter or expand within Latin America's largest market. We'll look at the case of a cardiovascular device company whose critical product launch was jeopardized overnight by the new digital mandate. Their story highlights the severe financial and strategic costs of being unprepared for abrupt regulatory changes in Brazil. Key Questions Answered: 1. What are the three biggest technical mistakes companies make on the new ANVISA portal? 2. How does this digital shift affect submission timelines for Class III and IV devices? 3. Are there any unannounced changes to the technical dossier requirements? 4. How can you leverage this change to potentially speed up your approval process? 5. What does this move signal about ANVISA's long-term regulatory strategy? 6. Is your local distributor truly equipped to handle this level of regulatory complexity? 7. How will this impact foreign manufacturers compared to local Brazilian companies? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, acting as your local representative and using advanced AI tools to streamline technical submissions. Don't let regulatory surprises derail your market access strategy. Contact us for a consultation at info@pureglobal.com or learn more by visiting https://pureglobal.com/.

Pure Global: Brazil's AI MedTech Brief—Decoding ANVISA's Sudden SaMD Rule Shift.

Sat, 28 Feb 2026 05:03:49 -0400

This week, we dive into a critical regulatory update from Brazil's ANVISA that is reshaping the landscape for digital health and Software as a Medical Device (SaMD). The new guidance introduces stringent requirements for AI technologies, cybersecurity, and local data management, catching many international MedTech companies off guard. We explore why existing FDA or CE Mark documentation is no longer enough for the Brazilian market. This episode breaks down the new rules and discusses how adapting to them can provide a significant competitive advantage in Latin America's largest and most lucrative MedTech market. **Case Study:** A U.S. startup with a cutting-edge AI diagnostic tool was poised to launch in Brazil. Despite having their clinical data and technical file ready, their submission was abruptly halted. The reason? It lacked a detailed cybersecurity vulnerability report adapted to Brazil's specific data privacy laws (LGPD). This unexpected roadblock could delay their launch by over a year, creating an opening for local competitors to seize market share. Are you prepared for this new reality? **Key Questions Answered:** * What specific cybersecurity standards has ANVISA now mandated for all SaMD products? * How does the new guidance re-classify your AI-powered medical software? * Are your existing clinical validation studies sufficient for the new Brazilian requirements? * What are the three most common documentation pitfalls for foreign firms under the new guidelines? * Why is appointing a local Brazil Registration Holder now more critical than ever? * How can you turn Brazil's tough new regulations into a strategic advantage? At Pure Global, we specialize in demystifying complex regulatory landscapes. Our local experts in Brazil, combined with our AI-driven data tools, provide end-to-end support for your MedTech and IVD products. We transform regulatory hurdles into market opportunities. Ready to accelerate your entry into Brazil? Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil & Mexico's MedTech Manufacturing - The Local Production Gambit.

Fri, 27 Feb 2026 05:03:49 -0400

This week on LATAM MedTech Insights, we explore the significant shift in Latin America's medical device industry. The region is rapidly moving from being a net importer to a powerful hub for local MedTech manufacturing. We unpack the key drivers behind this acceleration, including supply chain strategy, cost benefits, and new government incentives in major markets like Brazil and Mexico. We dive into the real-world challenges and opportunities this trend presents. We analyze the complex decision-making process for companies weighing the benefits of local production against the formidable regulatory hurdles set by agencies like ANVISA and COFEPRIS. It's a strategic gamble that could redefine market leadership in the region. What you'll learn in this episode: - Why are multinational MedTech companies suddenly prioritizing local manufacturing in Latin America? - What are the hidden regulatory costs of setting up a production line in Brazil versus Mexico? - How can a company leverage local manufacturing to gain a competitive advantage? - What is the number one mistake companies make when aligning with ANVISA's manufacturing practices? - Are local supplier networks in countries like Colombia and Costa Rica mature enough for complex devices? - How does in-country production change the strategy for post-market surveillance? - What specific government incentives are most attractive for new MedTech manufacturers in 2026? Navigating the transition to local manufacturing requires deep, on-the-ground expertise. Pure Global offers end-to-end regulatory solutions for MedTech companies, combining local experts with advanced AI tools to streamline market access. Whether you're developing a regulatory strategy for a new plant or registering your locally produced device, we act as your local representative in over 30 markets, including Brazil, Mexico, and Colombia. Let us help you turn complex regulatory challenges into a competitive advantage. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Cracking Brazil's New MedTech Cybersecurity Code - ANVISA's Unexpected Hurdle.

Thu, 26 Feb 2026 05:03:49 -0400

Brazil's health agency, ANVISA, has just introduced a stringent new cybersecurity regulation for all connected medical devices. This sudden move, aimed at enhancing patient safety and data protection, presents immediate and complex challenges for manufacturers. It escalates compliance costs and extends timelines, demanding a new level of technical documentation that many were not prepared for. This podcast episode breaks down what the new rules demand and explores the strategic implications for companies operating in Latin America's largest market. We analyze the specific requirements, the reasons behind this abrupt shift, and how it will reshape the competitive landscape for both local and international MedTech firms. **Key Takeaways:** * What are the three core technical requirements of ANVISA's new cybersecurity rule? * How does this new mandate affect devices already on the Brazilian market versus new submissions? * Why is this change happening now, and is it part of a larger LATAM regulatory trend? * What are the biggest compliance blind spots for foreign manufacturers entering Brazil? * Can proactive compliance with this new rule become a competitive advantage? * How will this impact the device registration timeline and budget for 2026? * What specific documentation, like a Software Bill of Materials, is now non-negotiable? Is your MedTech device ready for Brazil's new cybersecurity landscape? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise with advanced AI to streamline your market access and ensure you stay ahead of critical changes like this. Don't let regulatory surprises derail your strategy. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.

Pure Global: Brazil's MedTech Fast-Track - The Hidden Cost of ANVISA's New Rules

Wed, 25 Feb 2026 05:03:49 -0400

This week, we dissect a groundbreaking regulatory shift in Latin America's largest market. Brazil's ANVISA has just unveiled a new, accelerated pathway for high-risk medical devices by recognizing approvals from major global agencies, signaling a major push to attract cutting-edge technology. But this speed comes with a hidden cost. The new framework also introduces some of the strictest post-market surveillance demands seen in the region. We explore the critical balance between rapid innovation and patient safety, and what this means for MedTech companies eyeing the Brazilian market. Imagine your company's AI-powered surgical device received FDA approval and can now use a fast-track process for Brazil. You cut your time-to-market by more than a year, but now ANVISA is demanding real-world performance data from Brazilian hospitals to validate its effectiveness locally. How do you leverage the speed of entry without getting buried in this new, intensive compliance burden? Key Takeaways: - What is the AREE reliance pathway and which foreign approvals does ANVISA now recognize? - How does this new rule change the submission strategy for Class III and IV devices in Brazil? - What are the unwritten expectations for post-market surveillance for fast-tracked devices? - How can you prepare a real-world data collection plan for the Brazilian market? - Does this regulatory shift in Brazil signal a wider trend across Latin America? - What are the biggest compliance risks for companies under this new paradigm? - How do you manage technical dossier requirements when leveraging a foreign approval? - What are the key operational costs associated with these new post-market rules? At Pure Global, we specialize in navigating these complex regulatory shifts. Our combination of local expertise and advanced AI tools helps MedTech and IVD companies streamline market access, from initial strategy to post-market surveillance. We turn regulatory hurdles into opportunities for growth. To learn how we can help you succeed in Brazil and over 30 other markets, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's New Device Regs & The Risk Management Blind Spot.

Tue, 24 Feb 2026 05:03:49 -0400

This week, we dive into a critical regulatory update from Brazil. ANVISA has just rolled out a new resolution that reshapes the essential safety and performance requirements for medical devices, placing a heavy new emphasis on lifecycle risk management and international harmonization. This change impacts everything from technical file preparation to post-market surveillance. We explore the specific new requirements for high-risk devices, software, and the increased demand for locally relevant clinical data. This episode is essential for any MedTech company currently in or planning to enter the Brazilian market, as non-compliance with these new rules could lead to significant delays and rejections. **Case Study:** A European MedTech company, confident with their CE-marked cardiac monitoring software, submits to ANVISA. They are unexpectedly rejected. The reason? Their risk management file, which was perfectly acceptable for the EU, failed to meet Brazil's new, stringent requirements for post-market data collection and cybersecurity vulnerability monitoring. Their market entry is now delayed by at least a year, forcing a costly overhaul of their compliance documentation. **What You'll Learn:** - What specific event triggered ANVISA's major regulatory overhaul last week? - How does the new 'lifecycle' approach to risk management change your submission strategy? - Are your existing international clinical studies still valid under the new rules? - What are the three new documentation requirements for Software as a Medical Device (SaMD)? - Why might your current Quality Management System be non-compliant in Brazil right now? - What is the single biggest mistake foreign manufacturers are making in their new ANVISA submissions? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions, from market access strategy to local representation, using advanced data tools to streamline your path to compliance in over 30 markets, including Brazil. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can help.

Pure Global: Brazil's AI MedTech Gambit—Navigating ANVISA's New Fast-Track Paradox.

Mon, 23 Feb 2026 05:03:49 -0400

This week, we dive into a landmark regulatory shift in Brazil. ANVISA has just launched a new, expedited approval pathway for AI-powered medical software, potentially slashing market entry timelines. This episode breaks down the immense opportunity this presents for MedTech innovators looking to enter Latin America's largest market. But there's a critical catch. This accelerated access comes with a new, aggressive post-market surveillance system that demands continuous real-world data reporting. We explore this paradox: while the front door is easier to open, the rules for staying inside have become far more complex. We discuss what this means for manufacturers, from operational burdens to the risk of registration suspension. **Key Takeaways:** * What specific change did ANVISA just implement for AI-powered medical software? * Why is faster approval only half the story for manufacturers entering Brazil? * What are the new, stringent quarterly data reporting requirements? * How does this shift the regulatory burden from pre-market to post-market? * What kind of operational systems must companies now build to ensure compliance? * Which foreign approvals can be leveraged for this new fast-track process? * Could this new Brazilian model become a blueprint for other LATAM countries? At Pure Global, we specialize in navigating these complex regulatory landscapes. From initial market strategy and registration to fulfilling rigorous post-market surveillance requirements, our local experts and advanced AI tools ensure you can access and maintain your presence in over 30 global markets, including Brazil. Get in touch with us to future-proof your MedTech products in Latin America. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's SaMD Shake-Up - Navigating ANVISA's Unseen AI Hurdles

Sun, 22 Feb 2026 05:03:49 -0400

This week on LATAM MedTech Insights, we analyze the seismic new draft regulation from Brazil's ANVISA that is set to overhaul the rules for Software as a Medical Device (SaMD). This proposal introduces stringent new requirements for AI technologies and local data management, promising to reshape market access for all foreign MedTech companies targeting Brazil. We dive into the real-world impact by examining the case of a European AI diagnostics firm. Their expansion strategy, once clear, is now facing critical roadblocks due to unexpected demands for in-country clinical studies and data hosting, threatening significant delays and cost overruns. This story is a crucial lesson for any innovator looking to enter Latin America's most complex market. Key Takeaways: - Why is ANVISA suddenly proposing a major revision to its two-year-old SaMD regulation? - What are the specific new cybersecurity and data hosting rules for AI medical devices? - Will your existing FDA clearance or CE Mark still be enough for your software registration in Brazil? - What defines a "representative Brazilian population" for the new mandatory clinical validation studies? - How can you submit feedback on this draft regulation before it becomes law? - What strategies can turn these new regulatory barriers into a competitive advantage? - How should this change affect your company's five-year expansion plan for Latin America? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI tools to streamline global market access. Whether you are navigating new draft regulations or planning a multi-market launch, we build efficient pathways for your products. Confused about the new ANVISA rules? Contact us at info@pureglobal.com or visit https://pureglobal.com/ for a strategic consultation.

Pure Global: Brazil's High-Risk Device Code Unlocked - The New ANVISA Reliance Shortcut.

Sat, 21 Feb 2026 05:03:49 -0400

Brazil's regulatory agency, ANVISA, has just rolled out game-changing new rules that create a fast-track pathway for high-risk medical devices. This episode breaks down the new "reliance" mechanism that allows manufacturers to use existing international approvals for quicker market access, and what the new clinical trial law means for MedTech innovation. We explore how these changes are dismantling long-standing barriers to entry in Latin America's largest market. For any company with an advanced medical device, what was once a multi-year waiting game has just become a strategic race. We discuss how this impacts market entry strategy, cost, and the overall opportunity in Brazil. --- **This Episode's Deep Dive:** Consider a US-based company with an innovative cardiovascular implant (a Class IV device) with full FDA approval. The pain point for them has always been the Brazilian market entry: a separate, two-to-three-year ANVISA review process, huge costs, and unpredictable timelines. Now, with the new reliance pathway, that entire calculus has changed. They can leverage their existing FDA clearance to potentially secure Brazilian registration in under a year, turning a long-term aspiration into an immediate strategic possibility. --- **Key Takeaways (本期干货):** * What exactly is ANVISA's new reliance pathway and does my product qualify? * How does this regulatory shortcut change the ROI calculation for entering Brazil? * Which specific international approvals (like FDA, CE) are recognized for this process? * What are the critical documentation requirements for a successful reliance submission? * Beyond reliance, how does Brazil's new clinical trial law affect our global R&D strategy? * Are there any hidden complexities or potential pitfalls in this new accelerated process? * How should our regulatory team adapt its strategy to capitalize on this change now? --- At Pure Global, we specialize in turning complex regulatory changes into market opportunities. Our local experts in Brazil and our AI-powered data tools provide end-to-end support, from developing the optimal reliance strategy to managing your submission with ANVISA. We help you navigate the new landscape efficiently to accelerate your market access. To learn more about how we can help you successfully launch your MedTech or IVD products in Brazil and over 30 other markets, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's AI Diagnostic Gold Rush: Pure Global on ANVISA's Hidden Data Hurdles

Fri, 20 Feb 2026 05:03:49 -0400

In this episode, we dissect the groundbreaking news from Brazil's health agency, ANVISA. Last week, they launched "Agiliza IA Saúde," a new fast-track approval program for AI-powered medical software. This move could unlock massive opportunities in Latin America's largest market, promising to slash registration times for innovative diagnostic technologies. While the opportunity is immense, it comes with a critical challenge. The fast-track is gated by a strict compliance audit tied to Brazil's stringent data protection law, the LGPD. This has created a hidden barrier for international companies who are unprepared for the deep level of data traceability and AI "explainability" that ANVISA now requires, potentially derailing their market entry strategies. **Featured Case:** A European MedTech scale-up with a market-leading AI diagnostic tool saw Brazil's new program as their golden ticket into LATAM. They were ready for a full-scale launch but were stopped cold during the pre-submission phase. Their pain point: they could not adequately prove compliance with LGPD's data processing and localization requirements, a detail they had completely overlooked. Their entire expansion timeline is now on hold, forcing a costly redevelopment of their data governance framework. **Key Takeaways From This Episode:** * What are the specific eligibility criteria for ANVISA's new AI software fast-track program? * How does Brazil's data protection law (LGPD) directly create new challenges for SaMD manufacturers? * What is the "right to explanation" and how does it impact AI-based medical devices? * What are the most common compliance mistakes foreign companies make when entering the Brazilian market? * Is this new ANVISA policy a sign of a wider regulatory trend across Latin America? * How can you build a regulatory strategy that balances speed-to-market with deep compliance? * What level of data traceability and cybersecurity is now considered the standard for Brazil? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise in markets like Brazil with advanced AI tools to streamline global market access. We help you navigate complex requirements like ANVISA's new program to ensure a fast and successful launch. To learn more, contact us at info@pureglobal.com or visit us at https://pureglobal.com/.

Brazil's SaMD Cybersecurity: Pure Global on ANVISA's Hidden Data Demands.

Thu, 19 Feb 2026 05:03:49 -0400

This week, we dissect the groundbreaking new cybersecurity resolution from Brazil's ANVISA that is sending ripples through the MedTech world. The new rules for Software as a Medical Device (SaMD) go far beyond international standards, demanding a proactive, localized approach to cybersecurity and data validation that presents both challenges and opportunities. We explore how this regulation transforms the compliance burden, requiring continuous threat monitoring and incident reporting tailored specifically for the Brazilian market. This is no longer a simple paperwork exercise; it's a fundamental shift in how MedTech companies must manage their products' lifecycle in Latin America. A case in point: An EU-based scaleup, with a fully CE-marked AI diagnostic software, initiated their Brazilian market entry, assuming a smooth process. They were stalled for nine months. The reason? ANVISA's new rule required them to prove their algorithm's efficacy and lack of bias using a specific, anonymized dataset from three different Brazilian states, a requirement not explicitly detailed in the main resolution but enforced during the technical review. This unforeseen obstacle forced them into costly and time-consuming local clinical partnerships, delaying their revenue generation by almost a year. Key takeaways from this episode: - How does ANVISA's new lifecycle approach to cybersecurity change your post-market surveillance duties? - Are your global cybersecurity incident response plans sufficient for Brazil's new 72-hour reporting rule? - What are the new, unwritten rules for validating your AI or ML algorithm with local Brazilian patient data? - Why might your existing international technical dossier now be rejected by ANVISA? - How can you turn these stringent data requirements into a competitive advantage in the Brazilian market? - What specific documentation is now required to prove your software's resilience against cyber threats? - How will this new regulation impact market access timelines and costs for foreign SaMD manufacturers? Pure Global offers end-to-end regulatory consulting to help MedTech and IVD companies navigate these complexities. From developing a robust regulatory strategy and compiling a compliant technical dossier to acting as your official local representative, we streamline global market access. Our expertise, combined with advanced AI tools, ensures you can meet demanding local requirements efficiently. Don't let regulatory surprises derail your launch. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence in Brazil.

Brazil SaMD Shake-Up: Pure Global on ANVISA's Hidden Compliance Traps

Wed, 18 Feb 2026 05:03:49 -0400

This week on LATAM MedTech Insights, we dissect the groundbreaking new Software as a Medical Device (SaMD) regulation just released by Brazil's ANVISA. This isn't just another update; it's a complete strategic reset for any digital health company targeting the Brazilian market. We explore the critical changes in risk classification for AI-driven software and the stringent new cybersecurity mandates that have just come into effect. Imagine a cutting-edge European AI diagnostics startup, poised to enter Brazil as its gateway to Latin America. Last week, their entire market access strategy was invalidated by ANVISA's new resolution. Their product's classification has jumped from low-risk to high-risk, demanding extensive clinical data they haven't prepared for. This episode details the pivots and strategies companies in this exact situation must now consider. Key Takeaways: 1. What specific event triggered ANVISA's major overhaul of its SaMD regulations? 2. How do the new AI risk classifications diverge from established FDA or EU guidelines? 3. What are the most overlooked cybersecurity requirements in the new Brazilian framework? 4. For SaMDs now classified as high-risk, what are the specific clinical evidence demands? 5. How will this regulatory shift impact foreign investment in Brazil's digital health sector? 6. Are there any provisions for legacy software already on the market? 7. What new documentation for data privacy is now mandatory for submission? Navigating this new landscape is complex, but Pure Global is built for this challenge. We offer end-to-end regulatory consulting, using our local Brazilian expertise and advanced AI tools to streamline your path to market. From developing a new regulatory strategy to compiling your technical dossier for ANVISA, we ensure your innovation meets these new standards efficiently. Don't let regulatory shifts derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market access.

Pure Global: Brazil's AI MedTech Gold Rush. ANVISA's Secret Fast-Track to Market Access.

Tue, 17 Feb 2026 05:03:49 -0400

This week, we dissect the groundbreaking new resolution from Brazil's ANVISA that's set to revolutionize the AI-powered medical device landscape. We explore how this regulatory shift dramatically accelerates market access for Software as a Medical Device (SaMD) companies. Learn what this means for startups and established players eyeing the largest MedTech market in Latin America, and how the rules have fundamentally changed for innovators who were previously locked out by slow, hardware-focused regulations. A real-world pain point: Imagine spending two years and hundreds of thousands of dollars trying to get your innovative diagnostic AI approved in Brazil, only to be stuck in a regulatory framework designed for physical hardware. That was the reality. We discuss how the new rules directly address this critical pain point, potentially turning a 24-month nightmare into a 6-month opportunity. Key Takeaways: * What specific changes did ANVISA just implement for AI medical software? * How does the new risk classification system impact my product's registration timeline? * Which types of AI devices benefit the most from this fast-track process? * Is this a signal for other LATAM regulators like COFEPRIS or INVIMA to follow? * What are the immediate steps my company should take to leverage this opportunity? * Are there any hidden compliance traps in the new Brazilian regulations? * How can foreign companies navigate the updated submission process effectively? At Pure Global, we specialize in navigating these complex regulatory shifts. Our combination of local expertise in Brazil and advanced AI tools can streamline your market access strategy under these new rules. For end-to-end regulatory consulting for MedTech and IVD companies, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's RDC 751 Maze: Pure Global on MedTech Registration's Hidden Traps

Sun, 15 Feb 2026 05:04:04 -0400

Brazil's medical device market has undergone its most significant regulatory overhaul in two decades with the full implementation of RDC 751/2022. This new framework replaces the long-standing RDC 185/2001, introducing a new risk classification system and technical documentation structure that aligns more closely with global standards like the EU MDR. While this harmonization presents long-term benefits, the immediate transition creates critical challenges for MedTech manufacturers. Companies must now navigate new submission pathways, restructure their technical dossiers to meet IMDRF standards, and ensure their labeling and post-market activities are fully compliant, facing risks of rejection and market access delays if unprepared. A US-based scaleup, planning a routine renewal for their Class II device in Brazil, recently discovered their existing technical file was obsolete under RDC 751. They are now facing a complete dossier overhaul and the risk of a gap in their market authorization, jeopardizing a key distribution contract and threatening their revenue stream in the region. What You'll Learn: - How does the new four-class risk system in Brazil impact your existing product portfolio? - What are the critical differences between the old submission process and the new technical dossier requirements? - Is your current product labeling and IFU compliant with the latest ANVISA updates? - What are the most common rejection points for submissions under the new RDC 751? - How can leveraging your EU MDR documentation give you a head start in Brazil? - What specific post-market surveillance changes must you implement immediately? - Are there any critical transition deadlines you might have missed? Pure Global offers end-to-end regulatory consulting to navigate these complex changes. We combine local expertise in Brazil with advanced AI tools to streamline your market access. Don't let regulatory shifts disrupt your strategy. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/ for a consultation.

Pure Global: Brazil's New SaMD Hurdle & ANVISA's Unspoken Rules.

Sat, 14 Feb 2026 05:04:04 -0400

This week on LATAM MedTech Insights, we dissect the immediate impact of a surprise guidance note issued by Brazil's ANVISA. This new clarification on regulation RDC 751 is tightening the screws on foreign medical device manufacturers, especially those in the digital health and SaMD space. We explore the heightened requirements for technical dossiers and clinical data that are catching companies off guard. Discover why your existing FDA or CE mark documentation may no longer be enough for the Brazilian market. We use the real-world example of an AI diagnostic company suddenly facing major delays and costs, highlighting the critical need for a proactive and localized regulatory strategy to avoid common pitfalls. Key questions from this episode: - What specific change in ANVISA’s enforcement of RDC 751 caught the industry by surprise last week? - Why is foreign clinical data now facing greater scrutiny for SaMD submissions in Brazil? - How has the role of the Brazil Registration Holder (BRH) shifted from a legal formality to a critical strategic partner? - What are the three biggest mistakes manufacturers make when preparing their technical dossier for ANVISA? - Is Brazil's regulatory landscape becoming a barrier or an opportunity for high-quality MedTech? - Could your device's cybersecurity protocols be the hidden factor that leads to rejection? - How do you demonstrate clinical applicability to Brazil's diverse population without running entirely new trials? Navigating complex regulatory shifts like this is what we do best. Pure Global offers end-to-end solutions for MedTech companies, combining local experts in Brazil with advanced AI tools to streamline your path to market. From regulatory strategy and local representation to compiling your technical dossier, we ensure you're prepared for ANVISA's toughest questions. Don't let regulatory hurdles block your entry into Latin America's top market. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Pure Global: Brazil's SaMD Surprise—Decoding ANVISA's Hidden Cybersecurity Rules

Fri, 13 Feb 2026 05:04:04 -0400

Brazil's digital health market is booming, but a recent regulatory update from its agency, ANVISA, has changed the rules of the game for 2026. The new guidance for Software as a Medical Device (SaMD) goes far beyond basic registration, introducing stringent cybersecurity and lifecycle management requirements that are catching many international companies off guard. In this episode, we break down what these changes mean for you. We explore why your existing FDA or CE Mark documentation is no longer sufficient for Brazil and how adapting to these new rules can become your key competitive advantage in Latin America's largest market. **Case Study:** Imagine your company has a cutting-edge AI diagnostic tool, ready to conquer the Brazilian market. You’ve prepared your clinical data, but you suddenly face a rejection because your submission lacks a detailed cybersecurity vulnerability report adapted to Brazil's data privacy laws (LGPD). This unexpected roadblock could delay your launch by over a year, allowing local competitors to capture the market first. Are you prepared for this new reality? **Key questions answered in this episode:** * What specific cybersecurity standards has ANVISA recently mandated for SaMD? * How can you leverage your existing technical file for a successful Brazilian submission? * What are the three most common pitfalls for foreign firms under the new guidelines? * Why is post-market surveillance now as critical as the initial registration? * How does Brazil's new framework signal a larger regulatory trend across LATAM? * What is the crucial first step to take before submitting your digital health product to ANVISA? At Pure Global, we specialize in demystifying these complex regulatory landscapes. Our local experts in Brazil, combined with our AI-driven data tools, provide end-to-end support for your MedTech and IVD products. We transform regulatory hurdles into market opportunities. Ready to accelerate your entry into Brazil? Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's SaMD Surprise: Hacking ANVISA's New Rules | A Pure Global LATAM MedTech Insight

Thu, 12 Feb 2026 05:04:04 -0400

This episode of LATAM MedTech Insights dives into the critical new regulatory guidance from Brazil's ANVISA for Software as a Medical Device (SaMD). As Brazil doubles down on localized requirements, we explore why simply having FDA or CE approval is no longer enough to guarantee market access. We uncover the hidden complexities of ANVISA's risk classification and the growing importance of local data and cybersecurity compliance. We examine a case study of a digital health company whose market launch was delayed by nine months due to unexpected data privacy requirements. This costly setback highlights a critical pain point: underestimating Brazil's unique regulatory interpretation can derail your entire market entry strategy, even with a globally successful product. Key Questions Answered: - Is ANVISA's evolving SaMD framework a hidden barrier or a clear pathway for prepared companies? - How can your SaMD's risk classification unexpectedly change when entering Brazil? - What are the three most common LGPD (Brazil's Data Protection Law) mistakes foreign MedTech firms make? - Why is your choice of a local Brazil Registration Holder (BRH) more critical than ever for software devices? - What post-market surveillance strategies for SaMD will satisfy ANVISA's new focus? - How can you leverage your existing clinical data for the Brazilian market without starting from scratch? Navigating global markets requires more than just a great product; it demands expert regulatory strategy. Pure Global offers end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline market access in over 30 countries, including Brazil. Whether you're a startup or a multinational, we are your local representative, ensuring a clear path to registration and post-market compliance. Don't let regulatory hurdles block your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more.

Pure Global: Brazil's AI Software Maze - Cracking ANVISA's New Unspoken Code

Wed, 11 Feb 2026 05:04:04 -0400

Brazil's regulatory landscape for AI and software medical devices just got a lot more complex. In this episode, Pure Global dives into ANVISA's latest unspoken rules that demand localized clinical data and stricter adherence to Brazil's data privacy laws, moving beyond simple acceptance of FDA or CE marks. We explore why your existing global dossiers might now be insufficient for the Brazilian market. We break down the new expectations for cybersecurity and the critical importance of validating your technology on local patient populations to ensure a successful product registration. **Case Study:** A U.S. diagnostics firm with a breakthrough AI-powered imaging tool had their Brazilian market entry delayed by six months. Their mistake? They submitted their FDA-cleared validation package without a supplemental study on a Brazilian patient cohort, leading to a cascade of questions from ANVISA that brought their launch to a halt. **Key Takeaways:** * Why is ANVISA now looking beyond FDA and CE approvals for SaMD? * What specific type of local clinical data can make or break your AI device submission in Brazil? * How can Brazil's data privacy law (LGPD) unexpectedly block your medical device approval? * What are the new cybersecurity vulnerabilities ANVISA is actively screening for? * Is it possible to use this regulatory shift to gain an advantage over slower competitors? * What is the number one assumption foreign companies make that leads to rejection? Struggling to keep up with the fast-paced changes in LATAM's regulatory landscape? Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline your market access. We act as your local representative, manage technical submissions, and ensure post-market compliance. Don't let regulatory hurdles block your expansion. Contact us for a strategic consultation at info@pureglobal.com or visit us at https://pureglobal.com/.

Pure Global: Brazil's AI Medical Software Rules - ANVISA's Surprise Roadblock.

Tue, 10 Feb 2026 05:04:04 -0400

This week, we dive into a sudden and impactful regulatory shift in Brazil. ANVISA, the country's health agency, released a new resolution last week that specifically targets Software as a Medical Device (SaMD), creating significant new hurdles for manufacturers, especially those using AI and machine learning. This update introduces stringent cybersecurity protocols, challenging data localization laws, and a more rigid process for software updates. We explore what these changes mean on the ground through a practical case study. A U.S. diagnostics company, on the verge of launching its FDA-cleared AI cardiac software in Brazil, now finds its entire market entry strategy jeopardized by these new rules. Their reliance on U.S.-based cloud servers and agile development cycles directly conflicts with ANVISA's new mandates, forcing them to consider a costly strategic pivot or abandon the market. Key Takeaways: - What are the three core pillars of ANVISA's new SaMD regulation announced last week? - Why is the new data sovereignty rule a major obstacle for global MedTech companies? - How does the updated change control process impact companies using agile development? - What specific cybersecurity standards are now mandatory for software devices in Brazil? - Can you still leverage your FDA or CE marking for an expedited review under these new rules? - What is the first step you should take if your product is affected by this sudden change? Navigating the complexities of LATAM's regulatory environment is critical for success. At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. Whether you're dealing with new software regulations in Brazil or planning a multi-market launch, we provide the strategic guidance and in-country representation you need. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Pure Global: Brazil's AI Software Maze - Cracking ANVISA's New Code

Sun, 08 Feb 2026 05:04:02 -0400

In this episode, we dissect the breaking news from Brazil where the regulatory agency, ANVISA, has just rolled out a comprehensive and stricter framework for AI-powered Software as a Medical Device (SaMD). This sudden move creates significant new barriers to entry in Latin America's most lucrative MedTech market. We explore the immediate and costly implications for international manufacturers, whose existing global dossiers and market-entry strategies may now be insufficient. We use the real-world example of a company poised to launch its innovative diagnostic software, only to be stopped in its tracks by a new, unexpected demand for local clinical data and cybersecurity compliance, forcing a difficult decision between a costly new trial or abandoning the market. Key Takeaways: - What are the three most critical changes in ANVISA's new SaMD regulation? - Why is Brazil now demanding local clinical data for AI algorithm validation? - How does this new framework impact your existing device classification and submission strategy? - What specific cybersecurity protocols are now mandatory for market access? - Can your existing technical file from the US or EU be leveraged, or must you start from scratch? - What are the hidden costs and timelines associated with this new regulation? - How can you turn this regulatory hurdle into a long-term competitive advantage in the LATAM region? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI tools to streamline global market access. We act as your local representative in Brazil and over 30 other markets, developing efficient pathways for regulatory approval. Turn regulatory complexity into a strategic advantage. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Mexico's MedTech Shortcut - Unpacking COFEPRIS's New Hurdles

Sat, 07 Feb 2026 05:04:02 -0400

Mexico just opened a new door for MedTech companies. Last week, the country's health authority, COFEPRIS, launched an accelerated approval pathway for devices with existing FDA or CE credentials. This could slash market entry timelines from years to months, but it comes with a catch. This episode dives deep into the opportunities and the hidden compliance traps of this new regulation. We uncover the specific requirements for data privacy and cybersecurity that are unique to Mexico, creating unforeseen challenges for even the most prepared global firms. A US-based company with an innovative, FDA-cleared diagnostic tool sees the news from Mexico and rushes to apply through the new fast-track system. They submit their existing technical file, assuming their robust cybersecurity measures will suffice. Two months later, their application is stalled. The reason: their documentation fails to address Mexico’s specific laws on patient data rights, a nuance they completely overlooked. Now they face significant delays and the costly process of redrafting their submission. Key Questions from this Episode: * Is your medical device eligible for Mexico's new fast-track approval pathway? * What specific documentation from your FDA or CE submission will COFEPRIS accept? * Why is the new 'Cybersecurity and Data Privacy Addendum' the most critical new hurdle? * How do Mexico's data protection laws for medical devices differ from HIPAA and GDPR? * What are the common pitfalls that can lead to rejection under this new system? * How can you leverage your existing approvals to gain a competitive advantage in LATAM? * What are the key responsibilities of a local representative in this new process? Don't let regulatory shifts derail your market entry. At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI tools to streamline your access to markets like Mexico. Contact us at info@pureglobal.com or visit https://pureglobal.com/ for a strategic consultation.

Pure Global: Brazil's AI MedTech Maze - Cracking ANVISA's New SaMD Rules.

Fri, 06 Feb 2026 05:04:02 -0400

This week, we dive into a major regulatory shift in Latin America's largest MedTech market. Brazil's agency, ANVISA, has just released new, stringent guidance for AI-powered Software as a Medical Device (SaMD). This development creates significant new barriers for foreign manufacturers, moving beyond simple acceptance of international certifications and demanding a highly localized compliance strategy. We explore the three core pillars of this new update: the requirement for clinical data representative of the Brazilian population, specific cybersecurity mandates for data privacy, and the complex new rules for managing self-learning AI algorithms post-market. This episode is essential for any MedTech innovator targeting Brazil. Case Study Spotlight: A French MedTech scale-up, celebrated for its AI diagnostic software with a CE mark, was planning an aggressive Brazilian launch this quarter. Their strategy relied on leveraging their European clinical data. The new ANVISA guidance has abruptly halted their plans, as their data is now deemed insufficient, forcing a costly and time-consuming local validation study they were unprepared for. Key Takeaways: - Does your AI's training data meet ANVISA's new demographic requirements for Brazil? - Is your global cybersecurity plan adequate for Brazil's new, specific reporting protocols? - How will you manage and document post-market changes for your 'learning' algorithm? - Is your existing technical dossier now obsolete under these new SaMD guidelines? - What constitutes a "significant change" for an AI algorithm that requires re-submission to ANVISA? - How can you build a compliant Algorithm Change Protocol from scratch? Navigating the complexities of Brazil's evolving regulatory landscape requires deep local expertise and a proactive strategy. At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. Our team of local experts, combined with advanced AI tools, helps you develop efficient pathways for regulatory approval, compile technical dossiers, and act as your official in-country representative. We turn regulatory hurdles into market opportunities. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market access.

Pure Global: Brazil's ANVISA Shift & The Hidden Dossier Trap

Thu, 05 Feb 2026 05:04:02 -0400

This week, we dive into a major regulatory shift in Brazil that is catching international MedTech companies off guard. ANVISA's RDC 751/2022 is entering a critical new phase, and the latest clarifications on technical dossier requirements are creating significant hurdles for manufacturers seeking market access. We break down what these changes mean and why your existing FDA or CE mark documentation may no longer be enough. We explore the challenges through a common scenario. Imagine a successful European MedTech company, confident in their CE-marked diagnostic tool, targeting Brazil for their next big expansion. They suddenly face a submission rejection from ANVISA due to "insufficient clinical data" under the new RDC 751 rules. Their launch is now stalled, competitors are gaining ground, and they face the costly, time-consuming task of generating new evidence for a market they don't fully understand. Key Takeaways: * What is the crucial difference between an EU technical file and a Brazilian dossier under RDC 751? * Why is ANVISA's new classification system causing unexpected delays for device makers? * Is your clinical data robust enough for Brazil's heightened scrutiny? * What is the number one documentation mistake companies make when submitting to ANVISA? * How can you turn Brazil's tough regulatory environment into a competitive advantage? * Why might your risk management file be non-compliant, even if it was accepted elsewhere? * What are the unwritten rules for expediting your registration process in Brazil? Navigating the complexities of global markets like Brazil is what we do best. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline market access. Don't let regulatory hurdles derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can secure your entry into Latin America.

Brazil's Digital Health Gauntlet: Pure Global on Cracking ANVISA's New SaMD Code.

Tue, 03 Feb 2026 05:04:20 -0400

Brazil's national health agency, ANVISA, has just launched a new, comprehensive regulatory framework for Software as a Medical Device (SaMD), with a major focus on AI and digital health technologies. This pivotal update ends years of uncertainty but introduces stricter rules that are reshaping the market entry strategy for all MedTech innovators targeting Latin America's biggest economy. In this episode, we dissect the critical details of this new resolution. We explore the updated risk classification system, the surprising new requirements for local clinical data, and the stringent cybersecurity mandates that now apply. This is a must-listen for any manufacturer or investor who wants to understand the new cost, timeline, and strategic implications of launching a digital health product in Brazil. **Case Study Spotlight:** Imagine your AI-powered diagnostic tool, previously on a straightforward path to market as a Class II device, is suddenly reclassified as high-risk Class III by the new ANVISA rules. This shift instantly triggers the need for expensive, time-consuming local clinical trials, potentially delaying your launch by more than a year. We unpack how to navigate this exact scenario and what it means for your budget and global strategy. **Key Takeaways:** * What are the three most critical changes in ANVISA's new SaMD framework? * How do the new cybersecurity requirements differ from FDA or CE standards? * Is my existing telehealth platform now considered a regulated medical device in Brazil? * What is the single biggest mistake foreign companies make when submitting AI-based digital health dossiers to ANVISA now? * How does this regulatory shift in Brazil impact future trends in Colombia and Mexico? * Are there any new fast-track approval pathways for certain types of SaMD under this resolution? * What kind of local partnerships have become essential for ensuring compliance with these new rules? At Pure Global, we specialize in demystifying complex regulatory landscapes like this. Our integrated approach combines local, in-country experts with advanced AI and data tools to deliver end-to-end solutions—from initial market strategy and technical dossier submission to post-market surveillance. We act as your local representative, ensuring you not only enter the market but thrive in it. To streamline your entry into Brazil or over 30 other markets, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's SaMD Shake-Up: Pure Global on ANVISA's Hidden AI Rules

Mon, 02 Feb 2026 05:04:20 -0400

In this episode, we dissect the groundbreaking new regulation from Brazil's ANVISA for Software as a Medical Device (SaMD). The country has officially aligned its framework with the global IMDRF standards, a move that promises to streamline market access for international manufacturers. But this harmonization comes with a uniquely Brazilian twist. We explore the hidden complexities beneath the surface. While alignment with international standards simplifies dossier preparation, ANVISA has embedded stringent local requirements for cybersecurity and data privacy, directly linked to Brazil's powerful General Data Protection Law (LGPD). This creates a new hybrid regulatory landscape where a simple copy-paste of your global submission is a recipe for rejection. A real-world case illustrates the challenge. A MedTech company with an FDA-cleared AI diagnostic tool gets its Brazilian application rejected. Their critical mistake was assuming their HIPAA-compliant cybersecurity protocols would satisfy the LGPD-specific requirements now hardwired into ANVISA's SaMD rules, leading to costly delays and rework. Key Takeaways for This Episode: - Is Brazil's new SaMD regulation an open door or a hidden trap for global innovators? - How does the new IMDRF alignment truly impact your existing technical dossier? - What are the most common cybersecurity and data privacy mistakes companies make when entering Brazil? - How could your SaMD's risk classification change under ANVISA's new framework versus the FDA or EU? - Beyond the device itself, what new software validation and lifecycle management proofs are now required? - How can you leverage Brazil's strict LGPD data law as a competitive advantage? - What are the hidden costs of non-compliance with these new localized requirements? Navigating this new environment requires deep local expertise combined with a global perspective. At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies, using our local experts in Brazil and advanced AI tools to streamline market access. We turn regulatory complexity into your competitive advantage. To learn more about our services, contact us at info@pureglobal.com or visit us at https://pureglobal.com/.

Pure Global: Brazil's New AI Regs—Fast-Track Approval or Data Privacy Nightmare?

Sun, 01 Feb 2026 05:04:20 -0400

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has just launched a new "Agile Approval Program" promising rapid, sub-90-day registration for AI-powered medical software. This move is designed to attract top-tier global technology and accelerate innovation within Latin America's largest market. While the fast-track approval sounds like a golden ticket, it comes with a significant catch. The new regulation includes a strict data privacy addendum linked to Brazil's LGPD law. This creates a critical new set of challenges for foreign manufacturers, focusing on algorithmic bias and data sovereignty. We explore how this seemingly minor detail could derail market entry plans and add unexpected costs and delays. A prime example is a European AI diagnostics firm, poised for rapid entry into Brazil's market. They are now facing unexpected delays and significant costs due to unforeseen local data hosting and algorithmic bias validation requirements. Their initial strategy, built on leveraging their existing FDA clearance, is now obsolete, forcing a costly scramble to meet local data compliance. Key Takeaways: - What is Brazil's new fast-track pathway for AI-powered medical devices? - How could ANVISA's new data privacy rules unexpectedly block your market entry? - Why is proving your AI is free from demographic bias now a regulatory requirement in Brazil? - Are you prepared for mandatory local data handling protocols and their hidden costs? - How can a regulation designed to speed up approvals actually slow you down? - What steps can you take to turn Brazil's complex LGPD rules into a competitive advantage? - Is your existing technical dossier sufficient for this new, data-centric review process? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative, develop efficient regulatory strategies, and use advanced AI to compile and submit technical documents, ensuring you can navigate complex challenges like Brazil's new AI regulations. To prepare your market access strategy, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's RDC 751 Maze: Pure Global on MedTech's Hidden Submission Traps.

Sat, 31 Jan 2026 05:04:20 -0400

This episode of LATAM MedTech Insights dives into the critical challenges emerging from Brazil's new medical device regulation, RDC 751/2022. As of last week, an increasing number of international manufacturers are facing surprising rejections from ANVISA. The issue goes far beyond simple paperwork; it reflects a fundamental misunderstanding of the heightened scrutiny now applied to clinical data, risk management, and technical documentation. We explore the hidden complexities that are tripping up even experienced regulatory affairs teams. We break down the specific areas where ANVISA is focusing its attention, from demanding localized clinical evidence to flagging minor inconsistencies in product labeling. This episode is essential for any MedTech company looking to enter or maintain its presence in the Brazilian market. **What You'll Learn:** - Why is Brazil's RDC 751 proving to be more than just a document reformatting exercise? - What is the single biggest mistake foreign manufacturers are making in their new ANVISA submissions? - How can your existing CE-marked or FDA-approved clinical data lead to a rejection in Brazil? - Are you correctly understanding the difference between device 'grouping' (agrupamento) and 'kits' (conjunto)? - What are the unwritten expectations from ANVISA reviewers when they examine your technical dossier? - How can you avoid a six-month delay by getting your Instructions for Use and labeling right the first time? - How can you transform the challenges of RDC 751 into a strategic advantage for market entry? Navigating global markets requires deep local expertise and cutting-edge tools. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging local experts in Brazil and advanced AI to streamline market access. From initial regulatory strategy to post-market surveillance, we act as your local representative to ensure your success. To learn how we can help you conquer the Brazilian market, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's RDC 751 Quagmire - A MedTech Survival Guide.

Fri, 30 Jan 2026 05:04:20 -0400

This week on LATAM MedTech Insights, we dissect the ongoing regulatory shake-up in Brazil. ANVISA's RDC 751/2022 is now in full force, and medical device manufacturers are facing a complex new reality. We unpack the critical changes, moving beyond the headlines to explore the on-the-ground impact of the new technical dossier structure and reclassification rules. We explore the long-term vision behind this push for harmonization with global standards and contrast it with the immediate, resource-intensive hurdles companies must overcome. This episode is essential listening for any MedTech professional with stakes in the Brazilian market. For example, consider a successful US-based IVD manufacturer whose product has been on the Brazilian market for years. Under RDC 751, their device is now in a higher risk class and their existing technical file is obsolete. How can they possibly compile, translate, and submit a completely new dossier that meets the stringent new structure before their current license expires and their multi-million dollar revenue stream is cut off? What You'll Learn: - What are the three most common deficiencies ANVISA is finding in new RDC 751 submissions? - How does the new technical file structure differ from the US FDA 510(k) or EU MDR requirements? - Is your current Brazil Registration Holder (BRH) equipped to handle these complex new requirements? - What's the biggest mistake companies make when updating their risk management files for ANVISA? - Could this regulatory challenge actually be a strategic opportunity to leapfrog competitors? - How will Brazil's alignment with the IMDRF framework impact your expansion plans in other LATAM countries? At Pure Global, we specialize in transforming regulatory complexity into market opportunity. Our team of local experts in Brazil, combined with our AI-powered data tools, provides end-to-end solutions for MedTech and IVD companies. Whether it's conducting a gap analysis for RDC 751, managing technical dossier submissions, or acting as your official local representative, we streamline your path to market. Don't let regulatory changes disrupt your business. Contact us for a consultation at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Brazil's MedTech Shift: Decoding ANVISA's 2027 Roadmap - A Pure Global Insight.

Thu, 29 Jan 2026 05:04:20 -0400

Brazil's health agency, ANVISA, just dropped its regulatory agenda for 2026-2027, and it’s set to reshape the landscape for medical device manufacturers. This new roadmap signals a major pivot from one-time market approval to a continuous, full-lifecycle approach to regulation, with big implications for SaMD, clinical data, and post-market surveillance. For any MedTech company with a high-risk device, the pain point is immediate. Your existing FDA or CE Mark clinical data might no longer be enough to secure or maintain your registration in Brazil. You're now facing the challenge of generating local Real-World Evidence, a potentially costly and complex process. But the attraction is clear: successfully navigating these new requirements unlocks continued access to one of the world's most lucrative and rapidly growing healthcare markets. Key Takeaways: - How will ANVISA's new agenda impact your 2026 product registration timeline? - Is your Software as a Medical Device prepared for Brazil's new cybersecurity standards? - What now constitutes acceptable Real-World Evidence for the Brazilian population? - Could a new fast-track process for low-risk devices actually increase your compliance burden? - How does ANVISA's focus on lifecycle management affect your post-market responsibilities? - Are your global clinical studies designed to meet Brazil's new data expectations? - What changes do you need to make to your quality management system right now? At Pure Global, we specialize in turning these regulatory shifts into strategic advantages. With our local expertise in Brazil and advanced AI tools, we develop efficient pathways for regulatory approval, manage technical dossier submissions, and act as your local representative to ensure you not only enter the market but thrive in it. Don't let regulatory changes disrupt your plans. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Brazil's SaMD Shift: Pure Global on Cracking ANVISA's New Digital Health Code

Wed, 28 Jan 2026 05:04:20 -0400

A major regulatory shift just hit Brazil, Latin America's top MedTech market. Last week, the national agency ANVISA rolled out a completely new framework for Software as a Medical Device (SaMD), creating urgent challenges and new opportunities for digital health companies worldwide. This update introduces a stricter, four-tiered risk classification system and demands more rigorous technical documentation, especially for AI- and machine learning-driven software. This change means the old way of registering your SaMD product in Brazil is no longer valid. Consider a European startup with an innovative AI diagnostic tool that analyzes patient data to predict disease progression. Under the previous, more ambiguous rules, they were preparing for a mid-tier regulatory process. Now, their product is definitively classified as high-risk, requiring extensive new evidence on clinical validation, data privacy, and cybersecurity that they hadn't budgeted for, potentially delaying their market entry by months. Key questions from this episode: - How does ANVISA's new risk classification system impact your AI-powered diagnostic tool? - What specific cybersecurity and data privacy documents are now mandatory for your submission? - How has the definition of a medical device been expanded to include your wellness or diagnostic app? - What are the new, stringent requirements for clinical validation for high-risk SaMD? - How can you perform a gap analysis between your existing technical file and the new Brazilian requirements? - Will your existing ISO 13485 certification be enough to meet the new quality management system expectations for software? - How will these changes affect registration timelines and costs for entering the Brazilian market? At Pure Global, we specialize in navigating these complex regulatory landscapes. We provide end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI tools to streamline your market access. Whether you're a startup or a multinational, we can help you adapt your strategy, update your technical dossiers, and ensure a successful launch in Brazil and over 30 other markets. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Mexico's 10-Year MedTech Rule - The New Compliance Marathon

Tue, 27 Jan 2026 05:04:20 -0400

In this episode, we dissect a major regulatory shift in Mexico. A new reform to the General Health Law has extended medical device registration renewals to a 10-year cycle, a significant jump from the previous five years. This change presents a massive opportunity for manufacturers, offering long-term market stability and reduced administrative burdens. While this extension is a welcome development, it also introduces a new paradigm of compliance. With a decade-long gap between renewals, the focus intensifies on continuous post-market surveillance and vigilance. We explore the strategic pivot required for companies to thrive in this new environment, moving from a short-term renewal sprint to a long-term compliance marathon. A Case to Consider: Imagine your company has just secured a 10-year registration for its flagship diagnostic device in Mexico. The immediate cost savings are clear. But the real challenge is ensuring your vigilance and quality systems are robust enough to stand up to a decade of scrutiny from COFEPRIS without the regular check-in of a 5-year renewal. How do you maintain perfect compliance over such a long period? Key Takeaways: - What specific article of Mexico's General Health Law has changed for medical devices? - How does a 10-year registration cycle fundamentally alter a manufacturer's financial planning? - Why might this change make Mexico a more attractive long-term investment than other LATAM markets? - What are the hidden compliance risks of having a longer period between renewal submissions? - How must companies adapt their post-market surveillance strategies for this new "marathon"? - Could this strategic move by COFEPRIS influence regulators like ANVISA or INVIMA? - What kind of local operational support becomes critical for maintaining a 10-year registration? At Pure Global, we specialize in navigating these complex regulatory landscapes. Our end-to-end solutions, combining local expertise with advanced AI tools, streamline global market access. We handle everything from initial strategy to post-market surveillance, ensuring your innovation reaches the market and stays there. Don't let regulatory hurdles slow you down. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Brazil's SaMD Shake-Up: A Pure Global Guide to ANVISA's New Digital Health Rules.

Mon, 26 Jan 2026 05:04:20 -0400

This week, we dive into a critical regulatory shift in Latin America's largest MedTech market. Brazil's ANVISA has just issued new, stringent guidelines for Software as a Medical Device (SaMD), specifically targeting the booming field of AI-powered diagnostics. This update reshapes the pathway to market for innovators both inside and outside Brazil. We break down exactly what has changed, focusing on the new risk classifications and the intensified requirements for local clinical data. This episode is essential for any MedTech manufacturer, investor, or regulatory professional looking to understand the evolving landscape in Brazil and what it takes to succeed there now. **Case Study Spotlight:** Imagine your company has an innovative AI tool for detecting diabetic retinopathy, ready for Brazilian launch with a Class II strategy. Suddenly, new ANVISA guidance reclassifies your product to high-risk Class III, demanding extensive local clinical trials and delaying your launch by over a year. We discuss the strategic pivot required to overcome this exact challenge. **In this episode, you will learn:** - What are the key differences in ANVISA's new SaMD classification system for AI? - How do the new Brazilian guidelines align with international standards like the EU MDR? - What specific clinical evidence is now required for a high-risk SaMD submission in Brazil? - Does this new framework create more barriers or opportunities for foreign developers? - What are the most common pitfalls to avoid when submitting your AI SaMD for approval under the new rules? - How can you leverage existing global data while satisfying the new local requirements? - What does this mean for the future of digital health investment in Latin America? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI to streamline market access in complex, evolving markets like Brazil. Facing challenges with the new SaMD regulations? Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/ for a strategic consultation.

Mexico's 10-Year MedTech Registration: Pure Global on COFEPRIS's Hidden Compliance Trap

Sun, 25 Jan 2026 05:04:20 -0400

In this episode, we dissect the breaking news from Mexico's health authority, COFEPRIS. A new reform extends medical device registration renewals from five years to a full decade. This change is poised to reshape market strategy for all MedTech companies in the region. While this extension appears to be a major win by reducing administrative burdens, it introduces subtle but significant long-term risks. We explore the hidden compliance traps, the increased importance of post-market surveillance, and why this regulatory gift could become a major liability for businesses that fail to adapt their operational mindset from cyclical renewals to continuous vigilance. A real-world example of the risk is a company that secures a 10-year registration for its Class II device. In year four, COFEPRIS issues a new guidance on cybersecurity reporting for software-enabled devices. The company, focused on other market entries and no longer preparing for a renewal, misses the update. In year seven, a minor audit reveals this non-compliance, leading to fines and a potential suspension of their registration, jeopardizing a decade of projected revenue. Key questions from this episode: - Why does a 10-year approval cycle demand more vigilance, not less? - How will COFEPRIS likely shift its enforcement focus now? - What is the biggest mistake a company can make after securing a 10-year registration in Mexico? - How does this regulatory change impact your long-term budget planning? - Is your current post-market surveillance system robust enough for this new paradigm? - What tools can ensure your technical file remains a 'living document' for a full decade? - How can you turn this regulatory change into a competitive advantage? Navigating the complexities of long-term market access requires local expertise and global strategic oversight. Pure Global offers end-to-end regulatory consulting for MedTech companies, using advanced AI and data tools to streamline global market access and ensure continuous compliance. Let us help you build a robust, decade-long regulatory strategy. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's SaMD Shift: Pure Global on ANVISA's 2026 Regulatory Gambit

Sat, 24 Jan 2026 05:04:20 -0400

Brazil's health agency, ANVISA, has just unveiled its ambitious 2026-2027 regulatory agenda, signaling one of the most significant shifts in the Latin American MedTech landscape in years. This isn't just a minor update; it's a fundamental move towards stricter, globally harmonized standards that will redefine market access. This episode of LATAM MedTech Insights dives deep into the two most critical changes: a complete overhaul of the rules for Software as a Medical Device (SaMD) and the game-changing proposal to make MDSAP audits mandatory for all manufacturers. We break down the immediate operational and strategic impact these changes will have on your business. A US-based digital health startup just received FDA clearance for its AI-powered diagnostic tool. They saw Brazil as their next big market, but the planned revision of RDC 657 means their existing validation data might be insufficient for ANVISA. They now face a potential rework of their entire technical file, delaying market entry by over a year and adding unexpected six-figure costs. We discuss how to avoid this trap. This Episode's Key Questions: - How will ANVISA's new SaMD regulation impact AI and machine learning devices? - Is mandatory MDSAP participation a certainty for Brazil, and what is the deadline to prepare? - What are the three key documents you need to update in your technical file for the new software rules? - How can you leverage your existing certifications to streamline the new Brazilian requirements? - What is the number one mistake foreign manufacturers make when interpreting ANVISA's agenda? - Will the validity of Good Manufacturing Practices certificates finally be extended to align with product registrations? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. With our local experts in Brazil and advanced AI tools, we streamline the entire market access process, from regulatory strategy and technical dossier preparation to acting as your official in-country representative. Don't let regulatory hurdles block your entry into one of the world's largest MedTech markets. Contact us at info@pureglobal.com or visit https://pureglobal.com to secure your market presence.

Pure Global: Mexico City's MedTech Shift - COFEPRIS's 10-Year Bet on Device Renewals.

Fri, 23 Jan 2026 05:04:20 -0400

In this episode, we dive into a major regulatory shift that just happened in Mexico. Last week, COFEPRIS officially extended the renewal period for medical device registrations from five to ten years. This change presents a massive opportunity for MedTech manufacturers, reducing long-term costs and administrative burdens. We explore the practical implications of this reform, discussing how it repositions Mexico as a more attractive market within the LATAM region. We also uncover the potential challenges and new expectations this places on companies, particularly regarding long-term post-market surveillance and compliance. This isn't just a simple extension; it's a strategic move that requires a new way of thinking about your market presence in Mexico. **Key Takeaways:** * What specific change in Mexico's General Health Law doubles the life of a device registration? * How does the new 10-year renewal period impact the long-term cost and strategy for my products in Mexico? * Are all classes of medical devices eligible for this new extension? * With a longer registration, what are COFEPRIS's new expectations for post-market surveillance? * Should this regulatory shift in Mexico cause me to reconsider my expansion plans in other LATAM countries like Brazil or Colombia? * What steps should I take now to prepare my existing registrations for this new ten-year cycle? At Pure Global, we offer end-to-end regulatory consulting solutions to help MedTech and IVD companies navigate exactly these kinds of changes. We combine local expertise with advanced AI and data tools to streamline global market access, manage your technical dossiers, and ensure continuous compliance. Let us help you turn regulatory changes into strategic advantages. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's 3D-Printed MedTech Scramble - Inside ANVISA's Surprise Rule Shake-up.

Thu, 22 Jan 2026 05:04:20 -0400

Brazil's regulatory agency, ANVISA, has just released a surprise draft guidance for personalized, 3D-printed medical devices, sending shockwaves through the MedTech industry. With a very short 30-day window for public feedback, international companies are now scrambling to understand the complex new rules for software validation and data privacy that could disrupt their market access strategies. This episode dives deep into the specific challenges and hidden opportunities within this proposal. We analyze the potential requirement for Brazil-specific software validation, which may conflict with existing FDA or CE Mark approvals. We also unpack the ambiguous data localization clauses that could threaten the global operational models of many manufacturers. **Case Study Spotlight:** Imagine your company has perfected a workflow for creating patient-specific implants in a central European facility. You're on the verge of expanding into Brazil, but ANVISA's new rules could suddenly make your data transfer processes non-compliant, forcing a multi-million dollar investment in local infrastructure. Is your current regulatory strategy agile enough to handle this? **Key Questions Answered:** * Is ANVISA's 30-day feedback window a genuine consultation or a new barrier to entry? * What are the specific cybersecurity and data privacy risks hidden in the new draft? * How can you effectively challenge a proposed regulation that conflicts with your global model? * What are the unwritten rules for submitting feedback to ANVISA that actually gets considered? * Could Brazil's new framework for personalized devices set a new, complex standard for all of LATAM? Pure Global offers end-to-end regulatory consulting to help MedTech innovators navigate precisely these kinds of challenges. We combine local, in-country expertise with advanced AI tools to streamline global market access and ensure you're always ahead of regulatory changes. Don't let surprise regulations derail your expansion. Contact us at info@pureglobal.com or visit us at https://pureglobal.com/.

Pure Global: Brazil's SaMD Shift - Unpacking ANVISA's Hidden Hurdles for Foreign Tech

Wed, 21 Jan 2026 05:04:20 -0400

In this episode of LATAM MedTech Insights, we dissect the critical regulatory updates from Brazil's ANVISA that are reshaping the landscape for Software as a Medical Device (SaMD). This is not a minor tweak; it's a fundamental shift demanding that foreign manufacturers, especially in the AI and digital health sectors, rethink their entire market entry strategy. We explore the immediate implications of these new clarifications, focusing on the heightened demands for localized clinical data and the stringent requirements of Brazil's data privacy laws. This episode provides essential insights for any company looking to stay compliant and competitive in Latin America's largest and most complex market. **A Real-World Challenge:** Imagine you are a US-based scale-up with a revolutionary AI diagnostic tool, poised to enter the Brazilian market. Suddenly, you discover your extensive US and EU clinical data is deemed insufficient by ANVISA. You are now facing an unexpected, year-long delay to conduct local studies, jeopardizing your funding and first-mover advantage. How do you navigate this without derailing your entire LATAM launch? **Key Takeaways From This Episode:** * What specific clinical evidence is ANVISA now demanding for foreign SaMD? * How does Brazil's data privacy law (LGPD) impact your software's architecture? * Why is the risk classification for your AI-driven device more complex than you think? * What is the biggest mistake companies make when interpreting these new guidelines? * Could these stricter regulations hide unforeseen opportunities for well-prepared companies? * How can you leverage regulatory reliance pathways to potentially streamline this process? * What are the three essential questions to ask your local regulatory partner today? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. We help you turn regulatory hurdles into market opportunities. To learn more about navigating Brazil's evolving landscape or expanding into over 30 other global markets, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's AI MedTech Surprise: Decoding ANVISA's New Rules with Pure Global

Tue, 20 Jan 2026 05:04:20 -0400

This week, we dissect the breaking news from Brazil's regulatory landscape. ANVISA has just rolled out RDC 884, a new resolution that specifically targets AI and machine learning-powered medical software. This move signals a profound shift, moving Brazil away from reliance on foreign approvals and establishing a new, sophisticated framework for digital health technology. In this episode, we explore the critical details of this new regulation. We break down the stricter classification system, the controversial new requirements for localized clinical data, and the tough cybersecurity standards now being enforced. Learn what this means for MedTech innovators and how it will redefine the pathway to one of Latin America's largest markets. **Case Study:** Imagine you're a successful SaMD scale-up with FDA clearance, eyeing expansion. Your entire Brazilian market entry plan, built on leveraging your existing approvals, was just upended by ANVISA's announcement last week. Are you now required to run a costly and time-consuming local clinical trial? How do you prove your algorithm works for Brazil's unique population demographics? **This episode will answer:** - What are the three biggest changes in ANVISA's new AI software regulation? - Why might your existing FDA or CE Mark documentation now be rejected in Brazil? - Is a local clinical investigation mandatory for all AI-driven medical devices? - How can the new cybersecurity rules impact your product's architecture? - What are the hidden costs associated with the new data validation requirements? - Does this resolution create a new competitive advantage for locally-developed AI? - How should this change your strategic approach to the entire LATAM region? Struggling to keep up with regulatory shifts in Latin America? Pure Global offers end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI tools to streamline global market access. Whether it's market strategy, local representation, or technical dossier submission, we make global expansion clear and efficient. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Pure Global: Brazil's MedTech Renewal Ambush & ANVISA's Costly Registration Traps

Mon, 19 Jan 2026 05:04:20 -0400

This week, we dive into a silent but significant threat to MedTech companies in Brazil: the complexities of ANVISA's registration renewal process. Many manufacturers of Class I and II devices are unaware of the critical differences between a 'Notificação' and a 'Cadastro' approval, leading to a false sense of security. We explore how this simple misunderstanding can lead to the sudden cancellation of a product license, halting all sales and imports. This episode is a crucial guide for any company that wants to maintain its foothold and avoid the costly pitfalls of non-compliance in Latin America's largest market. **Case Study:** Imagine your company's Class II device has been successful in Brazil for nine years. Business is stable. Suddenly, you discover that your ANVISA registration is about to be cancelled permanently because your team missed the one-year deadline for the mandatory renewal application. Your entire Brazilian operation is now at risk from a single administrative oversight. **Key Questions from this Episode:** * Is your Brazilian device approval a one-time 'Notificação' or a time-limited 'Cadastro'? * Do you know the exact expiration date of your current ANVISA registration? * When is the final deadline to submit your renewal application before you risk cancellation? * What key documents are required for re-registration that weren't needed for the initial approval? * How can your local Brazil Registration Holder (BRH) fail to protect you from this risk? * Could this simple administrative mistake cost your company millions in lost revenue? * What is the first step to take today to audit your compliance status? Navigating the complexities of global markets is our expertise. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local experts with advanced AI to streamline market access. From acting as your local representative to managing the entire submission and renewal process, we ensure your market presence is secure. Don't let regulatory surprises disrupt your business. Contact us for a consultation at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's New SaMD Rules - Unseen Compliance Traps for Innovators.

Sun, 18 Jan 2026 05:04:20 -0400

Brazil is tightening its grip on the rapidly growing Software as a Medical Device (SaMD) market. A recent clarification from its regulatory agency, ANVISA, has introduced new, more stringent requirements for clinical evidence and cybersecurity, creating unexpected hurdles for global MedTech innovators. This move, aimed at increasing patient safety, could stall market entry plans for companies unprepared for this new level of scrutiny. This episode of LATAM MedTech Insights dives deep into what this new guidance practically means for manufacturers. We break down the specific documentation changes, analyze the strategic implications for companies targeting Brazil, and discuss the broader trend of increasing regulatory sophistication across Latin America. Case Study Spotlight: Imagine your cutting-edge diagnostic AI, already cleared in the US, is ready to launch in Brazil. Suddenly, ANVISA releases this new guidance demanding extensive local clinical data and cybersecurity protocols you don't have. Your launch is now stalled, and your investors are asking questions. This episode tackles that exact scenario. Key Takeaways in this Episode: * What are the three new documentation requirements for SaMD in Brazil that most companies will miss? * How does ANVISA's new cybersecurity expectation differ from the FDA's framework? * Is your existing clinical data from Europe or the US sufficient for a Brazilian submission now? * What specific local factors must be addressed in your risk management file for Brazil? * Could this new guidance actually create an advantage for companies that are prepared? * How will this impact the timeline and cost for registering a new SaMD product? At Pure Global, we specialize in demystifying complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, leveraging local expertise and advanced data tools to streamline market access in over 30 countries, including Brazil. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can help.

Pure Global: Brazil's MedTech Shift - Cracking ANVISA's New Digital Labyrinth.

Sat, 17 Jan 2026 05:04:20 -0400

This week on LATAM MedTech Insights, we dive into the mandatory transition to ANVISA's new digital submission platform in Brazil. While the goal is to accelerate approvals, the reality is a wave of new, technical challenges stalling market access for many MedTech companies. We explore the hidden pitfalls of this digital shift, moving beyond traditional regulatory concerns to the critical importance of technical and IT compliance. Discover why perfectly valid clinical dossiers are being rejected for reasons like metadata errors and incompatible file formats, and what this means for your 2026 registration strategy. **Case Study Spotlight:** A European manufacturer of advanced diagnostic software had their Brazilian market entry delayed by over six months. Their clinically-sound dossier was rejected three times by ANVISA's new platform. The problem? Not their data, but undocumented digital formatting requirements. Find out what they were and how to avoid them. **Key Questions Answered:** * Why is ANVISA’s promise of faster digital approvals leading to unexpected delays? * What are the most common, yet undocumented, digital errors causing submission rejections? * How must you adapt your dossier preparation strategy for a digital-first review? * Is your current local partner in Brazil equipped to handle these new IT challenges? * What specific metadata is causing the most frequent mismatches in the new portal? * How can you pre-validate your submission package to avoid cryptic platform errors? * What is the true cost of a failed digital submission in terms of time and resources? Struggling to navigate the complexities of global market access? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise in over 30 markets, including Brazil, with advanced AI and data tools to streamline your registration and ensure compliance. Let us be your local representative and technical navigator. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's AI MedTech Rush—Fast-Track or Data Privacy Trap?

Fri, 16 Jan 2026 05:04:20 -0400

This week, we dissect a major regulatory shift in Latin America's largest market. Brazil's ANVISA has just launched RDC 987, a new fast-track approval process for AI-powered medical devices. While this promises to slash market entry timelines, it also introduces complex and unprecedented data privacy requirements tied to the LGPD. This episode explores the dual nature of this regulation. It is both a golden opportunity for tech-forward companies and a potential minefield of compliance. We uncover the hidden challenges that could stall even the most innovative products, turning a supposed shortcut into a costly detour. **Case Study:** Imagine a European AI diagnostics firm, ready to capitalize on Brazil's new fast-track lane. They've prepared their technical dossier, but their submission is suddenly halted. The reason? The patient data used to train their groundbreaking algorithm years ago doesn't meet Brazil's strict new LGPD-based anonymization rules. Their multi-million dollar expansion is now trapped in a web of data compliance they never anticipated. **Key Takeaways:** * What specific documentation is now required under ANVISA's RDC 987? * How can you verify if your AI's legacy training data meets Brazil's new LGPD standards? * Is the "fast-track" a genuine opportunity or a resource trap for non-local companies? * What are the legal liabilities and costs of appointing a local Data Privacy Representative? * Can you leverage your existing FDA or CE marking to simplify this new process? * What are the new post-market surveillance requirements for AI devices under this rule? * How will this change impact reimbursement and market adoption in Brazil? At Pure Global, we specialize in turning these regulatory complexities into clear market access strategies. With our deep local expertise in Brazil and our advanced AI-driven data tools, we help MedTech and IVD companies navigate regulations like RDC 987 efficiently. Our end-to-end solutions cover everything from initial regulatory strategy and technical dossier submission to serving as your official local and data representative. Don't let compliance hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn how we can streamline your entry into over 30 global markets.

Pure Global: Brazil's ANVISA Shockwave - Navigating the New Digital MedTech Registration Chaos.

Tue, 13 Jan 2026 05:04:54 -0400

In this episode, we dissect the sudden and disruptive launch of ANVISA's new mandatory digital submission platform in Brazil, which has caught many international MedTech manufacturers off guard. We explore the immediate operational challenges, from language barriers to technical glitches, and discuss the strategic implications for companies planning to enter or expand within Latin America's largest market. We delve into the real-world impact through the case of a European firm whose multi-million dollar product launch was jeopardized overnight. Their meticulously prepared technical dossier was rendered incompatible with the new system, forcing them into a desperate race against time to reformat and resubmit, highlighting the critical need for regulatory agility and expert local representation. 本期干货 1. What are the three most critical technical changes in ANVISA's new PDR platform? 2. Why was no grace period offered for such a major regulatory transition? 3. How does this shift specifically impact the approval timeline for high-risk devices? 4. What are the hidden documentation requirements not listed in the official guidance? 5. How can AI-powered tools accelerate the adaptation of your technical dossier for the new format? 6. Is your current local representative equipped to handle this digital-only transition? 7. What are the key financial risks associated with submission errors on the new platform? 8. How can you leverage this regulatory shift as a competitive advantage? Struggling with market access in Latin America? Pure Global offers end-to-end regulatory consulting, leveraging local expertise and advanced AI to streamline your path to market in over 30 countries, including Brazil, Mexico, and Colombia. Don't let regulatory surprises derail your launch. Contact our experts at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

Pure Global: Mexico's COFEPRIS Shortcut - A New MedTech Backdoor for US/EU Devices?

Mon, 12 Jan 2026 05:04:54 -0400

This week, we dive into the groundbreaking news from Mexico's regulatory agency, COFEPRIS. A new fast-track "equivalency agreement" has been announced, set to revolutionize market access for medical device companies with existing US FDA or European CE Mark approval. This episode unpacks the details of this new pathway, exploring the immense opportunities it creates for international MedTech firms. We break down what this regulatory shift means for your business strategy in Latin America. This isn't just a minor update; it's a strategic move by Mexico to become the primary landing spot for MedTech innovation and investment in the region. We analyze the immediate benefits and the potential long-term competitive advantages for companies that act quickly. ## What You'll Learn: * What is the new COFEPRIS "equivalency agreement" and how does it actually work? * Which specific device classes are eligible for this new fast-track process? * How does this change Mexico's position against other LATAM markets like Brazil? * What are the critical documentation requirements needed to leverage your existing FDA or CE approval? * Are there any hidden pitfalls or new compliance details to watch out for in this streamlined process? * How can this new rule drastically reduce your company’s time-to-market and registration costs? * What does this mean for local Mexican manufacturers and the competitive landscape? * Is this the first step toward broader regulatory harmonization across Latin America? Navigating these complex changes requires local expertise and a global perspective. Pure Global offers end-to-end regulatory consulting for MedTech companies, combining local experts with AI tools to streamline global market access. We act as your local representative to ensure you can capitalize on new regulations efficiently. To learn how we can accelerate your entry into the Mexican market, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's AI MedTech Gold Rush: ANVISA's Hidden Rules | Pure Global Insights

Sun, 11 Jan 2026 05:04:54 -0400

This week, we dissect the groundbreaking news from Brazil's ANVISA: a new fast-track approval pathway for AI-powered medical devices. This move promises to slash approval times and revolutionize the digital health landscape, but the opportunities are wrapped in complex new challenges. We go beyond the headlines to explore the intricate new requirements for clinical data, cybersecurity, and local data privacy laws that could derail even the most prepared global companies. Discover why this "shortcut" might be a longer road than expected without the right local strategy. A specific case: A successful European AI diagnostic tool, fully approved in the EU, gets rejected by ANVISA's new fast-track system. The fatal flaw? Its clinical data wasn't validated on Brazil's diverse population demographics, making it unusable in the local context. This is the exact pitfall we help you avoid. Key Takeaways This Episode: - What are the three specific types of AI software ANVISA is prioritizing? - Why might the 90-day approval promise be misleading for foreign manufacturers? - How does Brazil's LGPD data privacy law create new compliance traps in the fast-track application? - What's the number one mistake companies make when submitting clinical data for the Brazilian market? - How can you prove your algorithm is free from demographic bias for ANVISA's review? - Which specific cybersecurity protocols are now mandatory for the fast-track application? - Is it now easier or harder for startups to compete with established players under this new system? Navigating the complexities of market access in Latin America requires localized expertise and a strategic partner. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local experts and advanced AI to streamline your path to market. To tackle challenges like ANVISA's new regulations and accelerate your entry into Brazil, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's AI MedTech Shake-Up: Pure Global on Cracking ANVISA's New Cybersecurity Code

Fri, 09 Jan 2026 05:04:30 -0400

This week, we dive into a major regulatory shift in Brazil that's sending shockwaves through the digital health sector. ANVISA, the national health surveillance agency, has just released RDC 899, a groundbreaking resolution that imposes stringent new cybersecurity and data privacy rules for all Software as a Medical Device (SaMD). This update creates immediate challenges for MedTech companies, especially those leveraging AI and machine learning. The resolution requires deep integration with Brazil's data protection laws (LGPD) and demands unprecedented transparency into algorithm validation. We break down the core components of RDC 899 and what they mean for your products, whether you're seeking new registration or preparing for a renewal. A European AI diagnostics company, with a device already successful in the Brazilian market, is now facing a critical challenge. Their upcoming registration renewal requires them to retroactively create an entire cybersecurity risk portfolio and provide detailed validation data for their proprietary algorithms. This unexpected task threatens to delay their renewal, potentially costing them millions in revenue and market position. How can you avoid this costly pitfall? Key Takeaways This Episode: * What are the three mandatory documents now required under ANVISA's RDC 899? * How does Brazil's data protection law, the LGPD, now directly impact your SaMD's software architecture? * For AI-driven devices, what specific information about your training datasets must now be submitted to ANVISA? * What is the immediate risk for devices that are already registered and approaching their renewal date? * How can you turn this new regulatory hurdle into a competitive advantage in the Brazilian market? * What are the unwritten expectations from ANVISA when reviewing these new cybersecurity files? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. We act as your local representative in over 30 markets, including Brazil, ensuring you can navigate complex changes like RDC 899 without delaying your growth. Don't let regulatory surprises derail your launch. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

Pure Global: Brazil's ANVISA 2025 Regs - Navigating Hidden Compliance Traps.

Thu, 08 Jan 2026 05:04:30 -0400

This week on LATAM MedTech Insights, we dissect the latest 2025 medical device registration guidance from Brazil's ANVISA. While the new framework aims to streamline market access, it has introduced a host of undocumented challenges that are causing significant delays for international manufacturers. We explore the gap between the official regulations and the practical hurdles companies are facing right now. From the specific demands of the new digital submission portal to the increased technical scrutiny placed on local representatives, this episode provides a crucial look at the unwritten rules of Brazilian MedTech regulation. We uncover the real reasons behind recent submission rejections and offer insights into how companies can avoid common pitfalls and accelerate their path to market in Latin America's largest economy. **Case Study:** A US-based orthopedic device company prepared their ANVISA submission based on their recent FDA 510(k) clearance. They were confident in their data, but their application was stalled for months. The issue? Their designated Brazil Registration Holder (BRH) was unable to adequately respond to ANVISA's technical questions regarding the specific biomechanical properties of the device, a level of scrutiny the company had never anticipated, forcing them to find a new, technically proficient local partner and restart the clock on their review. **Key Takeaways This Episode:** * Is your technical dossier truly prepared for ANVISA's new, unwritten formatting rules for 2025? * How can you adapt your existing FDA or CE Mark data to satisfy Brazil-specific risk analysis requirements? * Is your chosen Brazil Registration Holder (BRH) merely an administrative contact, or a true technical expert? * What are the most common, unexpected reasons for rejection under the new digital submission system? * How do you build a realistic timeline that accounts for unpredictable INMETRO certification delays? * Are you prepared for ANVISA's increasingly deep technical questions during the review phase? Navigating these regulatory mazes is our expertise. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise in markets like Brazil with advanced AI tools to streamline your global market access. Don't let regulatory hurdles derail your launch. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can help.

Pure Global: Decoding Brazil's Shock ANVISA Shift on MedTech Clinical Data.

Wed, 07 Jan 2026 05:04:30 -0400

This week, we dissect the surprise technical note from Brazil's ANVISA that just reshaped the rules for market entry. This clarification to RDC 751 demands more stringent, localized clinical evidence for high-risk devices, creating a significant new hurdle for international MedTech manufacturers looking to enter Latin America's largest market. We explore the immediate impact on companies that have long relied on their FDA or CE Marking data for Brazilian submissions. This isn't just a new piece of paperwork; it represents a fundamental shift in regulatory philosophy that could delay product launches, inflate budgets, and force a complete strategic rethink for companies targeting Brazil. **Case In Point:** A US-based orthopedic device manufacturer was weeks away from submitting their ANVISA application for a novel spinal implant. Their entire submission was built on extensive US and EU clinical trials. The new guidance has put their entire launch on hold, forcing them to confront the unexpected need for a local bridging study, potentially setting their timeline back by over a year and adding millions to their budget. **In this episode, you will learn:** - What specific clinical evidence is ANVISA now demanding under the new RDC 751 clarification? - Why is your existing international clinical data suddenly not enough for the Brazilian market? - Which high-risk device categories are most affected by this regulatory shift? - How can you determine if your current technical dossier meets these new, stricter requirements? - What are the strategic options for generating Brazil-specific clinical evidence without breaking the bank? - Is this new stance from ANVISA a leading indicator for similar changes in other LATAM countries? - How can proactive regulatory planning turn this potential barrier into a competitive advantage? At Pure Global, we specialize in transforming these complex regulatory challenges into clear market access strategies. With our end-to-end consulting, local expertise in over 30 markets, and advanced AI data tools, we streamline the path for MedTech and IVD companies entering markets like Brazil. We act as your local representative, manage technical dossiers, and provide the continuous regulatory monitoring needed to stay ahead of changes like this one. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

Pure Global | Brazil's MedTech Shift: Cracking ANVISA's New Digital Certificate Code

Tue, 06 Jan 2026 05:04:30 -0400

Brazil's health agency, ANVISA, has just launched a new digital portal, ending weeks-long delays for essential medical device certificates. This major shift from paper to a fully online system promises to accelerate market access, enhance transparency, and slash the administrative burden that has long frustrated manufacturers trying to enter Latin America's largest market. This episode breaks down what this digital transformation truly means for the industry. Consider a company whose multi-million dollar product launch was stalled for two months, not by regulatory hurdles, but by the wait for a single, physical GMP certificate. We explore how the new instant, online process eliminates this critical bottleneck, changing the game for logistics, sales, and getting vital medical technology to patients faster. **Key Takeaways:** * Which specific certificates are now available through ANVISA's new digital portal? * How does this change impact the timeline for post-approval market launch in Brazil? * What are the immediate operational steps your company must take to use this new system? * Does the digital certificate hold the same legal weight for customs and distributors? * How can this move signal broader digital transformation trends within other LATAM agencies? * What are the potential cybersecurity concerns with a fully digital certification process? * Are there new fees associated with these online requests compared to the old system? At Pure Global, we offer end-to-end regulatory solutions to navigate these changes seamlessly. Our local experts in Brazil and advanced AI tools streamline market access, from registration strategy to post-market surveillance. Let us help you turn regulatory updates into a competitive advantage. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Mexico's DigiReg Shift - Navigating COFEPRIS's Simplification Paradox

Sat, 03 Jan 2026 05:04:13 -0400

In this episode of LATAM MedTech Insights, we dissect the chaotic rollout of COFEPRIS's new mandatory digital platform, 'DigiReg'. Launched in the last week of December 2025, this platform was meant to be the final step in simplifying medical device registration in Mexico. Instead, it has created a maze of technical glitches and undocumented requirements. We explore how this "simplification paradox" is catching foreign manufacturers off guard. For instance, a leading European diagnostics firm found their application for a new IVD product stalled. They were perfectly compliant with the rules published just months ago, but the DigiReg platform is now rejecting their submission due to cryptic data validation errors, with no clear guidance from COFEPRIS on how to resolve them, putting their entire market entry strategy at risk. Key Takeaways for this episode: - What are the top three undocumented requirements in the new DigiReg platform causing immediate rejections? - How has the supposedly 'simplified' registration pathway become more complex for foreign manufacturers? - Why is your existing technical dossier suddenly non-compliant with the new digital standards? - What are the critical advantages of having a local representative to navigate DigiReg's interface and communication hurdles? - How can you adapt your submission strategy to avoid the common pitfalls of this new system? - Are there any workarounds for the platform’s current technical glitches to keep your registration on track? Navigating sudden regulatory shifts in fast-moving markets like Mexico is our expertise. Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. With our local experts in Mexico and advanced AI tools, we streamline the entire submission process, ensuring your technical dossier meets the latest digital requirements of platforms like DigiReg. Don't let regulatory surprises delay your market access. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.

Pure Global: Mexico's MedTech Shift - Unseen Hurdles in Post-Market Surveillance

Fri, 02 Jan 2026 05:04:13 -0400

This episode dives into the most overlooked but critical MedTech trend in Latin America as of late 2025: the dramatic tightening of post-market surveillance rules. While most companies focus on getting their device approved, regulatory bodies like Mexico's COFEPRIS and Brazil's ANVISA have shifted their focus to what happens *after* a product hits the market. We uncover the new requirements for faster reporting, real-world evidence, and data transparency that are creating major compliance risks for unprepared foreign manufacturers. We explore a case study of a European wearables company that recently gained market access in Mexico. Their seemingly routine over-the-air software update triggered a major regulatory compliance issue under the new COFEPRIS framework, putting their entire market registration at risk. This example highlights the critical "transparency gap" between a manufacturer's actions and the regulator's new expectations. Key questions answered in this episode: - What is the single biggest mistake MedTech companies make after getting COFEPRIS approval? - Why is a simple software update now a major regulatory event in Mexico and Brazil? - How are new transparency rules changing the public's access to your device's performance data? - Are your vigilance systems prepared for dramatically shorter adverse-event reporting deadlines? - What is the "post-approval blindspot" and how can it jeopardize your market presence? - How can you leverage local representation to navigate these complex new surveillance requirements? - What steps should you take to turn proactive post-market surveillance into a competitive advantage? Struggling to keep up with shifting regulations after your product launch? Pure Global offers end-to-end regulatory consulting, including robust post-market surveillance and local representation services to ensure you maintain compliance and market presence. Contact us for a strategic consultation at info@pureglobal.com or visit https://pureglobal.com.

Mexico's Fast-Track Trap: Pure Global on AI MedTech's Hidden Cybersecurity Hurdles.

Sun, 21 Dec 2025 04:37:14 -0400

Mexico's MedTech market is buzzing with the news of COFEPRIS's new fast-track approval pathway, promising quicker market access for devices with existing international approvals. This move positions Mexico as a key entry point into Latin America, attracting significant global interest. However, beneath this promising headline lies a complex new reality. The updated regulations include stringent new requirements for AI-driven software and connected devices, focusing heavily on cybersecurity and local data privacy laws. Many companies, eager to leverage the fast-track system, are being caught off guard, leading to unexpected rejections and costly delays. This episode unpacks the hidden complexities of Mexico's new regulatory landscape. A prime example is a European AI diagnostics company. They eagerly submitted their CE-marked product for the new fast-track approval, only to be rejected for failing to meet Mexico's specific cybersecurity and data protection standards, which were not part of their original technical file. This misstep has cost them a projected six-month delay and significant rework costs. Key questions answered in this episode: - What are the specific new cybersecurity requirements COFEPRIS is now demanding for SaMD? - How can you leverage your existing FDA or CE approval while avoiding common pitfalls in the new Mexican system? - Why is compliance with Mexico's personal data protection law a new critical point for dossier submission? - What's the biggest mistake companies are making when applying for the new fast-track registration? - How can you conduct a gap analysis to ensure your technical file is ready for these new standards? - Are there new labeling requirements for AI-powered devices under this framework? - What kind of post-market surveillance is required for software that uses machine learning? At Pure Global, we specialize in navigating these complex regulatory shifts. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise in markets like Mexico with advanced AI tools to streamline global market access. Whether it's developing a new regulatory strategy, compiling a compliant technical dossier, or acting as your local representative, we turn regulatory hurdles into market opportunities. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Argentina's SaMD Data Tango: Pure Global on ANMAT's Sudden Cybersecurity Shift.

Sat, 20 Dec 2025 04:37:14 -0400

This week, we dive into a sudden and seismic regulatory shift in Argentina. ANMAT's newly issued Resolution 785/2025 has introduced strict data localization and cybersecurity audit requirements for all Software as a Medical Device (SaMD) and connected devices, sending shockwaves through the industry. This episode breaks down the immediate implications for foreign manufacturers, who now face a tight 180-day deadline to overhaul their data infrastructure. We explore the strategic challenges posed by this new regulation, from the technical complexities of data migration to the uncertainty surrounding the list of approved local auditors. This is a must-listen for any MedTech company operating in or planning to enter the Argentinian market, providing a clear-eyed look at the new reality of digital protectionism in Latin America and what it takes to maintain compliance and market access. A specific case we discuss involves a leading European AI radiology software provider. Their platform relies on centralized servers in Brazil, and they now face the daunting and costly task of migrating their entire operation to a local Argentinian data center within 180 days. This unexpected mandate threatens to disrupt their services for existing hospital clients and could derail their growth strategy in the region. Key questions for this episode: - What are the exact requirements of ANMAT's new Resolution 785/2025? - How does the data localization mandate impact cloud-based SaMD and IoT devices? - What are the first three steps your company must take to assess its compliance risk? - Why are even well-established products with existing registrations in Argentina at risk? - How can you find and qualify a local data hosting partner that meets ANMAT's new stringent standards? - What specific cybersecurity documentation must be added to your technical dossier for submission? - Is this new Argentinian rule a blueprint for future regulations in other major LATAM markets? Struggling with sudden regulatory shifts in LATAM? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. From acting as your local representative in Argentina to developing a new regulatory strategy for data compliance, we ensure you maintain your market presence without disruption. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Pure Global: Brazil's AI Device Gambit—ANVISA's New Rules Create Unexpected Hurdles.

Fri, 19 Dec 2025 04:37:14 -0400

This week, we dissect a game-changing regulatory shift in Latin America's largest market. Brazil's ANVISA has just proposed a new fast-track approval process for AI-driven medical software, promising to slash market entry timelines for devices already approved by agencies like the FDA. But a closer look reveals a complex new challenge that could catch even the most prepared companies off guard. Imagine you're a global MedTech company with an FDA-cleared diagnostic AI. You see the 'fast-track' news from Brazil and plan for a quick launch. But your planned submission is suddenly non-compliant, citing a new, demanding annex on data traceability and cybersecurity specific to the Brazilian population that your initial regulatory package never accounted for. This is the hidden reality companies will now face. What you'll learn in this episode: - What is ANVISA's new proposed fast-track for AI medical devices? - Why is the new data governance requirement a hidden barrier for foreign manufacturers? - How do these proposed Brazilian rules differ from standard FDA or Health Canada requirements? - Could this 'fast-track' pathway actually delay market entry for unprepared companies? - What immediate steps should you take to assess your AI's training data for compliance? - Which specific local data protection protocols (LGPD) are now integrated into regulatory clearance? - How can this change be leveraged to build a stronger, more defensible market position in Brazil? Don't let regulatory surprises derail your LATAM expansion. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline market access in Brazil and over 30 other markets. We help you navigate complex changes like ANVISA's new AI rules, ensuring your technical dossier is compliant from day one. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

Brazil's SaMD Gambit: Unlocking ANVISA's New Fast-Track with Pure Global.

Thu, 18 Dec 2025 04:37:14 -0400

This week, we dissect a game-changing regulatory shift in Latin America's largest market. Brazil's ANVISA has just launched a new resolution for Software as a Medical Device (SaMD), creating an unprecedented fast-track pathway for innovative digital health products. This move promises to slash approval times and attract global investment. But there's a catch. While the new "fast-track" leverages existing international approvals, it also imposes stricter, more sophisticated requirements on technical documentation, cybersecurity, and clinical data relevance for the Brazilian population. This episode explores how savvy MedTech companies can seize this opportunity while avoiding the hidden pitfalls that could lead to rejection. **Case Study:** A European AI-driven diagnostic software company, already holding a CE mark, has been planning its entry into Brazil. The new ANVISA resolution seems like a golden ticket to bypass the historically long review times. But will their existing technical file be enough? Are their cybersecurity protocols compliant with Brazil's specific data laws? We break down the critical gaps they must fill to turn this opportunity into a market reality. **Key Questions Answered:** - What are the specific criteria to qualify for ANVISA's new SaMD fast-track pathway? - How can you leverage your existing FDA or CE marking approval for a faster Brazilian registration? - What are the top three new documentation requirements that most companies will overlook? - Why is adapting your clinical data to Brazilian demographics now non-negotiable? - What specific cybersecurity vulnerabilities is ANVISA now scrutinizing more than ever? - How has the role of the Brazil Registration Holder (BRH) evolved from a legal requirement to a strategic necessity? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.

Brazil's SaMD Cybersecurity Shockwave: Pure Global on ANVISA's Hidden Demands.

Wed, 17 Dec 2025 04:37:14 -0400

Last week, Brazil's ANVISA unleashed a pivotal update for Software as a Medical Device (SaMD) with its new resolution, RDC 992/2025. While appearing to align with international standards, this new regulation introduces complex cybersecurity and data privacy requirements tied specifically to Brazil's LGPD law, creating unexpected hurdles for global manufacturers. In this episode of LATAM MedTech Insights, we dissect the fine print of ANVISA's new rules. We explore the immediate operational impacts, from mandatory local data protection officers to new clinical data requirements for AI-driven software, and discuss the strategic adjustments companies must make to maintain or gain market access in Latin America's largest market. Case Study: Imagine you're a US-based scaleup with a groundbreaking AI diagnostic tool. Your EU MDR and FDA clearances are in hand, and Brazil is your next target. Suddenly, your registration is stalled. Why? Your application didn't address specific LGPD data transfer protocols and your designated data officer isn't based in Brazil. This is the new reality—a costly and time-consuming roadblock that a standard regulatory checklist would have missed. Key Takeaways: 1. What are the three 'hidden' requirements in ANVISA's new SaMD rule that most foreign companies will miss? 2. How does Brazil's LGPD law now directly impact your medical device's technical file? 3. Is your current cybersecurity plan sufficient for the new Brazilian standards? 4. Why might your existing AI/ML validation data be rejected by ANVISA? 5. What's the new mandatory role you might need to hire in Brazil to keep your SaMD on the market? 6. How does this update affect legacy SaMD products already registered in Brazil? 7. What are the critical deadlines you cannot afford to ignore over the next six months? Navigating the evolving regulatory landscape in Latin America requires more than just a checklist; it demands localized, expert strategy. At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise with advanced AI tools to streamline your global market access. We act as your local representative, manage your technical dossier, and ensure continuous compliance. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

Brazil's MDR Surprise: ANVISA's Hidden Clause for MedTech Imports | Pure Global

Tue, 16 Dec 2025 04:37:14 -0400

This week, we dissect the immediate fallout from ANVISA's surprise regulatory shift in Brazil. While the move towards EU MDR alignment was expected, a hidden clause mandating local usability studies for high-risk devices has caught many international MedTech firms by surprise, threatening to delay launches and inflate budgets. We explore the specifics of the new RDC 987/2025 resolution and what it means for companies who previously relied on their CE marking for a smoother entry into Latin America's largest market. This episode is a must-listen for regulatory affairs professionals, product managers, and executives focused on global expansion. A leading German cardiac stent company had its Brazilian launch plan finalized, with its budget approved and timeline set. Last week’s ANVISA announcement instantly invalidated their strategy. Now, they're facing an unexpected nine-month delay and an unbudgeted six-figure cost for a mandatory local study they never saw coming. Key questions from this episode: - Does ANVISA's new rule make your existing technical file obsolete for Brazil? - What are the hidden costs and timeline impacts of the mandatory in-country usability studies? - How can you leverage your existing data to potentially streamline this new local requirement? - Could this regulatory shift in Brazil signal a trend for other LATAM markets? - Is your local representative in Brazil equipped to manage these new complex clinical requirements? - What steps should you take today to de-risk your 2026 LATAM launch plans? Navigating sudden regulatory changes requires deep local expertise and a proactive strategy. At Pure Global, we offer end-to-end regulatory consulting, acting as your local representative in over 30 markets, including Brazil. We use advanced AI and data tools combined with on-the-ground expertise to streamline global market access and ensure you're always ahead of the curve. Don't let regulatory surprises derail your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

Brazil's ANVISA AI Gambit: Pure Global on Hacking the MedTech Approval Backlog.

Mon, 15 Dec 2025 04:37:14 -0400

Last week, Brazil's regulatory agency, ANVISA, unveiled a groundbreaking 2025 plan to tackle its notorious medical device approval backlogs. The initiative, named "AnvisAI," leverages artificial intelligence to create an automated fast-track system for lower-risk devices, aiming to cut review times by more than half and reshape the market access landscape. This move signals a major shift, potentially transforming Brazil from one of the most challenging LATAM markets into a hub for MedTech innovation. This episode unpacks the details of the AnvisAI project, exploring what it means for manufacturers' regulatory strategies and the immediate opportunities it creates for faster market entry. We explore a critical case study: Imagine launching an innovative Software as a Medical Device (SaMD) and facing a 24-month approval delay, tying up capital and stalling growth. ANVISA's new AI-driven pathway could slash that wait time to just a few months, completely changing the financial and strategic calculus for entering Brazil. Key Takeaways: 1. What exactly is the "AnvisAI" project and how will it re-classify devices for the new fast-track? 2. Which specific device classes stand to benefit the most from automated approvals? 3. What are the hidden data and documentation requirements for submissions to the new AI system? 4. How does this decision position Brazil against other LATAM markets like Mexico and Colombia? 5. What are the immediate actions MedTech companies should take to adapt their registration strategy? 6. Will this new system require changes to post-market surveillance and vigilance reporting? 7. How does this initiative align with Brazil's broader National AI Strategy? Navigating Brazil's rapidly evolving regulatory landscape requires local expertise and advanced technological tools. At Pure Global, we offer end-to-end regulatory consulting solutions, combining on-the-ground experts in Brazil with proprietary AI tools to streamline your market access. From regulatory strategy and dossier preparation to acting as your local representative, we help you leverage these new opportunities for faster growth. To learn how we can accelerate your entry into the Brazilian market, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global: Brazil's MedTech Leap to Digital - The Hidden Compliance Traps.

Sun, 14 Dec 2025 04:37:14 -0400

This week, we dissect a major regulatory shake-up in Latin America's largest MedTech market: Brazil. ANVISA, the national health surveillance agency, has just initiated a pivotal shift from paper to digital, while simultaneously revoking its traceability regulations. This move promises to cut costs and streamline logistics for manufacturers but introduces a new host of digital compliance and supply chain challenges. We explore how this digital-first policy impacts a device manufacturer's entire operational playbook overnight. Imagine being able to update a user manual with a single click instead of recalling thousands of product kits. This episode details the immediate opportunities and the hidden risks, from ensuring digital access in rural clinics to addressing new cybersecurity threats. Key Takeaways From This Episode: - How does Brazil's new digital leaflet policy impact my product launch timeline? - What are the hidden cybersecurity risks of shifting to digital-only documentation? - ANVISA revoked traceability rules, so what does this mean for my supply chain integrity? - Is this digital trend isolated to Brazil, or is it spreading across LATAM? - How can I update my Quality Management System to handle digital compliance? - What new software and validation processes are now required? - Does this change affect my existing product registrations or do I need to re-submit? Navigating these rapid shifts is where Pure Global excels. We offer end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline market access. Don't let regulatory changes disrupt your strategy. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/ for a consultation.

São Paulo SaMD Shake-Up: Pure Global on ANVISA’s Unwritten Rules for AI

Sat, 13 Dec 2025 04:37:14 -0400

Brazil's MedTech landscape is buzzing as its regulatory agency, ANVISA, puts Software as a Medical Device (SaMD) back under the microscope. In its newly released 2024-2025 agenda, ANVISA has signaled major revisions to the existing framework, a move that comes sooner than many in the industry expected. This suggests that the initial guidelines are already being outpaced by rapid advancements in digital health, especially in AI and machine learning. This episode dives deep into the implications for MedTech manufacturers. While Brazil's alignment with international standards has created opportunities, navigating the specifics of its regulatory environment remains a complex challenge. For companies with innovative SaMD, particularly those leveraging adaptive AI, the upcoming changes could mean the difference between market leadership and costly compliance failures. We explore what these revisions might entail and how companies can prepare for a more stringent regulatory future. A real-world example: A US-based scaleup has a powerful AI-driven diagnostic platform. Their biggest pain point is regulatory ambiguity. They are uncertain if their adaptive algorithm fits ANVISA's current risk classification and are struggling to prepare cybersecurity documentation that will satisfy local requirements, which differ from those of the FDA. This uncertainty is delaying their entry into one of LATAM's largest markets, costing them valuable time and revenue. What you'll learn in this episode: 1. Why is ANVISA revisiting its SaMD regulations so soon after the 2022 framework was established? 2. What are the three key areas, including AI and cybersecurity, likely to see the strictest new rules? 3. How does Brazil's approach to classifying adaptive AI software differ from the EU or US? 4. What are the most common documentation gaps that lead to SaMD registration delays in Brazil? 5. Is your current change control process robust enough for ANVISA's evolving expectations? 6. How can you leverage your existing international technical files for a faster Brazilian submission? 7. What are the unspoken post-market surveillance challenges unique to digital health in LATAM? 8. How do you determine if a software update is a minor change or requires a completely new registration? Ready to streamline your market access in Brazil and beyond? Pure Global offers end-to-end regulatory consulting solutions, combining local expertise with advanced AI to accelerate your success. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can be your local partner for global growth.

Pure Global LATAM Insights: Brazil's SaMD Shakeup - Decoding ANVISA's 2025 Digital Health Playbook.

Fri, 12 Dec 2025 04:37:14 -0400

Brazil's regulatory agency, ANVISA, is updating its rules for Software as a Medical Device (SaMD) as a key priority for 2025. This major overhaul will align Brazil’s digital health landscape with global standards like the EU MDR, introducing stricter requirements for cybersecurity, interoperability, and technical documentation. This change presents a critical challenge for MedTech innovators. For example, a US-based AI diagnostics company eager to enter the lucrative Brazilian market now faces new, complex questions. How can they ensure their existing cybersecurity protocols meet ANVISA's new, currently undefined standards? The fear of a delayed or rejected submission due to non-compliance with these evolving rules could stall their entire LATAM expansion strategy, making proactive guidance essential. Key Takeaways: 1. How will ANVISA's new SaMD framework specifically align with the EU's MDR, and what does this mean for documentation? 2. What new cybersecurity and data privacy requirements must your software meet to gain approval in Brazil? 3. Will the updated regulations create a faster or more complex path to market for digital health startups? 4. What specific changes to Instructions for Use (IFU) will be mandatory for all SaMDs? 5. How can you prepare your technical dossier now for the anticipated 2025 changes? 6. What are the new expectations for demonstrating software interoperability with existing hospital systems? 7. How will the risk classification for SaMDs change under the new Brazilian framework? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative, develop efficient regulatory strategies, and use AI to compile and submit technical documents. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.

Pure Global: Brazil's MedTech Data Shock - ANVISA's New Cybersecurity Surprise

Thu, 11 Dec 2025 04:37:14 -0400

Last week, Brazil's ANVISA implemented a sudden and strict new regulation for cybersecurity in connected medical devices. This unexpected move introduces mandatory data localization, forcing companies to store Brazilian patient data on servers within the country, creating significant technical and financial hurdles for global manufacturers. This episode of LATAM MedTech Insights unpacks the immediate impact of this new rule. We explore the specific technical requirements, the short 90-day compliance window, and what this means for companies with existing products in the market or those planning to enter Brazil's lucrative MedTech space. Imagine your state-of-the-art, cloud-powered diagnostic device, already approved in Europe and the US, is suddenly blocked from the Brazilian market. The reason is ANVISA's new data localization law, passed just last week, which makes your global cloud architecture non-compliant overnight. This is the urgent new reality facing MedTech innovators in Brazil. Key questions from this episode: - What are the three critical actions you must take to comply with ANVISA's new cybersecurity note? - How does the mandatory data localization rule affect your existing global cloud strategy? - Are there any exemptions for small-scale startups or SaMD products? - What specific encryption standards are now mandatory, and which are obsolete? - How can you update your technical dossier to prevent import delays and rejections? - What does this shift signal for the rest of the Latin American market? Is your business ready to navigate sudden regulatory shifts in Latin America? At Pure Global, we offer end-to-end solutions to ensure your MedTech and IVD products meet complex local requirements. From developing a robust regulatory strategy and compiling technical dossiers with our AI-powered tools to acting as your official local representative, we streamline your path to market access. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can secure your market presence in over 30 countries.

Brazil's AI MedTech Leap: Pure Global on Cracking ANVISA's New SaMD Code

Wed, 10 Dec 2025 04:37:14 -0400

Brazil's regulatory agency, ANVISA, has just redefined the future of digital health in Latin America with its new, comprehensive framework for AI-powered Software as a Medical Device (SaMD). This landmark regulation introduces a stricter risk classification system and new requirements for algorithm validation and cybersecurity, directly impacting any MedTech company looking to enter or grow in the region's largest market. This episode of LATAM MedTech Insights provides a crucial analysis of these changes. We uncover what the new four-tiered risk system means for your product, how to manage the lifecycle of your AI algorithms under the new rules, and why aligning with Brazil's data privacy laws is now more critical than ever. This isn't just a regulatory update. it's a strategic shift that will influence the entire LATAM region. **Case Study:** Imagine your AI-powered diagnostic tool, which has been operating in a regulatory gray area, is suddenly reclassified as a high-risk device under the new ANVISA framework. You now face urgent demands for more extensive clinical data, a formal algorithm change protocol, and stricter cybersecurity measures, potentially delaying your market access by months. Are you prepared to meet this new, higher standard. **Key Takeaways:** * What are the most significant changes in ANVISA's new SaMD regulation. * How does Brazil's new AI framework compare to the FDA and EU MDR standards. * Why might your SaMD's risk classification change overnight in Brazil. * What specific cybersecurity vulnerabilities is ANVISA now targeting. * Has the Brazilian market become more challenging or more predictable for foreign SaMD companies. * How will this decision impact regulatory trends in other LATAM markets like Mexico and Colombia. * What are the immediate next steps your regulatory team must take to ensure compliance. Navigating these regulatory shifts requires local expertise and a global strategy. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using advanced AI and data tools to streamline global market access. We help you turn regulatory complexity into a competitive advantage. To secure your position in the evolving Latin American market, contact us at info@pureglobal.com or visit us at https://pureglobal.com/.

Pure Global: Brazil's Clinical Trial Overhaul - The MedTech Insider's Playbook

Tue, 09 Dec 2025 04:37:14 -0400

This week on LATAM MedTech Insights, we're diving into a groundbreaking regulatory shift in Brazil. For years, launching a clinical trial in Latin America's largest market was a high-risk gamble due to unpredictable and lengthy approval processes. Now, everything has changed. A new Clinical Research Statute is dismantling these old barriers, aiming to slash approval times and make Brazil a global hub for MedTech innovation. We explore the concrete changes to the ethics review system and what this means for international companies that had previously put their Brazilian market entry plans on hold. A U.S. MedTech startup with a novel cardiovascular device had to shelve its plans to enter Brazil because of the dreaded 18-month approval delays, which threatened their investment timeline. Now, the new law presents a clear, predictable path to starting their clinical trial in under six months, completely changing their strategic calculus for the LATAM region. This Episode’s Key Takeaways: - Why was Brazil’s old clinical trial system a major roadblock for MedTech innovators? - How exactly does the new Clinical Research Statute reduce approval timelines? - What is the role of the new INEP ethics board, and how does it differ from the old system? - Are the responsibilities for trial sponsors now easier to manage in Brazil? - What immediate steps should a foreign MedTech company take to leverage this new regulation? - Is Brazil poised to become the new leader for clinical research in Latin America? - What are the hidden risks or remaining challenges in this new regulatory environment? At Pure Global, we offer end-to-end regulatory consulting solutions to help MedTech and IVD companies navigate complex markets like Brazil. We combine local expertise with advanced AI and data tools to streamline global market access, from initial strategy and technical dossier submission to post-market surveillance. Let us be your local representative and strategic partner in over 30 markets worldwide. To turn these insights into your market success story, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Navigating Brazil's ANVISA RDC 751 & RDC 830: A Pure Global Guide to LATAM MedTech & IVD Market Access Success

Fri, 17 Oct 2025 19:38:02 -0400

This episode of LATAM MedTech Insights dives deep into the most significant regulatory shift in the region's largest market: Brazil. We explore ANVISA's new regulations, RDC 751/2022 for medical devices and RDC 830/2023 for IVDs, which align Brazil's framework more closely with international standards like the EU MDR. This is a critical update for any MedTech company looking to enter or expand its footprint in Latin America. We unpack what this harmonization means in practical terms. Consider this: a medical device company with CE marking for its product previously faced a complex, 18-month process to reformat its entire technical dossier for Brazil. Today, that same dossier can be leveraged to gain market access in a fraction of the time and cost. This episode explains how you can capitalize on this change and avoid common pitfalls during the transition. Key Takeaways: * How does Brazil's new RDC 751/2022 fundamentally change the market entry strategy for your medical device? * What is the critical June 1, 2024 deadline for IVD manufacturers under RDC 830/2023 and what must be done? * Can your existing EU or FDA technical documentation be used for a submission in Brazil now? * How does Brazil's regulatory shift compare to changes happening in Mexico and Colombia? * What are the key differences between the old 'cadastro' system and the new 'notificação' pathway? * Why is having an expert local representative in Brazil more crucial than ever under these new rules? * What are the most common mistakes companies make when transitioning their legacy products to the new regulations? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline your global market access, from initial strategy to post-market surveillance. To navigate the complexities of the LATAM market, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Unlocking LATAM MedTech: How Pure Global Leverages Market Intelligence on Colombia and Brazil for Strategic Entry

Thu, 16 Oct 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we explore why a one-size-fits-all approach to entering the Latin American medical technology market is a recipe for failure. The region is not a monolith but a collection of unique countries, each with its own distinct regulatory, economic, and healthcare systems. Success depends on moving beyond surface-level data and leveraging deep market intelligence. We dissect how granular market briefs provide the critical insights needed to build a winning go-to-market strategy. We contrast the opportunities in a market like Colombia, which heavily relies on imports, with the complex regulatory hurdles of a giant like Brazil. This episode will show you how the right data can illuminate your path, save you from costly mistakes, and give you a decisive competitive advantage. A Tale of Two Markets: Imagine targeting Colombia, where an 80% import dependency for medical devices signals a ready-made demand for your product. Now, picture Brazil, where your market entry is halted before it begins because you were unaware of the mandatory pre-submission GMP inspection by ANVISA. This single regulatory detail could delay your launch by over a year and add tens of thousands to your budget. Which path would you rather take? Key Takeaways: * Why is treating LATAM as a single market the most common strategic error? * What does Colombia's 80% import dependency really mean for your sales strategy? * How can Brazil's ANVISA pre-registration requirements completely alter your budget and timeline? * Beyond market size, what are the most critical data points a market brief must contain? * How does deep market intelligence inform your choice between direct entry and a distributor model? * What hidden regulatory hurdles could derail your launch in promising markets? * How can you leverage existing international approvals to potentially fast-track your LATAM entry? * What economic indicators should you monitor that directly impact medical device reimbursement? At Pure Global, we transform this critical data into actionable strategy. We offer end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline your global market access. Stop guessing and start strategizing. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can help you succeed in Latin America and beyond.

Pure Global's Deep Dive into Brazil: Mastering ANVISA MedTech Regulations with an Integrated Registration & PMS Strategy

Wed, 15 Oct 2025 19:38:02 -0400

Brazil's MedTech market offers immense opportunity, but its regulatory body, ANVISA, demands flawless execution. A fragmented approach, where different teams handle registration and post-market compliance, often leads to costly delays and strategic dead ends. This episode explores why an integrated strategy is non-negotiable for success. We break down the four pillars of Brazilian MedTech regulation: correct device classification, meticulous technical documentation in Portuguese, the critical choice of a Brazil Registration Holder (BRH), and robust post-market surveillance. Learn how these elements are interconnected and why managing them under one expert team provides a significant competitive advantage in this complex market. **A cautionary tale:** Imagine spending over a year and thousands of dollars to prepare your device registration, only to discover that the distributor you appointed as your local representative (BRH) has decided to partner with a competitor. Because they legally own your registration license, you have completely lost market access and must start the entire process from scratch, giving your competition a two-year head start. **In this episode, you will learn:** * Why is Brazil's four-class risk system more nuanced than it appears? * What are the most common documentation mistakes that lead to ANVISA rejections? * How can the choice of your Brazil Registration Holder (BRH) make or break your entire LATAM strategy? * Are you truly in control of your device registration if your distributor is your BRH? * What specific post-market surveillance activities does ANVISA require beyond simple adverse event reporting? * Why is having a single, integrated team for registration and post-market support a competitive advantage in Brazil? * What is BGMP certification and why is it non-negotiable for higher-risk devices? At Pure Global, we offer end-to-end regulatory solutions for MedTech and IVD companies. Our integrated approach combines local Brazilian expertise with advanced AI tools to streamline market access, from initial strategy to post-market surveillance. Contact us to learn how our unified team can de-risk and accelerate your entry into the Brazilian market. Email us at info@pureglobal.com or visit https://pureglobal.com/.

Fast-Track Your LATAM Entry: Pure Global’s Guide to Colombia’s Automatic Registration for Low-Risk MedTech and Navigating High-Risk Approvals.

Tue, 14 Oct 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we dive deep into the unique regulatory landscape of Colombia, a pivotal market for any device manufacturer looking to enter Latin America. We uncover how INVIMA's dual-track system offers a strategic gateway for MedTech companies that know how to leverage it. We explore the powerful "automatic registration" pathway for low-risk devices that can get your product to market and generating revenue faster than you think. We also break down the complexities and extended timelines associated with the rigorous pre-approval process for high-risk technologies, and how to plan for them effectively. A Case for Strategy: Imagine trying to launch your entire device portfolio, from simple monitors to complex implants, into a new continent at once. The pain point is the immense upfront cost and the years of waiting for approvals before seeing a single dollar in return. One company flipped this challenge on its head. They launched their Class I device in Colombia in just a few months, using the immediate cash flow to fund the lengthy, data-intensive registration for their groundbreaking Class III product. This is how a regulatory landscape becomes a competitive advantage. This episode's key takeaways: 1. What is Colombia's "automatic registration" and which specific devices qualify? 2. How can a fast-track for low-risk products actually fund your entire LATAM expansion? 3. What are the most common documentation pitfalls that lead to rejection in an "automatic" submission? 4. How do you prepare a technical dossier for a high-risk Class III device that satisfies INVIMA's stringent review? 5. Why is a staggered, portfolio-based market entry strategy essential for success in Colombia? 6. How does your Colombian approval act as a potential stepping stone for other LATAM markets? 7. What are the critical roles and responsibilities of a local Legal Representative in the INVIMA process? At Pure Global, we specialize in transforming complex regulatory landscapes into clear, actionable market access strategies. Our teams of local experts, powered by advanced AI and data tools, offer end-to-end solutions for MedTech and IVD companies. Whether you are navigating Colombia's INVIMA for the first time or expanding across the continent, we streamline your path to market. Ready to build your LATAM strategy? Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Cracking Argentina's ANMAT: A MedTech Manufacturer's Guide to Local Registration Success with Pure Global

Mon, 13 Oct 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we demystify the complex process of medical device registration in Argentina. We provide a detailed guide on navigating the requirements of the national regulatory authority, ANMAT, from appointing a local registration holder to preparing a compliant technical dossier in Spanish. We break down the critical steps and common pitfalls that can lead to costly delays and rejections. Learn why your choice of a local partner can make or break your market access strategy and how your existing international approvals, like CE or FDA, fit into the Argentinian framework. We share a real-world case where a simple oversight in device grouping strategy tripled a company's registration costs and delayed market entry by a full year, highlighting the financial and strategic importance of local know-how. Key questions answered in this episode: - Why is selecting the right Argentina Registration Holder (ARH) your most critical first step? - What are the specific Spanish language requirements for your technical file that most companies miss? - How can a proper device family strategy cut your ANMAT submission costs and timeline? - What is the one common document error that causes the longest delays with ANMAT's review clock? - Are your existing CE or FDA approvals enough to guarantee a smooth registration in Argentina? - What are the realistic timelines you should expect for ANMAT approval for different device classes? - How can you avoid having your registration "held hostage" by a local commercial partner? At Pure Global, we provide end-to-end regulatory solutions for MedTech companies seeking to enter or expand in Latin America. Our local experts in Argentina, combined with our advanced AI tools, streamline the ANMAT registration process, from strategy and dossier preparation to post-market compliance. Let us be your dedicated partner in unlocking this key market. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Pure Global's Guide to Peru: Navigating DIGEMID and the Essential Role of a Local Registration Holder for MedTech Success

Sun, 12 Oct 2025 19:38:02 -0400

Peru's MedTech market offers immense growth opportunities, but entry is strictly controlled by its regulatory authority, DIGEMID. A critical step for any foreign manufacturer is appointing a local representative, known as a Peru Registration Holder. This isn't just a formality—it's a foundational strategic decision that dictates your control over your own products in the country. In this episode, we explore why the common shortcut of letting a distributor hold your product registration can lead to significant business risks, including a complete loss of market access. We'll walk through the strategic advantages of appointing an independent, professional representative to ensure you maintain full control over your commercial strategy and long-term success in Peru. Here is a situation we explore: Imagine your medical device has been selling in Peru for two years. Your relationship with your distributor, who also holds your DIGEMID registration, has broken down. You decide to switch partners, only to discover the distributor refuses to transfer the registration. They legally own your access to the market. You are now faced with a devastating choice: stay with an underperforming partner or pull your product and start the costly, year-long registration process all over again. This is a real and preventable crisis. Key Takeaways: 1. What is the precise function of a "Peru Registration Holder" for DIGEMID? 2. Why is it a significant risk to let your distributor be your registration holder? 3. What are the legal implications of who owns your product registration in Peru? 4. How does an independent local representative provide crucial commercial flexibility? 5. What happens to your market access if your relationship with your distributor-holder ends? 6. What are the key steps in the DIGEMID registration process that a local representative handles? 7. How does having a dedicated representative help in navigating post-market surveillance in Peru? At Pure Global, we specialize in demystifying complex regulatory landscapes like Peru's. We provide independent, expert local representation, ensuring you retain full control over your assets while we handle the complexities of DIGEMID. Secure your market access and build a flexible, scalable LATAM strategy. Contact us to learn more at info@pureglobal.com or visit our website at https://pureglobal.com/.

Pure Global's LATAM MedTech Insights: Unlocking a Decade of Market Access with Colombia's 10-Year INVIMA Registration.

Sat, 11 Oct 2025 19:38:02 -0400

This episode of LATAM MedTech Insights dives into one of the most stable and attractive regulatory environments in Latin America: Colombia. We explore how INVIMA, the national regulatory authority, offers a clear and predictable pathway for medical device manufacturers, standing in contrast to the complexities found elsewhere in the region. We specifically focus on the significant strategic advantage of Colombia's ten-year registration validity for most medical devices. This episode unpacks how this long-term approval cycle can reduce administrative burdens, lower costs, and enable companies to focus on sustainable market growth instead of constant regulatory upkeep. A real-world pain point we address is the risk of losing market access. Imagine a company thriving in Colombia, only to realize their local partner missed the critical 90-day renewal submission deadline with INVIMA. This oversight forces their product off the market, jeopardizing distributor contracts and revenue streams, all of which could have been avoided with proactive regulatory management. In this episode, you will learn the answers to key questions: 1. Why is a 10-year registration validity a game-changer for your MedTech commercial strategy in LATAM? 2. What is the single most important deadline you cannot miss when renewing your INVIMA registration? 3. How does a reliable local representative in Colombia provide value beyond just submitting paperwork? 4. What are the common pitfalls that cause companies to lose their market access in Colombia, even with a long validity period? 5. How can you leverage your stable Colombian registration to plan for expansion into other Andean markets? 6. What key documents should you be preparing years in advance of your 10-year renewal? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. We act as your local representative in Colombia and over 30 other markets, ensuring your registrations are managed proactively and your market presence is secure. To learn more, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Navigating Brazil's 2025 UDI Mandate: A Pure Global Guide to ANVISA's SIUD for MedTech Success in LATAM

Fri, 10 Oct 2025 19:38:02 -0400

Brazil, Latin America's largest MedTech market, is implementing a mandatory Unique Device Identification (UDI) system, with a critical deadline for high-risk devices looming in mid-2025. This change, mandated by ANVISA's RDC 591/2021, requires immediate action from manufacturers to ensure their products remain on the market. This episode of LATAM MedTech Insights breaks down the essential steps for preparing for Brazil's UDI rollout. We explore the unique challenge where device labeling is required before the official government database (SIUD) is fully active, creating significant operational hurdles. We'll provide a clear roadmap for what your company needs to do right now to avoid costly disruptions to your Brazilian operations. **Case Study Highlight:** Imagine your company manufactures a Class IV cardiovascular stent. You have all the clinical approvals, but your product is suddenly blocked from entering Brazil on July 11, 2025. The reason is a non-compliant label. Your team waited for final guidance on the UDI database, but the fixed labeling deadline passed, halting your sales and forcing an expensive, rushed relabeling project. This scenario is avoidable, and this episode explains how. **What You'll Learn (本期干货):** * What is the crucial compliance date in 2025 that affects all Class IV medical devices in Brazil? * Why do you need to change your product labels now, even if the SIUD database isn't live? * How do ANVISA's UDI data requirements differ from those of the US FDA or European MDR? * What are the first three steps every manufacturer should take to begin their UDI implementation project? * What is the essential role of a Brazil Registration Holder (BRH) in this new process? * How can you manage the artwork and logistical challenges of a full labeling redesign? * What are the most common pitfalls companies face when preparing for a new UDI system? At Pure Global, we offer end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges like Brazil's UDI implementation. We combine local expertise with advanced AI tools to streamline your path to compliance. For support with regulatory strategy, technical dossier submission, or local representation in Brazil, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Unlocking Brazil's MedTech Market: A Pure Global Deep Dive into ANVISA's Class I/II Notification and High-Risk Registration Pathways

Thu, 09 Oct 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we demystify the complex world of Brazil's medical device regulations under ANVISA. We explore the critical differences between the faster 'Notificação' pathway for low-risk devices and the intensive 'Registro' full-review process for high-risk products, revealing why your strategy for one won't work for the other. This episode is for any MedTech company that sees Brazil as a key market but is concerned about the regulatory hurdles. We break down the real-world implications of each pathway, from documentation requirements to the formidable challenge of the Brazilian Good Manufacturing Practices (BGMP) audit, ensuring you understand exactly what it takes to succeed. Key questions answered in this episode: * Why is Brazil's ANVISA a two-speed system for medical devices? * What is the critical difference between the *Notificação* and *Registro* pathways? * Could your Class II device from the US or EU require a full, lengthy review in Brazil? * What is the BGMP audit, and why is it often the biggest hurdle for high-risk device manufacturers? * How can a local Brazil Registration Holder (BRH) make or break your market entry strategy? * Are you underestimating the documentation requirements for a "simple" notification? * How does proper device classification at the start save you months, or even years, in delays? Pure Global offers end-to-end regulatory consulting to streamline your global market access. We combine local expertise in over 30 markets with advanced AI to get your MedTech and IVD products to market efficiently. To develop your tailored regulatory strategy for Brazil or beyond, contact us at info@pureglobal.com or visit https://pureglobal.com/.

LATAM MedTech Insights by Pure Global: Unlocking the Mexican Market with COFEPRIS's New Abbreviated Pathway and Homologation Reforms

Wed, 08 Oct 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we explore the groundbreaking regulatory reforms in Mexico that are set to accelerate market access for medical device manufacturers. We break down the new COFEPRIS abbreviated pathway, which leverages approvals from other international regulatory bodies to streamline the registration process. This shift marks a significant opportunity for MedTech and IVD companies to enter one of Latin America's largest markets faster than ever before. We discuss the practical implications of these homologation reforms, detailing how leveraging existing clearances from authorities like the European Union can drastically cut down approval timelines and costs, turning a previously lengthy process into a strategic advantage. Consider a medical device company with a CE-marked product that was previously facing a potential 18-month review cycle with COFEPRIS. The pain of this delay meant losing critical market share to competitors already established in Mexico. We explore how, under the new abbreviated pathway, this company could now potentially achieve registration in under six months, transforming their entire market entry strategy for the LATAM region. Key Takeaways: * What specific international approvals does Mexico's COFEPRIS now recognize for its abbreviated pathway? * How does the new COFEPRIS-04-050 procedure fundamentally differ from the traditional, full review process? * What are the critical documentation requirements for leveraging a foreign approval under the homologation reform? * What common mistakes can lead to delays or rejections even when using the new accelerated route? * Why is appointing a qualified local registration holder in Mexico more important than ever with these new changes? * Does the abbreviated pathway apply equally to all classes of medical devices and IVDs? * How can you strategically assess if your product portfolio is a good fit for Mexico's new regulatory environment? At Pure Global, we specialize in transforming these complex regulatory shifts into clear, actionable market access strategies. Our team of local experts in Mexico, combined with our advanced AI and data tools, ensures your submission for the new abbreviated pathway is seamless, compliant, and efficient. Don't let regulatory complexity slow your expansion into Latin America. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to get started.

Pure Global's Guide to Mexico's MedTech Market: The Critical Role of the COFEPRIS Registration Holder (MRH)

Tue, 07 Oct 2025 19:38:02 -0400

Mexico presents a golden opportunity for MedTech companies, but its regulatory body, COFEPRIS, has a critical requirement: all foreign manufacturers must appoint a local Mexico Registration Holder (MRH). This entity doesn't just submit your paperwork; they legally own your product registration, a detail that can make or break your business in the region. This episode of LATAM MedTech Insights dives deep into the strategic importance of this decision. We explore the significant risks of appointing a distributor as your MRH and how this can lead to a loss of market control, and we outline the powerful advantages of partnering with an independent, professional registration holder to secure your investment and ensure long-term business flexibility. Here is a real-world example. A promising diagnostics company spent nearly two years achieving COFEPRIS approval, only to realize their underperforming distributor, who they appointed as their MRH, legally owned their market access. When they tried to switch to a better commercial partner, the distributor refused to transfer the registration, effectively holding their multi-million dollar market entry hostage. Key Questions from this Episode: 1. Who legally owns your MedTech registration in Mexico? 2. What are the hidden risks of appointing your distributor as your COFEPRIS Registration Holder? 3. How can you change commercial partners in Mexico without losing your registration and starting over? 4. What is the difference between a Registration Holder and a local distributor? 5. Why is an independent MRH considered the gold standard for market entry? 6. What clauses must be in your MRH agreement to protect your company? 7. How does the MRH role impact your post-market surveillance obligations? At Pure Global, we specialize in securing your market access. We act as your independent, professional Registration Holder in Mexico and over 30 markets worldwide, ensuring you always remain in control of your valuable registrations. Our end-to-end regulatory solutions, powered by local expertise and advanced AI, are designed to protect your assets and streamline your global expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Navigating LATAM MedTech Regulations for Surgical Instruments & ESUs: A Pure Global Guide to Brazil's ANVISA & Mexico's COFEPRIS

Mon, 06 Oct 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we dissect the complex regulatory pathways for two key medical device categories in Latin America: surgical instrument sets and electrosurgical units. We explore the fragmented nature of LATAM regulations, moving beyond generalities to offer specific, actionable insights. We delve into the critical "family grouping" strategies required by Brazil's ANVISA for large instrument sets and contrast them with the requirements of Mexico's COFEPRIS. For active devices, we uncover the often-overlooked mandatory electrical safety certifications, like INMETRO in Brazil, that can halt a product launch in its tracks, even after clinical approval seems within reach. A common pain point for manufacturers is seeing their state-of-the-art electrosurgical unit, with CE Marking and FDA clearance, get stuck for an extra nine months before entering the massive Brazilian market. The reason? They were unaware that their existing electrical safety test reports were not enough and that mandatory, in-country INMETRO testing was required from the start. This oversight leads to unforeseen costs, major timeline delays, and loss of first-mover advantage. Key questions answered in this episode: - How can I register a surgical set with over 100 instruments in Brazil without filing 100 separate applications? - What is the critical non-medical certification required for electronic devices in Brazil that many companies miss? - Why is a local "Registration Holder" non-negotiable for market access in countries like Mexico and Brazil? - How do the registration requirements for a simple scalpel differ from a complex electrosurgical generator in Colombia? - Why isn't my FDA 510(k) or CE Mark a direct passport for market entry in Latin America? - What are the realistic timelines for getting a medical device approved by ANVISA versus COFEPRIS? - How can a proactive regulatory strategy for LATAM save hundreds of thousands of dollars in potential delays? At Pure Global, we specialize in navigating these complexities. We offer end-to-end regulatory consulting solutions for MedTech and IVD companies, acting as your local registration holder and managing the entire submission process with our in-country experts and advanced AI tools. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can streamline your market access.

LATAM MedTech Insights by Pure Global: Unlocking the Anesthesia Equipment Market in Brazil, Mexico, and Beyond - A Regulatory Deep Dive

Sun, 05 Oct 2025 19:38:02 -0400

The Latin American market for anesthesia machines and equipment is expanding rapidly, driven by significant investments in both public and private healthcare infrastructure. This growth presents a massive opportunity for MedTech manufacturers, but it comes with a formidable challenge: a highly complex and fragmented regulatory environment that can stop even the most prepared companies in their tracks. In this episode, we unpack the practical realities of entering this lucrative market. We go beyond the surface-level data to explore the specific, detailed requirements of key regulatory bodies like Brazil's ANVISA and Mexico's COFEPRIS. We'll discuss the critical differences in procurement strategies between elite private hospitals and large-scale public health systems and reveal the common pitfalls that lead to costly delays and rejections. Here is a real-world scenario. A promising European MedTech company developed a cost-effective anesthesia ventilator perfect for the public hospital systems in Brazil. They invested heavily in a market launch, anticipating a quick approval based on their CE Mark. However, their submission was stalled for over two years due to an unexpected and lengthy audit requirement of their manufacturing facility by ANVISA, a detail buried deep in the regulations. This delay allowed a local competitor to capture the market share they were targeting. Key Takeaways This Episode: 1. Why is a 'one-size-fits-all' regulatory strategy for Latin America guaranteed to fail? 2. What is the single biggest non-documentary hurdle for registering Class III devices like anesthesia machines in Brazil? 3. How do Mexican regulators use FDA or Health Canada approvals, and what is the crucial catch that many companies miss? 4. Why might your sales strategy for a hospital in São Paulo be completely different from one for a public tender in Colombia? 5. What are the most common and costly mistakes in technical dossier preparation for ANVISA and COFEPRIS? 6. Is it possible to leverage a single registration process for multiple LATAM markets? 7. How has the post-pandemic shift impacted the demand for specific features in anesthesia equipment? 8. What role does a local, in-country registration holder play, and why is choosing the right one so critical? At Pure Global, we transform these complex regulatory challenges into clear market access strategies. Our end-to-end solutions for MedTech and IVD companies combine deep local expertise in over 30 markets with advanced AI and data tools to streamline your global expansion. Don't let regulatory hurdles dictate your growth potential. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure and accelerate your market access in Latin America.

The LATAM Diabetes Tech Boom: Pure Global's Guide to Regulatory Success for Blood Glucose Monitors in Brazil, Mexico, and Argentina.

Sat, 04 Oct 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we explore the immense opportunities and significant regulatory challenges of bringing blood glucose monitoring devices to the Latin American market. We uncover the specific demands of key regulatory bodies like Brazil's ANVISA, Mexico's COFEPRIS, and Argentina's ANMAT. We break down the complex, country-specific requirements that often trip up manufacturers. Imagine launching your state-of-the-art continuous glucose monitor in Brazil, only to be rejected by ANVISA after a year-long review because of an overlooked electrical safety certification. This common pitfall highlights the critical need for local expertise, a topic we dissect with real-world examples to help you avoid costly delays and gain a competitive edge. What you will learn in this episode: - What are the key regulatory differences between Brazil's ANVISA, Mexico's COFEPRIS, and Argentina's ANMAT? - How can a US FDA approval fast-track your device registration in Mexico? - What is the most common reason for ANVISA submission delays for blood glucose monitors? - Why is a certified Spanish translation more than just a language requirement for Argentina's ANMAT? - What is a Brazil Registration Holder, and why is it legally essential for market access? - How do local clinical data requirements impact CGM device approvals in the region? - What are the critical post-market surveillance responsibilities you cannot ignore in these markets? At Pure Global, we provide end-to-end regulatory consulting to help MedTech and IVD companies seamlessly access over 30 global markets, including the complex LATAM region. By combining our deep local expertise with advanced AI tools, we streamline your path to market. Let us be your local representative and strategic partner. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

The Goldmine and the Maze: Pure Global's Guide to Launching Orthopedic Surgical Implants in Brazil, Mexico, and Beyond.

Fri, 03 Oct 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we delve into the booming orthopedic surgical implant market across Latin America. We uncover why a successful market-entry strategy requires more than just a great product and existing international approvals. We explore the complex and fragmented regulatory landscapes of key countries like Brazil, Mexico, and Colombia, highlighting the critical differences that can make or break your expansion plans. We share a cautionary tale of a premier German knee implant company, holding a valid CE mark, that faced a two-year delay in entering the Mexican market. Their mistake was assuming their European clinical data and technical file would suffice. They were caught off guard by COFEPRIS's requirement for in-country biocompatibility testing and their local sales distributor's inability to navigate the intricate submission process, leading to a costly and frustrating stalemate. Key questions from this episode: -Why is Brazil's ANVISA known to reject submissions that are easily approved by the FDA or EMA? -What are the biggest risks of appointing a commercial distributor as your legal registration holder in Mexico? -How can you leverage your existing approvals to potentially speed up registration in Colombia? -What are the most common labeling mistakes that lead to rejection by Argentina's ANMAT? -How do post-market surveillance requirements for orthopedic implants differ between Brazil and Mexico? -Are there hidden costs associated with improper Spanish and Portuguese technical translations in your dossier? -Is it possible to build a core technical file that can be adapted for multiple LATAM countries? -What specific local clinical data do authorities demand for high-risk orthopedic devices? At Pure Global, we specialize in transforming these regulatory hurdles into market opportunities. We offer end-to-end solutions for MedTech companies, combining deep local expertise in over 30 markets with advanced AI tools to streamline your global market access. Let us be your strategic partner in navigating the complexities of LATAM. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Navigating LATAM's Heartbeat: A Pure Global Deep Dive into Brazil's ANVISA & Mexico's COFEPRIS for Cardiac Monitoring & ECG Device Approval

Thu, 02 Oct 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we delve into the rapidly expanding but notoriously complex market for cardiac monitoring and ECG devices in Latin America. We uncover why the region's high demand, fueled by demographic shifts and a growing healthcare sector in countries like Brazil, Mexico, and Argentina, presents both a massive opportunity and a significant challenge for global MedTech manufacturers. We explore the fragmented regulatory maze, moving beyond theory to discuss the practical realities of dealing with powerful agencies like Brazil's ANVISA and Mexico's COFEPRIS. We share a detailed case study of a European company whose launch of an innovative wearable ECG patch was delayed by 18 months due to a critical oversight in their Brazilian submission, illustrating how a small gap in local knowledge can lead to major commercial setbacks and loss of market share. 本期干货: - Why is Brazil’s ANVISA one of the most difficult regulatory bodies for cardiac device approval? - What are the three most common mistakes companies make when submitting technical files to COFEPRIS in Mexico? - How is the rise of telemedicine in Colombia changing the rules for market entry? - What specific in-country testing is required for ECG devices in Argentina that isn't required for a CE mark? - How can you design a single regulatory strategy to efficiently target Brazil, Mexico, and Colombia simultaneously? - What are the hidden costs associated with not having an experienced local registration holder? - How do reimbursement policies in public versus private healthcare sectors impact your product's profitability? The Latin American market holds immense potential, but navigating its regulatory and commercial landscape requires deep, localized expertise. At Pure Global, we transform these complex challenges into clear market access strategies. With our local experts in over 30 countries and advanced AI-driven data tools, we streamline the entire process from initial strategy to post-market surveillance. Don't let regulatory hurdles dictate your growth. Contact us to build your customized pathway into the LATAM market at info@pureglobal.com or visit us at https://pureglobal.com/.

Pure Global LATAM MedTech Insights: Cracking the Code of the Digital X-ray Market in Brazil, Mexico, and Colombia - Your Guide to ANVISA & COFEPRIS Regulatory Hurdles.

Wed, 01 Oct 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we delve into the burgeoning market for digital X-ray and radiographic equipment in Latin America. We explore the powerful growth drivers, from government healthcare modernization projects in Brazil to the booming private medical sector in Mexico, revealing why this region is a key target for global MedTech innovators. However, this opportunity is guarded by a maze of complex and fragmented regulations. We uncover the specific challenges of navigating distinct regulatory bodies like Brazil's ANVISA, Mexico's COFEPRIS, and Argentina's ANMAT. Imagine your company has a groundbreaking portable X-ray device ready to launch. You target Brazil and Mexico, only to find your market entry stalled for months. ANVISA demands a complete dossier overhaul in Portuguese, while COFEPRIS requires a separate, equally complex process in Spanish. This common scenario leads to mounting costs and lost market share, a critical pain point we address. What you'll learn in this episode: - Why is the LATAM digital X-ray market a key area for growth? - What are the crucial differences between registering a device with ANVISA in Brazil and COFEPRIS in Mexico? - How does the requirement for a local Brazil Registration Holder (BRH) affect your market entry strategy? - What common documentation and labeling mistakes lead to registration delays in countries like Colombia and Argentina? - Why is a 'one-size-fits-all' regulatory approach destined to fail in Latin America? - What role do public healthcare systems, like Brazil's SUS, play in driving demand for new radiographic equipment? - How can you transform a fragmented regulatory landscape into a streamlined, multi-market access strategy? At Pure Global, we turn these complex regulatory challenges into a streamlined pathway to market access. We offer end-to-end solutions, acting as your local representative and using advanced AI tools to manage technical dossiers and submissions across multiple LATAM markets simultaneously. Stop letting regulatory hurdles block your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Unlocking LATAM's Vision: Pure Global's Expert Guide to Endoscopic Imaging Market Access in Brazil, Mexico, and Colombia

Tue, 30 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we dissect the burgeoning market for endoscopic imaging systems in Latin America. We explore the massive opportunities in key countries and expose the intricate regulatory hurdles that often lead to costly delays and market access failures for international MedTech companies. We move beyond theory to discuss the practical realities of registering advanced medical devices in this high-growth region. From Brazil's demanding ANVISA documentation and INMETRO certification to Mexico's unique COFEPRIS requirements and the critical need for a local legal representative, we provide actionable insights for manufacturers. Learn how to avoid common pitfalls and strategize for a successful launch across multiple LATAM markets. **Case Study:** A German MedTech innovator developed a state-of-the-art endoscopic camera with AI-driven diagnostic capabilities. They targeted Brazil's advanced private hospital network, but their launch was stalled for over a year. Their fatal error was assuming their CE marking would streamline the process. They were unprepared for ANVISA's demand for local clinical data to validate the AI algorithm on a Brazilian population and failed the initial INMETRO electrical safety inspection, forcing a product redesign and restarting a lengthy certification process. **Key Takeaways:** * Why might your existing clinical data be rejected by Brazil's ANVISA, and what can you do about it? * What are the critical differences between appointing a distributor versus an independent entity as your legal representative in Mexico? * How can INMETRO certification in Brazil become a hidden cause for significant product launch delays? * What specific dossier and labeling requirements for Colombia's INVIMA often get overlooked by foreign manufacturers? * How do you build a regulatory strategy that allows for a single, efficient submission process across multiple LATAM countries like Peru and Argentina? * What are the most common mistakes in translating technical documentation for Spanish and Portuguese-speaking regulatory bodies? **Unlock LATAM with Pure Global.** Navigating the fragmented regulatory systems of Latin America is a significant challenge. At Pure Global, we transform this complexity into a clear path to market. Our integrated solution combines in-country experts in Brazil, Mexico, Colombia, and beyond with advanced AI tools to streamline your registration process. We provide end-to-end support, from regulatory strategy and technical dossier submission to acting as your local legal representative and managing post-market surveillance. Don't let regulatory hurdles block your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to accelerate your entry into the LATAM MedTech market.

Unlocking LATAM's MedTech Potential: Pure Global's Guide to Navigating the Infusion Pump Market in Brazil, Mexico, and Colombia

Mon, 29 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we explore the lucrative yet complex market for infusion pumps in Latin America. As hospitals across the region upgrade their technology for better patient outcomes, the demand for advanced medication delivery systems is at an all-time high. However, gaining market access is a formidable challenge, with each country's regulatory agency—from Brazil's ANVISA to Mexico's COFEPRIS—imposing unique and stringent requirements. We uncover the specific hurdles manufacturers face, from lengthy manufacturing audits to critical translation errors that can derail a product launch. For instance, a leading MedTech company faced a nine-month delay in Mexico because their user manual's Spanish translation was not adapted to local clinical terminology, forcing a complete resubmission to COFEPRIS and a costly delay in revenue. Key Takeaways in this Episode: - Why does Brazil's ANVISA require an in-person audit of your factory, and how long could it delay your market entry? - What is the single most common submission mistake that leads to rejection by Mexico's COFEPRIS? - How can your existing FDA or CE Mark approval accelerate your registration in Colombia? - Why is having a local, in-country representative a non-negotiable for MedTech registration in LATAM? - What are the documentation requirements for a high-risk Class III device like an infusion pump? - How is the shift from standard IV drips to "smart pumps" creating new opportunities in the region? - What are the key differences between the 'Registro' and 'Cadastro' pathways in Brazil? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative and registration holder, developing efficient pathways for regulatory approval across more than 30 countries. To overcome these challenges and unlock the LATAM market, contact us at info@pureglobal.com or visit https://pureglobal.com/.

LATAM's New Breath: Navigating Brazil's Ventilator Surplus and Mexico's Regulatory Maze in Respiratory MedTech with Pure Global.

Sun, 28 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we move beyond the headlines of the pandemic to uncover the real state of the respiratory device market in Latin America. The urgent rush for ventilators has subsided, leaving behind a complex landscape of equipment surplus, shifting clinical needs, and formidable regulatory barriers. We explore how the focus is moving from emergency ICU equipment to long-term solutions for chronic conditions like COPD and sleep apnea, creating new opportunities for agile MedTech companies. Imagine you are a MedTech innovator with a cutting-edge respiratory device, ready to tap into the burgeoning Brazilian market. Your launch is stalled for months because the regulatory body, ANVISA, rejects your submission on a technicality that was buried in local-language guidelines. This common but costly scenario is the focus of our discussion, highlighting how navigating the unique regulatory maze of each LATAM country is the key to success. What you'll learn in this episode: 1. Why is the post-pandemic ventilator surplus a multi-million dollar opportunity for service and maintenance companies? 2. How is the demand for home-care respiratory devices changing the market in Mexico and Argentina? 3. What are the top 3 regulatory mistakes foreign companies make when submitting to ANVISA in Brazil? 4. Why is securing a local registration holder in Colombia so difficult and what are the risks? 5. Are local manufacturers a credible threat to established international brands? 6. How can you leverage your existing FDA or CE mark for a faster pathway in countries like Peru and Chile? 7. What specific clinical data do LATAM regulators want to see for respiratory devices? 8. How is telehealth integration becoming a key differentiator for new products in the region? At Pure Global, we transform these regulatory complexities into clear market access strategies. We provide end-to-end regulatory consulting and act as your official local representative in over 30 markets, including Brazil, Mexico, and Colombia. Our combination of local experts and advanced AI tools streamlines the submission process to authorities like ANVISA and COFEPRIS, getting your products to market faster. Don't let bureaucracy block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to get started.

Navigating Brazil & Mexico's Hemodialysis Market: A Pure Global Guide to ANVISA and COFEPRIS for MedTech Innovators in LATAM

Sat, 27 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we explore the rapidly growing but complex market for hemodialysis machines and dialyzers in Latin America. We uncover the key drivers behind the region's multi-billion dollar renal care industry, focusing on the specific regulatory, logistical, and commercial hurdles in key countries like Brazil, Mexico, and Colombia. We examine real-world scenarios where manufacturers have faced significant delays and strategic pivots. For example, a European dialyzer company with full CE marking was stalled for over a year trying to enter Brazil, simply because they were unprepared for the mandatory in-person ANVISA inspection of their overseas facility. This single oversight cost them millions in potential revenue and market share. We break down why such situations are common and how they can be avoided. Key Takeaways: - Are you prepared for the unique Brazilian GMP certification process required by ANVISA before your product can be sold? - How does your market entry strategy for Mexico account for COFEPRIS's specific dossier and labeling requirements? - What are the key differences in reimbursement models between Colombia and Argentina that could impact your sales strategy? - How can you build a resilient supply chain to handle customs and distribution challenges across diverse LATAM territories? - Is partnering with local dialysis clinics a better strategy than direct sales for your technology? - What are the post-market surveillance requirements you must maintain to ensure long-term compliance in the region? - How can you leverage your existing registrations to fast-track entry into smaller but growing markets like Peru and Chile? Navigating the complexities of the Latin American MedTech market is a challenge. At Pure Global, we offer end-to-end regulatory consulting solutions, combining local expertise with advanced AI to streamline global market access. We act as your local representative and registration holder, managing everything from initial strategy to post-market surveillance. Contact us to accelerate your growth in Latin America at info@pureglobal.com or visit https://pureglobal.com/.

Cracking the Code of LATAM MedTech with Pure Global: A Deep Dive into Peru's Supreme Decree 016-2011-SA and its Impact on Medical Device Registration

Fri, 26 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we demystify the medical device registration process in Peru by taking a close look at the foundational regulation: Supreme Decree Nº 016-2011-SA. We explore how the national authority, DIGEMID, uses a risk-based classification system and what this means for your specific device. We break down the critical requirements that often create barriers for foreign manufacturers, including the mandatory appointment of a Peruvian Registration Holder (PRH) and the specific documentation needed for your submission dossier. This episode provides essential, practical insights for any MedTech company considering Peru as their next market. A Real-World Challenge: Imagine your company has a CE-marked Class III device ready for the LATAM market. You find a distributor in Peru, but your shipment is stopped at customs. Why? Because you didn't appoint a Peruvian Registration Holder (PRH) and your technical dossier wasn't submitted to DIGEMID according to the specific rules of Supreme Decree 016-2011-SA. This episode breaks down how to avoid this costly and time-consuming mistake. What you'll learn in this episode: 1. What is the primary role of Supreme Decree 016-2011-SA in Peru's MedTech landscape? 2. How does Peru's risk classification system (Class I-IV) impact your registration strategy? 3. Why is a Peruvian Registration Holder (PRH) mandatory for all foreign manufacturers? 4. What is a Certificate of Free Sale, and why is it critical for your application to DIGEMID? 5. What are the most common documentation and language pitfalls for companies entering Peru? 6. How long is a Sanitary Registration valid, and what does the renewal process involve? 7. What are the key differences in requirements for low-risk versus high-risk devices? At Pure Global, we specialize in transforming these regulatory hurdles into market opportunities. We offer end-to-end solutions, from acting as your local Peruvian Registration Holder to compiling and submitting your technical dossiers with our advanced AI tools. Stop letting complex regulations slow down your LATAM expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to streamline your market access.

Navigating Chile's Technovigilance Maze: A Pure Global Breakdown of Resolution 1618/2020 for MedTech Market Access in LATAM

Thu, 25 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we provide a detailed analysis of Chile's Resolution Exenta No. 1618/2020, a landmark regulation that established a strict technovigilance framework for medical devices. We dissect the specific reporting obligations, mandatory timelines, and the critical role of the in-country legal representative. This session moves beyond theory to explore the practical challenges and common mistakes foreign manufacturers face when dealing with the Chilean health authority (ISP). We unpack the nuances of identifying trends from seemingly minor incidents and explain how failure to comply can lead to significant regulatory penalties and loss of market access. **What You’ll Learn:** * What is the precise definition of a "reportable adverse event" under Chilean law? * Are you aware of the crucial 10-day vs. 30-day reporting deadlines? * How can a series of minor device malfunctions escalate into a major compliance issue? * Why is your local Chilean representative absolutely essential for successful technovigilance reporting? * What are the most common reporting errors that foreign companies make with the ISP? * How can you differentiate between an isolated incident and a reportable trend? * What are the documentation expectations for an initial adverse event report versus a final one? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Let us be your local representative and navigate complex regulations for you. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Pure Global's MedTech Guide: Mastering Brazil's ANVISA RDC 497/2021 for Your Device Registration and GMP Certification Update

Wed, 24 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we dissect the crucial updates to Brazil's medical device regulations, specifically ANVISA's RDC 497/2021 and the recent amendment RDC 850/2024. We explore how these resolutions have fundamentally changed the administrative process for obtaining and renewing the essential Brazilian Good Manufacturing Practice (B-GMP) certificate. We uncover why the recent extension of B-GMP validity from two to four years makes a flawless submission more critical than ever. We'll walk you through a real-world case study of a diagnostic device manufacturer that faced a three-month market lockout due to minor administrative errors in their renewal application, highlighting the costly pitfalls of navigating these new standardized procedures without expert local knowledge. Key questions answered in this episode: 1. What is the true impact of RDC 497/2021 on my existing Brazilian device registration? 2. How did the recent RDC 850/2024 amendment change the game for B-GMP certificate renewals? 3. What are the most common and costly administrative pitfalls when submitting documents to ANVISA's Solicita system? 4. Why is a simple document codification error now enough to get my entire submission rejected? 5. How far in advance should I begin my B-GMP renewal process to avoid market disruption? 6. What specific steps can I take to ensure my technical dossier is compliant with the latest requirements? 7. How can I turn these regulatory updates into a strategic advantage for my company in Brazil? At Pure Global, we transform regulatory complexity into market access. Our team of local experts, powered by advanced AI tools, offers end-to-end solutions for MedTech and IVD companies in over 30 markets, including Brazil. From initial strategy to post-market surveillance, we act as your local representative to ensure your products reach the market efficiently and remain compliant. Don't let administrative hurdles block your growth in Latin America. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Information Not Found

Tue, 23 Sep 2025 19:38:02 -0400

A response indicating that the requested information could not be found.

Unlocking the Colombian MedTech Market: A Pure Global Expert Guide to Medical Device Registration under Decree 4725 of 2005

Mon, 22 Sep 2025 19:38:02 -0400

This episode of LATAM MedTech Insights offers a detailed guide to registering your medical device in Colombia, focusing on the foundational regulation, Decree 4725 of 2005. We break down the essential requirements set by Colombia's regulatory authority, INVIMA, providing manufacturers with a clear roadmap for successful market entry into one of Latin America's most dynamic healthcare markets. Imagine your company has developed an innovative Class IIb diagnostic device. You are ready to tap into the Colombian market, but your submission is rejected by INVIMA. The reason is a failure to properly appoint a local legal representative and your Instructions for Use (IFU) were not translated into Spanish according to specific regulatory standards. This single oversight delays your launch by over six months, allowing competitors to establish their footprint. This episode provides the details to avoid such costly mistakes. Key Takeaways: 1. What are the four distinct risk classifications for medical devices under Decree 4725 of 2005? 2. Does your product qualify for the faster "automatic registration" pathway in Colombia? 3. Why is a Certificate of Free Sale (CFS) from your device's country of origin an absolute must-have for your INVIMA submission? 4. What are the legal responsibilities of the mandatory in-country representative in Colombia? 5. What are the specific Spanish-language labeling requirements that can lead to an application's rejection? 6. How long is a medical device registration valid in Colombia, and what should you know about the renewal process? 7. What key technical documents are required by INVIMA for a Class IIb or Class III device submission? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions, from market strategy and local representation to AI-powered technical dossier preparation, ensuring your path to the Colombian market is efficient and successful. For expert guidance, contact us at info@pureglobal.com or visit us at https://pureglobal.com/.

LATAM MedTech Insights by Pure Global: Mastering Argentina's ANMAT Renewal Under Disposition 2318/2002 to Secure Your Market Access.

Sun, 21 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we demystify the seemingly simple but highly nuanced process of renewing medical device registrations in Argentina. We take a close look at the specific requirements outlined in ANMAT's Disposition 2318/2002, focusing on the critical 90-day submission deadline and the legally binding "sworn declaration." We explore the common pitfalls that can lead to costly delays and even market withdrawal. A minor change in your product's documentation or manufacturing process, considered insignificant in other markets like the EU or USA, could completely invalidate your renewal application in Argentina, forcing you into a lengthy and expensive new registration process. **What You'll Learn:** - What is the absolute deadline for submitting your renewal application to ANMAT, and what are the consequences of missing it? - How does ANMAT's definition of a "significant change" differ from that of the FDA or European Notified Bodies? - Why could a simple update to your Instructions for Use (IFU) derail your entire renewal? - What specific information is included in the "sworn declaration," and what are the legal risks involved? - When is a renewal not an option, forcing you to file for a completely new registration? - What is the critical role of the Authorized Local Representative (ARL) in ensuring a smooth renewal process? Struggling to keep up with the diverse and evolving regulatory requirements across Latin America? At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline global market access, acting as your local representative in over 30 markets, including Argentina. Let us help you ensure your products remain compliant and accessible. Contact us today at info@pureglobal.com or visit https://pureglobal.com/ for a consultation.

Pure Global Presents LATAM MedTech Insights: Mastering Mexico's NOM-241 GMP for Medical Device Manufacturing Success

Sat, 20 Sep 2025 19:38:02 -0400

This episode of LATAM MedTech Insights provides a detailed analysis of Mexico's mandatory Good Manufacturing Practices (GMP) standard, NOM-241-SSA1-2021. We explore the critical requirements for medical device manufacturers, importers, and distributors operating in Mexico, focusing on the pillars of a compliant Quality Management System (QMS), risk management, and supply chain control. We break down what COFEPRIS, Mexico's health authority, looks for during an audit and why simply being ISO 13485 certified is not enough. This episode is essential for any MedTech company looking to leverage Mexico's manufacturing advantages and access one of the largest markets in Latin America. We also look ahead to the upcoming changes with the 2025 version of the standard, helping you stay ahead of the regulatory curve. Consider this real-world scenario: a U.S. MedTech scale-up invests millions in a state-of-the-art manufacturing facility in Jalisco, aiming to supply the entire LATAM region. However, their market launch is halted after a COFEPRIS audit. The reason? Their risk management files were deemed static, and their supplier validation for a critical component sourced from Asia lacked the specific traceability data required by NOM-241, jeopardizing their entire investment and market-entry strategy. What You'll Learn: 1. Why is NOM-241 a mandatory gateway to the Mexican market and not just a guideline? 2. What are the core pillars of a Quality Management System that COFEPRIS auditors scrutinize? 3. How does NOM-241's approach to technovigilance impact the entire product lifecycle? 4. What are the most common documentation gaps that lead to GMP compliance failures in Mexico? 5. Are your supplier qualification processes robust enough for the standard's strict requirements? 6. How can you prepare your facility for the upcoming changes in the 2025 version of NOM-241? 7. Why might your existing quality certifications be insufficient for gaining approval in Mexico? 8. What specific risk management activities must be continuously updated to maintain compliance? Navigating complex local regulations like NOM-241 is critical for success. At Pure Global, we offer end-to-end regulatory consulting for MedTech companies, combining deep local expertise in over 30 markets with advanced AI tools to streamline your global market access. From initial regulatory strategy to acting as your local representative, we ensure your path to compliance is clear and efficient. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Cracking the Code of Mexican MedTech: Pure Global's Guide to NOM-137-SSA1-2008 Labeling for LATAM Success

Fri, 19 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we explore the intricate details of Mexico's medical device labeling standard, NOM-137-SSA1-2008. As one of Latin America's largest MedTech markets, Mexico presents a huge opportunity, but access is strictly controlled by its regulatory body, COFEPRIS. We break down the most common mistakes foreign manufacturers make, from language requirements to the specific data that must be present on your packaging. Learn how to navigate the nuances of primary versus secondary labels, the correct way to use supplementary stickers, and why your local distributor's information is a critical component for avoiding customs delays. Case Study: Imagine your multi-million dollar shipment of medical devices, fully approved in the US and EU, gets stuck indefinitely in Mexican customs. The reason? A single line of missing text on a small sticker. We explore a real-world scenario where a simple labeling mistake involving the distributor's address cost a company months of delays and significant financial loss—a completely avoidable problem. Key questions answered in this episode: 1. Why is simply translating my existing label into Spanish not enough for COFEPRIS?. 2. What specific information about my Mexican distributor must be on the packaging?. 3. How do labeling rules differ for primary sterile packaging versus the outer box?. 4. Can I use stickers to add Mexican requirements, and what are the rules to avoid rejection?. 5. What is a Sanitary Registration number and where must it appear on my label?. 6. Are there upcoming changes to NOM-137 that I need to be aware of right now?. 7. How must the 'Hecho en' (Made in) information be formatted to ensure compliance?. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Let us help you navigate the complexities of markets like Mexico. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

LATAM MedTech Insights: A Pure Global Guide to Brazil's INMETRO Ordinance 384/2020 for Medical Device Compliance and Market Access

Thu, 18 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we demystify the mandatory INMETRO certification for electro-medical devices in Brazil. We break down the critical requirements of Ordinance 384/2020, a regulation that serves as a vital gatekeeper to one of Latin America's most significant markets. We'll guide you through the conformity assessment process, from selecting a Certification Body to undergoing factory audits and product testing. We explore the distinct roles of ANVISA and INMETRO, clarifying how they work together and what manufacturers must do to satisfy both. We highlight common pitfalls, such as assuming your existing FDA or CE mark documentation is sufficient, and provide actionable insights to ensure a smoother path to certification. This episode is essential listening for any MedTech company planning to sell electro-medical devices in Brazil. A real-world example. A promising European MedTech scale-up developed an innovative portable ultrasound device. They secured CE marking and assumed their technical file was robust enough for global markets. Upon targeting Brazil, they were blocked for months. Their challenge was not the quality of their device, but their failure to understand the nuances of INMETRO's audit process under Ordinance 384/2020, which required specific traceability protocols not emphasized in their EU audit. This oversight led to costly delays and a scramble for local regulatory expertise. Key Takeaways This Episode: 1. What is the fundamental difference between ANVISA's market registration and INMETRO's conformity assessment? 2. How do you select the right INMETRO-accredited Certification Body for your device? 3. What are the three most common documentation mistakes that lead to delays in the certification process? 4. What can you expect during the mandatory on-site factory audit, regardless of your global location? 5. Are INMETRO certificates truly valid indefinitely, and what is the catch? 6. Why is the INMETRO Conformity Identification Seal more than just a label? 7. How can you leverage your Brazil registration strategy for other markets in Latin America? At Pure Global, we transform these complex regulatory hurdles into clear pathways for market access. Our team of local experts, powered by advanced AI and data tools, offers end-to-end solutions for MedTech and IVD companies. From initial regulatory strategy and technical dossier submission to acting as your local representative, we streamline your entry into over 30 global markets, including Brazil. Don't let regulatory complexities be a barrier to your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can accelerate your global expansion.

Pure Global's Deep Dive into ANVISA RDC 751/2022: Unlocking Brazil's MedTech Potential for Global Innovators

Wed, 17 Sep 2025 19:38:02 -0400

This episode of LATAM MedTech Insights unpacks the significant changes introduced by Brazil's new medical device regulation, ANVISA RDC 751/2022. We explore how this new framework moves Brazil towards harmonization with international standards, particularly the EU MDR, and what this means for global MedTech companies. We break down the practical impact of the updated risk classification system and the new technical dossier structure. This shift is a game-changer for manufacturers, promising to reduce complexity, time, and cost when entering Latin America's largest market. **Case Study:** Imagine a US-based MedTech scale-up with an innovative patient monitoring system that has already achieved CE marking in Europe. They view Brazil as a critical growth market but are hesitant due to its reputation for complex, unique regulatory requirements. Their primary pain point is the fear of investing months of work and significant capital to completely re-author their technical documentation just for one market. RDC 751 directly solves this by allowing them to leverage their existing EU MDR-compliant dossier, turning a potential roadblock into a streamlined entry point. **Key Takeaways From This Episode:** * How does the new four-tier risk classification system under RDC 751 affect your market entry strategy for Brazil? * What specific sections of your existing EU MDR or FDA technical file can now be repurposed for an ANVISA submission? * Are there changes to the requirements for Brazilian Good Manufacturing Practice (B-GMP) certification? * How does the new regulation impact the need for and the role of a local Brazil Registration Holder? * What are the updated pathways for low-risk versus high-risk devices, and how do they affect your launch timeline? * How will ANVISA's alignment with the IMDRF framework change your future global registration planning? * What are the key considerations for post-market surveillance under the new RDC 751? At Pure Global, we specialize in turning regulatory complexity into market opportunity. With our local expertise in Brazil and advanced AI tools, we offer end-to-end solutions to streamline your ANVISA registration process under RDC 751. Let us be your partner in unlocking the potential of the LATAM market. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

LATAM MedTech Insights: Pure Global's Guide to Brazil's 30-Day ANVISA Approval for Class II SaMD

Tue, 16 Sep 2025 19:38:02 -0400

Brazil's MedTech market is one of the largest in Latin America, but its regulatory landscape, governed by ANVISA, can seem complex. Many SaMD companies overestimate the time and difficulty of market entry, missing out on significant opportunities. This episode demystifies the process for Class II Software as a Medical Device. We reveal the streamlined 'notificação' pathway, a simplified notification process that can lead to market approval in as little as 30 days. We walk through a real-world example of a dermatology AI app, detailing how proper preparation of the technical dossier and leveraging local expertise led to a rapid and successful market launch, avoiding common delays that can stall companies for months. What you'll learn in this episode: - What is the difference between ANVISA's 'notificação' and 'registro' pathways? - How can a Class II SaMD be approved in under 30 days in Brazil? - What are the essential documents required for a successful SaMD submission? - Why is a Brazil Registration Holder (BRH) mandatory for foreign companies? - What are the most common mistakes that cause delays in ANVISA's review? - How does regulation RDC 751/2022 impact your device classification? - What specific cybersecurity information does ANVISA expect for a SaMD? At Pure Global, we specialize in transforming complex regulatory challenges into clear, actionable market access strategies. With our end-to-end solutions combining local expertise in over 30 countries and advanced AI tools, we help MedTech and IVD companies accelerate their global expansion. Contact us to streamline your entry into the LATAM market. Email us at info@pureglobal.com or visit us at https://pureglobal.com/.

Navigating Colombia's MedTech Market with Pure Global: Why Your Choice of Local Representative for INVIMA Registration is Mission-Critical for LATAM Success

Mon, 15 Sep 2025 19:38:02 -0400

Colombia's MedTech market is one of the fastest-growing in Latin America, offering significant opportunities for global manufacturers. However, navigating its regulatory landscape, managed by INVIMA, presents a unique challenge that can make or break your market entry strategy: the mandatory local legal representative. This episode of LATAM MedTech Insights unpacks this critical requirement. We explore why simply appointing your in-country distributor can be a catastrophic mistake, leading to a loss of control over your own product registration and effectively locking you out of the market. We'll detail the precise role of a legal representative and how choosing an independent partner ensures your business remains agile and in control of its own destiny. Imagine this scenario. You've successfully registered your medical device in Colombia through your distributor. After two years of building the brand, you decide to switch to a new commercial partner for better market penetration. That's when you get the bad news. Your distributor refuses to transfer the registration, which is legally in their name. Your only option is to start the entire expensive and time-consuming registration process from scratch, leaving you unable to sell your product for over a year. In this episode, you will learn the answers to these critical questions: - Why does INVIMA mandate a local representative for all foreign medical device companies? - What are the hidden legal and commercial risks of appointing your distributor as your representative? - How can you permanently lose the rights to your own device registration in Colombia? - What is the crucial difference between a commercial partner and a professional regulatory representative? - What are the key responsibilities a local representative handles beyond just submitting paperwork? - How does an independent representative give you the power to change your sales strategy without regulatory delays? - What specific qualities should you look for when selecting a local representative in Colombia? At Pure Global, we act as your professional, independent legal representative in Colombia and over 30 markets worldwide. We secure your registrations in your name, giving you the freedom to build the best commercial strategy for your products. Don't let a simple mistake lock you out of a key market. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we provide a secure and efficient pathway into Latin America.

Cracking COFEPRIS: Pure Global's Essential Guide to Mexico's Software Medical Device Labeling and Spanish Language Requirements

Sun, 14 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we explore the essential labeling and language regulations for Software as a Medical Device (SaMD) in Mexico. We unpack the specific requirements set by the national regulatory body, COFEPRIS, and highlight the critical importance of Spanish language localization for a successful market entry. We discuss a common pitfall through a case study: an innovative SaMD company faces a costly six-month delay in their COFEPRIS application. The reason? While all their documents were translated, the software's user interface, including simple menus and error messages, was left in English—a critical oversight that made their product non-compliant. This episode details how to avoid this and other regulatory hurdles. Key questions answered in this episode: - What is the single most important language requirement for medical device software in Mexico? - Which specific Mexican Official Standard (NOM) governs all labeling rules? - Does the language requirement apply to the software's user interface and error messages? - What specific information must be included in the electronic label of a SaMD? - How can a simple localization mistake lead to significant delays and costs with COFEPRIS? - Where must labeling information be placed for software that is downloaded versus distributed on physical media? - Why is treating translation as a final step a major risk for your market access strategy? At Pure Global, we specialize in streamlining global market access for MedTech companies. Our team combines local expertise with advanced AI tools to manage your entire regulatory lifecycle, from initial strategy and technical dossier submission to post-market surveillance. Let us be your local representative in Mexico and over 30 other markets. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Unlocking Brazil's SaMD Market: Why ISO 13485 Isn't Enough and How MDSAP is Your Key to Faster ANVISA Approval with Pure Global

Sat, 13 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we dissect the complex world of SaMD registration in Brazil. We go beyond the surface-level question of certifications and explore the strategic nuances that can define your success in Latin America's largest market. We explain why simply having an ISO 13485 certificate, the global standard for quality management, is not enough to get your software approved by ANVISA. We uncover the critical role of Brazilian Good Manufacturing Practices (BGMP) and reveal how the Medical Device Single Audit Program (MDSAP) can be your most powerful tool. Learn how leveraging MDSAP can slash your time-to-market from years to months, giving you a significant competitive advantage. Imagine you've developed a groundbreaking AI diagnostic tool. You have your ISO 13485 certificate and are ready to launch in Brazil. You submit to ANVISA, only to be told the wait for a mandatory quality system inspection is over two years long. Your entire commercialization plan is on hold. Meanwhile, your competitor, who also has ISO 13485 but strategically invested in an MDSAP certification, uses it to bypass the inspection queue. They are on the market in six months, capturing key clients while you are still waiting. This episode tells you how to be the competitor who wins. This episode's key takeaways: - Why is an ISO 13485 certificate insufficient for your ANVISA SaMD submission? - What exactly is Brazilian BGMP and which device classes require certification before market entry? - How can the MDSAP program reduce your time-to-market in Brazil by over 18 months? - Are lower-risk SaMD exempt from quality system requirements in Brazil? - What is the difference between a *notificação* and a *registro* pathway for SaMD? - Which specific Brazilian regulation, RDC 657/2022 or RDC 751/2022, governs your software's requirements? - How does a weak regulatory strategy create a two-year competitive disadvantage? At Pure Global, we specialize in turning regulatory hurdles into market opportunities. We offer end-to-end regulatory consulting for MedTech and IVD companies, combining local LATAM expertise with advanced AI tools to streamline your global market access. Let us be your local representative and build the most efficient regulatory pathway for your technology. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global's Insider Guide: Fast-Tracking Foreign AI Medical Device Registration with Mexico's COFEPRIS, a Deep Dive for MedTech Innovators.

Fri, 12 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we demystify the process of registering a foreign-made AI medical device in Mexico. As one of Latin America's largest and most promising markets, Mexico presents a significant opportunity for MedTech innovators. However, its regulatory body, COFEPRIS, has unique requirements that can stall market entry if not navigated correctly. We explore why COFEPRIS treats AI and Software as a Medical Device (SaMD) differently than other global agencies and reveal the single most effective strategy for expedited approval: the Equivalency Agreement. Learn how leveraging your existing FDA, Health Canada, or Japan MHLW clearance can cut your registration timeline in half. We will walk through a real-world case study of a U.S. company that successfully used this pathway, highlighting the critical documents and local requirements they needed to succeed. **This episode's key questions:** - What is the number one mistake foreign companies make when classifying their AI medical device for COFEPRIS? - How can your existing FDA clearance reduce your Mexico market entry timeline from over a year to just a few months? - Why is a Mexican Registration Holder (MRH) legally mandatory before you even submit your application? - What are the specific translation and labeling requirements that COFEPRIS strictly enforces? - How does the risk classification for a software-only device work without a physical component? - What common post-market surveillance duties for AI devices in Mexico often go overlooked? - Are there hidden fees in the COFEPRIS registration process that can surprise foreign applicants? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. If you're looking to enter the complex but rewarding Mexican market, let our experts guide your strategy. Contact us at info@pureglobal.com or visit https://pureglobal.com/ for more information.

Unlocking Brazil: Pure Global's Guide to ANVISA's Clinical Data Requirements for SaMD in LATAM

Thu, 11 Sep 2025 19:38:02 -0400

This episode of LATAM MedTech Insights dives deep into the complex world of clinical data requirements for Software as a Medical Device (SaMD) seeking approval from Brazil's regulatory body, ANVISA. We unpack the critical regulation RDC 657/2022 and explain how ANVISA's risk-based classification system directly dictates the level of clinical evidence your company must provide. We explore the specific pathways for both low-risk and high-risk SaMD. Learn what kind of evidence can be used for simpler devices and understand the rigorous demands for more complex, high-impact software. We highlight common pitfalls and strategic considerations that can make or break your market entry into one of LATAM's most vital healthcare markets. A real-world scenario: Imagine your company has an AI diagnostic tool with successful FDA clearance based on US clinical trials. You're ready to launch in Brazil, but ANVISA puts your application on hold. They are questioning whether your data, collected from a predominantly Caucasian population, is valid for the ethnically diverse population of Brazil. Your launch is now delayed, and you face the unexpected cost of running a local validation study. Key Takeaways: * How does ANVISA's four-tier risk classification for SaMD directly impact your clinical data strategy? * Is your existing clinical data from the US or EU automatically sufficient for a Brazilian submission? * For low-risk SaMD, what are the alternatives to conducting a full clinical trial? * Why might ANVISA challenge world-class clinical data based on patient demographics? * What is a Brazil Registration Holder (BRH), and why is it a non-negotiable requirement for market access? * Under what specific circumstances is a dedicated, local clinical trial absolutely necessary for your SaMD? * How can you effectively leverage data from "equivalent devices" to strengthen your ANVISA submission? * What are the most common documentation and translation mistakes that lead to delays? Navigating the specifics of ANVISA's requirements can be overwhelming. At Pure Global, we provide end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise in Brazil with advanced AI tools to streamline your path to market. From regulatory strategy and technical dossier submission to acting as your official Brazil Registration Holder, we manage the complexities so you can focus on growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to streamline your market access to Brazil and beyond.

Navigating ANMAT's Stance on AI Medical Devices in Argentina: A Pure Global LATAM MedTech Insights Deep Dive

Wed, 10 Sep 2025 19:38:02 -0400

This episode of LATAM MedTech Insights dives into a critical question for innovators: How does Argentina's regulatory authority, ANMAT, handle artificial intelligence and machine learning in medical devices? We cut through the ambiguity to reveal that while there isn't a specific AI-only regulation, these products are actively regulated under the existing robust framework for Software as a Medical Device (SaMD). We explore the practical steps for registering an AI-powered device in Argentina, from the crucial risk classification process to the detailed requirements for your technical dossier. Using the example of an AI tool for diagnostic imaging, we illustrate the challenges and necessities, such as providing extensive algorithm validation data and the mandatory appointment of a local Argentina Registration Holder. This episode provides a clear roadmap for companies looking to enter this key LATAM market with cutting-edge technology. Key Takeaways: * What is the current official stance of ANMAT on regulating AI-specific medical devices? * How does Argentina's four-tier risk classification system apply to Software as a Medical Device? * What are the essential components of a technical dossier for an AI algorithm submitted to ANMAT? * Why is appointing an Argentina Registration Holder a non-negotiable step for foreign manufacturers? * What is the role of the IMDRF in shaping the future of AI medical device regulation in Argentina? * How can you prove the safety and efficacy of a "black box" machine learning algorithm to regulators? * What are the most common pitfalls to avoid when submitting an advanced software device for approval in Argentina? At Pure Global, we specialize in demystifying complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise in over 30 markets with advanced AI tools to streamline your global market access. Let us be your local representative and strategic partner in Latin America and beyond. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Unlocking Colombia's MedTech Market: A Pure Global Deep Dive into INVIMA's Software as a Medical Device (SaMD) Registration Requirements

Tue, 09 Sep 2025 19:38:02 -0400

As Colombia's healthcare market embraces digital transformation, understanding the regulatory pathway for Software as a Medical Device (SaMD) is crucial for innovators. This episode of LATAM MedTech Insights demystifies the INVIMA registration process, revealing that SaMD is not regulated under a separate framework, but through the country's existing medical device decrees. We provide a clear, step-by-step guide for manufacturers looking to enter this promising market. We break down the essential requirements, from the critical first step of risk classification to the mandatory appointment of a local legal representative. We detail the specific documentation needed for your technical dossier, including software validation, cybersecurity measures, and the crucial Certificate of Free Sale. Learn why a simple translation of your documents isn't enough and how to avoid the common pitfalls that can lead to significant delays and rejections from INVIMA. A US-based startup with an FDA-cleared AI diagnostic tool learned this the hard way. They assumed their existing documentation would suffice for their INVIMA submission but faced a nine-month delay. The reason? Their risk analysis failed to address specific patient data privacy concerns relevant to Colombian law, and their software validation data was presented in a format that was unfamiliar to the INVIMA reviewer, leading to a cascade of questions they were unprepared to answer. This costly delay could have been avoided with localized regulatory expertise. What You'll Learn: 1. Why is there no dedicated "SaMD" regulation in Colombia, and what does that mean for your submission? 2. What is the single most important decision you'll make before starting your INVIMA application? 3. Do you need a physical office in Colombia to register your software device? 4. How crucial is a Certificate of Free Sale from your home country for the approval process? 5. What specific software validation documents does INVIMA expect to see in your technical file? 6. Beyond simple translation, what localization details are critical for your labeling and instructions for use? 7. What is the most common and costly mistake that leads to long delays in the INVIMA review process? 8. How do cybersecurity considerations play a role in the Colombian registration of SaMD? At Pure Global, we specialize in transforming these complex regulatory challenges into clear market access strategies. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise in over 30 markets with advanced AI and data tools to streamline your global expansion. From initial strategy to post-market surveillance, our team acts as your local representative to ensure your innovation reaches the market efficiently. Contact us to learn more at info@pureglobal.com or visit our website at https://pureglobal.com/.

Pure Global's LATAM MedTech Insights: Decoding COFEPRIS's New Rules for AI-Powered Medical Software Classification in Mexico

Mon, 08 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we explore the significant regulatory shift in Mexico concerning AI-powered medical software. Mexico's health authority, COFEPRIS, has updated its framework, moving away from treating software as a simple accessory to classifying it as a regulated medical device in its own right. This change is crucial for any MedTech company aiming to penetrate the vibrant Mexican market. We break down the new risk-based classification system—Class I, II, and III—and discuss how the intended use of your AI software determines its regulatory pathway. This episode provides essential information for developers and manufacturers, ensuring they understand the new rules of engagement to avoid costly delays and rejections. Case Study Spotlight: Imagine spending years developing a revolutionary AI tool that predicts cardiac risk from a selfie, only to have your market entry blocked by regulatory confusion. We examine the success story of Medsi AI, a company that successfully navigated the new COFEPRIS guidelines to get their AI-powered diagnostic platform approved as a Class II medical device, setting a vital precedent for the industry. Key Takeaways: - Why did COFEPRIS fundamentally change its regulations for Software as a Medical Device (SaMD)? - What are the specific criteria for Class I, II, and III risk classifications in Mexico? - How does my AI software's intended use directly impact its classification and submission requirements? - What key documentation was crucial for Medsi AI to secure its Class II approval? - Can I leverage my existing FDA or CE marking for an expedited review with COFEPRIS? - What are the most common pitfalls to avoid when submitting an AI SaMD application in Mexico? - How will this regulatory shift impact the future of digital health innovation in Latin America? Navigating the complex regulatory landscape of Latin America is our expertise. Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline your global market access. For a clear and efficient pathway into markets like Mexico, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global Presents: Decoding ANVISA's AI & SaMD Regulations for MedTech Success in Brazil & LATAM

Sun, 07 Sep 2025 19:38:02 -0400

This week on LATAM MedTech Insights, we demystify the regulatory maze of Brazil's ANVISA for companies developing AI and Software as a Medical Device (SaMD). As the largest market in Latin America, Brazil presents a massive opportunity, but its regulatory agency, ANVISA, has specific and stringent requirements that can stall market entry if you're unprepared. We explore the cornerstone regulation, RDC 657/2022, and how it interacts with the broader medical device framework. We break down the crucial four-tier risk classification system and explain how it dictates your entire path to market, from a simple notification for low-risk software to a full, complex registration for high-risk AI-driven diagnostics. Imagine your AI diagnostic tool, already successful in Europe with a CE mark, is ready for the Brazilian market. You begin the process, only to be stalled for months by unexpected demands for algorithm validation data, cybersecurity protocols, and the non-negotiable requirement for a local Brazil Registration Holder. This common pitfall can cost you valuable time, resources, and your first-mover advantage in a competitive landscape. Key Questions from this Episode: - What is the single most important ANVISA regulation you must know for SaMD in Brazil? - How does ANVISA classify the risk of your AI-powered medical software, and why is this the most critical step? - Does your low-risk SaMD need a full registration (*registro*) or a simpler notification (*notificação*)? - What specific documentation is required for high-risk AI devices that differs from traditional hardware? - Why is a Brazil Registration Holder (BRH) an absolute necessity for market entry? - How does ANVISA scrutinize the datasets used to train your machine learning algorithms? - What are ANVISA's expectations for post-market surveillance of adaptive AI that learns over time? - Can you leverage existing international approvals like a CE mark or FDA clearance to speed up your Brazilian submission? At Pure Global, we specialize in transforming these regulatory hurdles into strategic advantages. We offer end-to-end solutions, from developing your ANVISA submission strategy and compiling technical dossiers to acting as your local Brazil Registration Holder. Our blend of local expertise and advanced AI tools streamlines your path to market access across Latin America. Don't let regulatory complexity be a barrier to entry. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can accelerate your growth.

Navigating ANVISA in Brazil: Pure Global Explains the Surprising GMP Rule for Class I Medical Devices in LATAM

Sat, 06 Sep 2025 19:38:02 -0400

This episode of LATAM MedTech Insights tackles a critical question for manufacturers entering Brazil: Is a Good Manufacturing Practice (GMP) certificate really required for low-risk, Class I medical devices? We explore the common misconceptions surrounding ANVISA's RDC 751/2022 regulation and the simplified *notificação* registration pathway. Many companies assume the lack of an upfront certificate submission means compliance is optional. This can be a costly mistake. We reveal how ANVISA's post-market surveillance can place your market access at risk if you're not prepared, and discuss how programs like MDSAP can be a strategic asset for demonstrating compliance. **A Case Study in Risk:** Imagine your startup's Class I device is successfully launched in Brazil via the "easy" *notificação* route. Six months later, ANVISA announces a surprise inspection of your facility. Are you confident your Quality Management System is fully B-GMP compliant right now? If not, you face immediate product withdrawal, fines, and reputational damage. This episode tells you how to avoid that scenario. **Key Takeaways From This Episode:** - Do all device classes truly need a B-GMP certificate before registering in Brazil? - What is the crucial difference between compliance and submission under RDC 751/2022? - Why can the simplified *notificação* pathway for Class I devices become a regulatory trap? - How can a post-market surveillance audit jeopardize your entire Brazilian market presence? - What is the one program that can significantly streamline your ANVISA compliance process? - Is your Quality Management System truly ready for an unannounced ANVISA inspection today? - What is the real role of the Medical Device Single Audit Program (MDSAP) in Brazil? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative, develop regulatory strategy, and ensure ongoing compliance in over 30 markets, including Brazil. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can secure your market access.

Pure Global Presents: The LATAM Labeling Labyrinth - Mastering Low-Risk Medical Device Requirements with Brazil's ANVISA, Mexico's COFEPRIS & More

Fri, 05 Sep 2025 19:38:02 -0400

This episode of LATAM MedTech Insights dives deep into the often-underestimated challenge of labeling requirements for low-risk medical devices in Latin America. We uncover the fragmented regulatory landscape and reveal why a one-size-fits-all approach is doomed to fail. We explore the specific, nuanced requirements of key markets including Brazil (ANVISA), Mexico (COFEPRIS), Colombia (INVIMA), and Argentina (ANMAT), moving beyond simple language translation to discuss the critical data points that regulators are looking for. Imagine this scenario. A promising European startup ships its innovative Class I diagnostic device to Colombia. They've secured the "automatic" INVIMA registration and applied a Spanish-language sticker over their original CE-marked packaging. However, the shipment is seized by customs. The reason? The sticker, while translated correctly, failed to include the full name and address of their appointed Colombian importer and the specific INVIMA registration number. This small oversight leads to weeks of delays, costly storage fees, and a frantic effort to relabel the entire shipment, jeopardizing a critical product launch and damaging their relationship with their new distributor. This week's key takeaways: - Why does Brazil's ANVISA require more than just a Portuguese translation on your Class I device label? - What is the single most common labeling error that leads to customs detentions in Mexico? - For Colombia's "automatic" registration, what specific information must be on the label to avoid rejection? - Can you ever omit the Instructions for Use for a low-risk device in Argentina? - How do requirements for importer information differ between ANMAT and COFEPRIS? - What are the risks of assuming your FDA or CE-compliant label is "good enough" for LATAM? - Why can the labeling of individual components within a kit create a major compliance headache? - How can you manage label updates efficiently across multiple Latin American countries? Struggling to keep up with the diverse and ever-changing labeling rules across Latin America? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local, in-country expertise with advanced AI and data tools to streamline your global market access and ensure your products, including their labels, are fully compliant. Stop letting small details cause big problems. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

Unlocking Brazil's MedTech Market: The Critical Role of a Brazil Registration Holder for Class I Devices | A Pure Global Insight for LATAM Expansion

Thu, 04 Sep 2025 19:38:02 -0400

This episode of LATAM MedTech Insights dives into a critical, often misunderstood, aspect of entering the Brazilian market: the requirement of a Brazil Registration Holder (BRH) for low-risk, Class I medical devices. While these devices follow a simplified "notificação" process instead of a full registration, foreign manufacturers are still legally required to have a local entity representing them before the regulatory body, ANVISA. We explore why this requirement exists and the significant risks of appointing a commercial distributor as your BRH. This common mistake can lead to a loss of market access, create conflicts of interest, and severely limit your company's commercial flexibility and growth within Latin America's largest MedTech market. A US-based startup learned this the hard way. They developed a Class I software-as-a-medical-device and, believing the "low-risk" classification meant a simple process, allowed their first Brazilian distributor to become their BRH. When the partnership soured due to poor performance, the startup was shocked to find they couldn't simply switch distributors. The original partner owned the ANVISA registration and refused to transfer it, demanding a hefty buyout. The startup was trapped, unable to sell their product through any other channel, effectively halting their Brazilian expansion for 18 months until the issue was legally resolved. Key Questions from this Episode: 1. Why is a Brazil Registration Holder mandatory even for low-risk devices that only require a simple notification? 2. What are the hidden dangers of letting your distributor "own" your product registration with ANVISA? 3. How can the wrong BRH choice legally block you from working with other sales partners in Brazil? 4. What is the precise legal role of a BRH in post-market surveillance and incident reporting? 5. Is it possible to transfer your registration from one BRH to another, and what challenges might you face? 6. How does an independent BRH provide the flexibility needed to scale your business across Brazil? 7. What are the key differences between the 'notificação' and the 'registro' pathways at ANVISA? At Pure Global, we offer end-to-end regulatory consulting solutions, serving as your independent, professional Brazil Registration Holder. We combine local expertise with advanced AI and data tools to streamline your market access while giving you complete control over your commercial strategy. Decouple your regulatory compliance from your distribution network and secure your access to the Brazilian market. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Unlocking MedTech in Colombia: A Pure Global Guide to INVIMA's Fast-Track Notification for Low-Risk Devices in LATAM

Wed, 03 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we demystify the "automatic" registration process for low-risk medical devices in Colombia. We explore the requirements set by the national regulatory body, INVIMA, for Class I and IIa devices, detailing the specific documentation needed for a successful and speedy market entry. We break down why this streamlined pathway is a major advantage for MedTech manufacturers targeting the Colombian market. Learn how to leverage your existing approvals and what common administrative errors can cause significant delays, turning a fast-track process into a frustrating roadblock. Consider the case of a scale-up company with an innovative Class IIa device. They targeted Colombia for its efficient "automatic" registration, hoping for a quick launch. However, their submission was rejected. The reason was a simple administrative oversight: their translations were not officially certified and their home country approval lacked the required Apostille. This small error cost them an entire quarter of lost sales and market momentum, a painful lesson in the importance of local regulatory details. What You'll Learn: 1. What does INVIMA's "automatic" registration for low-risk devices really mean? 2. Which specific device classes are eligible for this streamlined process in Colombia? 3. What is the single most critical document you need from your home country to even begin? 4. Why can a simple mistake in document legalization derail your entire submission? 5. How can you ensure your Spanish translations meet INVIMA's strict requirements? 6. What are the key components of the technical dossier required for a Class I or IIa device? 7. How quickly can you start selling in Colombia after a successful submission? 8. What is the role of a local representative in this notification process? At Pure Global, we specialize in transforming these complex regulatory hurdles into clear pathways for market access. Our end-to-end solutions, combining local LATAM expertise with advanced AI tools, ensure your submission is right the first time. Stop letting paperwork stand in the way of your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can accelerate your entry into over 30 global markets.

Cracking the ANMAT Code with Pure Global: The Surprising Truth About Class I Medical Device Registration in Argentina

Tue, 02 Sep 2025 19:38:02 -0400

Entering Argentina's lucrative MedTech market presents a huge opportunity, but it's filled with regulatory complexities. A common and costly mistake manufacturers make is assuming that low-risk, Class I medical devices are exempt from registration with the national authority, ANMAT. This single misunderstanding can lead to product seizures at customs, unexpected costs, and a complete halt to your market entry strategy. In this episode, we uncover the truth behind this myth. We explore a real-world case of a surgical instrument company whose first major shipment was impounded at the border. They faced mounting demurrage charges and a frantic search for a solution, all because they lacked the mandatory registration for their "simple" Class I device. This story highlights the critical difference between a streamlined process and a non-existent one, and the essential role of a local registration holder. Key Takeaways: - Why is "exemption" a dangerous myth for any medical device class in Argentina? - What is ANMAT's four-tier classification system and how does it determine your registration pathway? - What specific steps and documents are required for the 'simplified' registration for Class I devices? - What is the HELENA system and who is authorized to use it for submissions? - Why should your Argentina Registration Holder (ARH) be independent from your distributor? - What happens to your market access if your relationship with your distributor-ARH ends? - How can you prevent your product from being detained by Argentinean customs? At Pure Global, we provide the local expertise and end-to-end regulatory solutions to navigate these challenges. We act as your independent Argentina Registration Holder, securing your market access and ensuring your business continuity. Don't let regulatory myths derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can streamline your entry into Latin America.

Cracking the COFEPRIS Code for LATAM Expansion: Pure Global's Expert Guide on Low-Risk Medical Device Registration in Mexico.

Mon, 01 Sep 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we demystify the process of registering a low-risk (Class I) medical device in Mexico. Don't let the "low-risk" classification fool you; navigating the requirements of COFEPRIS, Mexico's health authority, is a complex journey filled with potential pitfalls that can delay your market entry indefinitely. We break down the essential steps, from appointing a legally required Mexico Registration Holder (MRH) to compiling a flawless technical dossier. We uncover the most common mistakes foreign manufacturers make, such as improper document legalization and translation errors, which lead to costly rejections and wasted time. This episode is a must-listen for any MedTech company looking to tap into the lucrative Mexican market efficiently and successfully. **Case Study Highlight:** Imagine a US-based scaleup with an innovative Class I diagnostic tool. They've secured a major distributor in Mexico City, but their launch is stalled for over eight months. Why? Their technical dossier, perfectly valid for the FDA, was rejected twice by COFEPRIS due to improper Spanish translations and missing apostilles on their legal documents. This failure cost them crucial first-mover advantage and strained vital partner relations, a scenario that is all too common and entirely avoidable. **Key Questions Answered (本期干货):** * Why is a 'low-risk' classification from COFEPRIS not the same as a 'no-paperwork' registration? * What is the single most critical role of a Mexico Registration Holder, and how can choosing the wrong one jeopardize your business? * What is an apostille, and why could its absence on your documents lead to an instant rejection from COFEPRIS? * Are standard translation services sufficient for your technical dossier, or do you need a specific type of translator to be successful? * Can you really leverage your FDA 510(k) to speed up COFEPRIS approval, and what are the hidden catches? * What specific document in your dossier is most often submitted incorrectly by foreign companies? * How does the COFEPRIS Equivalency Agreement actually work, and is your device eligible? At Pure Global, we transform these complex regulatory challenges into clear market access strategies. We offer end-to-end solutions for MedTech and IVD companies, acting as your local representative in over 30 markets, including Mexico. Our blend of local expertise and advanced AI tools streamlines the registration process, saving you time and money. Stop letting regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to get started.

Brazil's MedTech Maze: A Pure Global Guide to ANVISA's "Cadastro" and "Notificação" for Class I Devices

Sun, 31 Aug 2025 19:38:02 -0400

This episode of LATAM MedTech Insights tackles the common misconceptions surrounding the registration of Class I medical devices in Brazil. We move beyond the outdated term "cadastro" to provide a detailed breakdown of the current "notificação" (notification) pathway managed by ANVISA. Learn why this simplified, faster route to market is often misunderstood by foreign manufacturers. We explore the critical, non-negotiable requirements that are often overlooked. From the strategic importance of selecting the right Brazil Registration Holder (BRH) to the necessity of a complete technical dossier that ANVISA can audit at any time, we cover the essential groundwork. We share a real-world example of a company whose product launch was delayed for months simply because their translated user manual didn't meet specific Brazilian formatting rules, highlighting how a small oversight can lead to significant commercial setbacks. This episode is a must-listen for any MedTech company looking to successfully enter the lucrative Brazilian market. Key Takeaways: * What is the crucial difference between the "cadastro" and the modern "notificação" process? * Why is your choice of a Brazil Registration Holder (BRH) the single most important decision for your market entry strategy? * Does a "simplified notification" mean you don't need a full technical dossier? * What are the specific labeling and language requirements that cause the most customs delays? * How do you determine if your Class I device needs a separate INMETRO certification? * What post-market surveillance responsibilities fall on your BRH? * Why is assuming "low-risk" means "low-compliance" a major financial risk in Brazil? At Pure Global, we specialize in transforming these regulatory hurdles into clear pathways for market success. We offer end-to-end solutions for MedTech and IVD companies, acting as your local representative and ensuring full compliance across Latin America and more than 30 markets worldwide. Let us handle the complexities of ANVISA, so you can focus on growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

The Mercosur MedTech Myth: Is a Single Device Registration for Brazil, Argentina, and LATAM a Reality? A Pure Global Deep Dive.

Sat, 30 Aug 2025 19:38:02 -0400

Many MedTech companies dream of a single registration process for the entire Mercosur market, including giants like Brazil and Argentina. Is this a reality, or just a regulatory myth? This episode of LATAM MedTech Insights dives deep into the current state of regulatory harmonization in the region. We uncover the practical challenges and strategic opportunities that exist today. While Mercosur is moving towards a unified framework, the reality on the ground is a complex patchwork of national adoptions and lingering local requirements. We break down why you can't use a single dossier and what this means for your market access strategy, timelines, and budget. **Key Questions Answered in this Episode:** * Is there truly a single registration dossier for all of Mercosur? * How does Brazil's ANVISA registration differ from Argentina's ANMAT, even under new Mercosur rules? * What is the most significant non-tariff barrier to entry in Brazil for medical devices? * Which specific GMC resolution is changing the game for MedTech in the region? * Why is a local, in-country representative still non-negotiable in each market? * How are countries like Uruguay and Paraguay adopting these harmonized standards? * What are the common pitfalls that delay product launches in LATAM? * How can you leverage one country's approval to potentially speed up the process in another? At Pure Global, we specialize in turning these complex regulatory challenges into clear market access strategies. Our team offers end-to-end solutions, from acting as your local representative in Brazil and Argentina to compiling technical dossiers with AI-powered efficiency. Don't let regulatory hurdles slow your growth in LATAM. Contact us for a consultation at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Colombia's INVIMA Timelines: A Pure Global Deep Dive on Medical Device Registration Delays and How to Navigate the LATAM Market

Fri, 29 Aug 2025 19:38:02 -0400

Colombia is one of Latin America's most promising MedTech markets, but gaining access requires navigating the complex regulatory landscape of its authority, INVIMA. While official timelines suggest a straightforward process, the reality on the ground can be quite different, with unexpected delays impacting launch plans and revenue forecasts. In this episode, we uncover the real-world timelines for medical device registration in Colombia. We explore a case study of a European orthopedic company that planned for an 8-month approval for their Class IIb device, only to be delayed by an additional five months due to a request for information regarding the applicability of their clinical data, costing them significant time and market opportunity. Key Takeaways: * What are INVIMA's official review timelines for different device classes? * Is there a fast-track 'automatic' registration process for certain devices? * Why do official timelines often not match reality in Colombia? * What is the single most common reason for significant registration delays? * How does a request for additional information (RFI) impact your approval clock? * Are there specific Spanish language requirements for technical dossiers that companies often miss? * How does your existing FDA or CE Mark approval impact your submission to INVIMA? * Why is having a local legal representative a non-negotiable first step? At Pure Global, we specialize in transforming these regulatory challenges into market opportunities. With our local expertise in Colombia and advanced AI tools, we streamline the INVIMA registration process, helping you avoid common pitfalls and accelerate your market access. Contact us to learn how we can help you at info@pureglobal.com or visit https://pureglobal.com/.

Cracking the Code of Brazil's BGMP: A LATAM MedTech Insight from Pure Global on Navigating ANVISA Inspections for Market Success.

Thu, 28 Aug 2025 19:38:02 -0400

Entering the Brazilian MedTech market is a massive opportunity, but it comes with a critical gatekeeper: the ANVISA Brazilian Good Manufacturing Practice, or BGMP, inspection. This episode of LATAM MedTech Insights demystifies this complex process for foreign manufacturers. We break down the step-by-step journey, from the initial application submitted by your Brazil Registration Holder to the intense, on-the-ground audit by ANVISA inspectors. We explore the nuances that go beyond standard ISO or MDSAP certifications and delve into the specific expectations of Brazilian regulators. This is your essential guide to understanding what it truly takes to get your manufacturing site approved for one of Latin America's most lucrative healthcare markets. Consider this common scenario: A U.S.-based device company, fully MDSAP certified, waited 18 months for their ANVISA inspection. They believed they were perfectly prepared, but the audit resulted in a critical non-conformity. Why? The inspectors discovered a subtle gap in their post-market surveillance data collection process that didn't align with Brazil's specific reporting requirements. This oversight led to a costly six-month delay and a complete re-submission, a frustrating setback that local expertise could have prevented. Key questions answered in this episode: 1. Why is your choice of a Brazil Registration Holder the most critical first step? 2. What are the three key documents ANVISA will scrutinize before they even schedule your visit? 3. How does an MDSAP audit differ from what a Brazilian inspector looks for on your factory floor? 4. What is the single most common reason foreign manufacturers fail their first BGMP inspection? 5. How can you prepare your shop-floor team for the detailed questions they will face? 6. What are ANVISA's expectations for traceability records, from raw material to finished device? 7. Are there new risk-based approaches that could help you bypass a physical inspection? At Pure Global, we specialize in turning these regulatory hurdles into market access pathways. We offer end-to-end regulatory consulting, acting as your local representative and leveraging AI-driven tools to ensure your submission is flawless. Don't navigate the complexities of ANVISA alone. Contact us for a strategic consultation at info@pureglobal.com or learn more by visiting https://pureglobal.com/.

Unlocking the Peruvian MedTech Market: A Pure Global Breakdown of Medical Device Registration Costs and Hidden Fees in LATAM

Wed, 27 Aug 2025 19:38:02 -0400

This episode of LATAM MedTech Insights dives deep into the real costs of registering a medical device in Peru. We uncover why the official DIGEMID government fees are just the tip of the iceberg and explore the significant hidden expenses in local representation, technical dossier translation, and costly time delays that can derail your market entry strategy. We break down the critical strategic decision of appointing a Peru Registration Holder (PRH). Imagine a medical device scaleup, excited to enter the Peruvian market. They budget for the official fees but are blindsided when their registration is tied to a single distributor who holds their market access hostage. This common pitfall prevents them from expanding their commercial network and costs them a year in lost revenue to fix. This episode teaches you how to avoid this and other costly mistakes. Key Takeaways: * Why are official government fees only 10% of your total registration cost in Peru? * What is a Peru Registration Holder (PRH), and why is choosing the wrong one a critical strategic mistake? * How can simple Spanish translation errors lead to a complete dossier rejection by DIGEMID? * What are the hidden operational costs associated with preparing a technical file for the Peruvian market? * How can you leverage existing approvals like an FDA 510(k) or a CE Mark to potentially speed up your process? * What is the true opportunity cost of a 12-month registration delay, and how can you mitigate it? * Why is an independent local representative often a better long-term investment than your distributor? At Pure Global, we provide end-to-end regulatory consulting to help MedTech companies navigate complex markets like Peru. Our integrated approach combines local, in-country expertise with advanced AI tools to streamline dossier preparation, manage submissions, and act as your independent local representative. We turn regulatory hurdles into market opportunities. To secure and accelerate your market access in Latin America, contact us at info@pureglobal.com or visit https://pureglobal.com/.

LATAM MedTech Insights by Pure Global: Leveraging FDA Approval & CE Marks for Medical Device Registration in Chile's Evolving Market

Tue, 26 Aug 2025 19:38:02 -0400

Many MedTech innovators see their FDA approval or CE mark as a golden ticket to Latin America, often targeting Chile first due to its reputation as an accessible market. However, the ground rules are changing fast. What was once a largely voluntary system is now shifting to a mandatory registration framework for all medical devices, creating new hurdles for unprepared companies. This episode of LATAM MedTech Insights dives into the reality of entering the Chilean market today. We uncover why your existing certifications are not a direct passport for sales but are the critical foundation for a successful regulatory submission to Chile's health authority, the ISP. What you'll learn in this episode: - Why was Chile historically considered an "easy" market in LATAM, and why is this no longer true? - Is registration with the ISP now mandatory for all medical devices? - Can I sell my device directly in Chile if it has FDA 510(k) clearance? - What is the role of a Certificate of Free Sale (CFS) in the Chilean registration process? - How does the ISP review technical dossiers based on CE marking or FDA approval? - What are the biggest mistakes companies make when entering the Chilean MedTech market? - Do I need a local legal representative or registration holder in Chile? - How long does the registration process typically take for a device with prior CE/FDA approval? Navigating the nuances of market access in Chile and across Latin America requires local expertise and a strategic approach. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, acting as your local representative and using advanced AI tools to streamline global market access. Let us help you turn your existing approvals into successful registrations. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Navigating INVIMA: A Guide to Colombia's Spanish Medical Device Labeling Requirements with Pure Global's Expert Insights

Mon, 25 Aug 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we explore the non-negotiable Spanish labeling requirements for medical devices in Colombia. We delve into INVIMA's regulations under Decree 4725 and explain why simply having FDA or CE approval isn't enough to guarantee a smooth market entry. We’ll walk through a real-world case study of a US company whose launch was delayed by six months due to overlooked translation of their device's software and manual. This costly mistake highlights the critical importance of a localized approach and the severe commercial impact of non-compliance. Learn what "labeling" truly covers and how to avoid common pitfalls. Key Questions Answered in This Episode: - What specific Colombian decree mandates Spanish for medical device labels? - Does "labeling" include just the box, or also the software and user manual? - Can I use a simple sticker with Spanish translation over my original English label? - What are the real business costs of getting the language requirement wrong in Colombia? - Why is a direct machine translation of my IFU a high-risk strategy? - How early in my product development should I plan for multi-language labeling? - What's the best practice for designing packaging for both US and Colombian markets? At Pure Global, we specialize in navigating these complex regulatory landscapes. We provide end-to-end solutions, from local representation to AI-powered technical dossier preparation, ensuring your MedTech and IVD products meet all local requirements in over 30 countries. Don't let language be a barrier to your success. Contact us for a consultation at info@pureglobal.com or visit https://pureglobal.com/.

Pure Global's Guide to ANMAT: Why Your Choice of Medical Device Registration Holder in Argentina Can Make or Break Your LATAM Market Access.

Sun, 24 Aug 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we dive into one of the most critical and often misunderstood aspects of entering the Argentine medical device market: the role of the local registration holder. While ANMAT's requirement for a local representative seems straightforward, the legal implications of who you choose can have massive consequences for your business. We explore why appointing your commercial distributor as your registration holder can be a high-risk strategy. This episode uncovers how this common practice can lead to a complete loss of market access, forcing companies to restart the costly and time-consuming registration process from zero. We detail the strategic advantages of separating your regulatory representation from your commercial partnerships to ensure business continuity and protect your investment. **What You'll Learn:** - Why is ANMAT's requirement for a local registration holder more than just an administrative step? - What are the hidden risks of appointing your distributor as your registration holder in Argentina? - Who legally owns your medical device registration in Argentina, and why does it matter? - If you split with your local partner, what happens to your hard-won market approval? - How can an independent representative provide business continuity and control over your assets? - Is this registration ownership model unique to Argentina, or is it a common theme in LATAM? - What key criteria should you use when selecting a local registration holder in Argentina? At Pure Global, we specialize in providing independent, expert local representation to safeguard your market access. We act as your registration holder across Latin America, ensuring you maintain full control over your assets while having the flexibility to build the best commercial strategy. Ready to secure and streamline your entry into Argentina? Contact us at info@pureglobal.com or visit https://pureglobal.com/ for a strategic consultation.

Navigating MedTech in LATAM: A Pure Global Deep Dive into Medical Device Classification Rules in Brazil, Mexico, and Colombia

Sat, 23 Aug 2025 19:38:02 -0400

In this episode of LATAM MedTech Insights, we demystify the complex web of medical device classification rules across Latin America's key markets. While most countries use a risk-based system, the specific requirements of agencies like Brazil's ANVISA, Mexico's COFEPRIS, and Colombia's INVIMA present unique challenges that can derail market entry for unprepared companies. We explore how seemingly minor details in documentation, translation, and local procedural norms can lead to major delays. This episode provides essential insights for any MedTech company looking to expand into this dynamic but demanding region, moving beyond the regulations to discuss real-world examples and common pitfalls. For example, consider a European MedTech company with a CE-marked Class IIa device. They targeted Colombia, assuming a smooth registration process due to the similar classification system. However, they faced a six-month delay because their technical dossier, while compliant in the EU, lacked specific local declarations and formatting required by INVIMA. This small oversight cost them a critical sales season and highlighted the importance of localized expertise. Key questions answered in this episode: - Why isn't there a single classification system for all of Latin America? - What's the crucial difference between Brazil's `Cadastro` and `Registro` pathways? - How can a reference country approval from the FDA help in Mexico, and what is the most common mistake companies make in the process? - Why does Colombia's EU-like system still catch experienced European manufacturers by surprise? - What are the top three documentation details that lead to registration rejection in these key markets? - How do device grouping or family definitions differ between ANVISA, COFEPRIS, and INVIMA? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. Our combination of local experts in over 30 markets and advanced AI-powered data tools ensures your path to registration is clear and efficient. Don't let regulatory details derail your LATAM expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can accelerate your market access.

From FDA to LATAM: How Pure Global Helps Navigate the COFEPRIS Medical Device Pathway in Mexico for Faster Market Access

Fri, 22 Aug 2025 19:38:02 -0400

This episode of LATAM MedTech Insights dives deep into the medical device approval process in Mexico, governed by the regulatory body COFEPRIS. We demystify the requirements, from device classification to the critical role of a local registration holder, providing a clear roadmap for international MedTech companies looking to enter this lucrative market. We explore the strategic pathways that can save you valuable time and resources. Discover how leveraging your existing approvals from bodies like the US FDA or Health Canada can dramatically accelerate your journey to market, transforming a potentially lengthy process into a streamlined and predictable one. A US-based scaleup with a novel Class II device faced this exact scenario. Their initial submission was stalled for over a year due to documentation errors and a lack of a clear strategy, costing them valuable time and market opportunity. This episode reveals how leveraging an often-overlooked equivalency pathway could have cut their approval time in half and avoided costly mistakes. Key Takeaways from this episode: 1. What are the four main risk classifications for medical devices in Mexico? 2. How can you use your existing FDA or Health Canada approval to speed up COFEPRIS registration? 3. What is a Mexican Registration Holder (MRH), and why is choosing the right one critical to your business's future? 4. What common documentation mistakes lead to costly delays with COFEPRIS? 5. How does the new "Abbreviated Pathway" coming in 2025 change the game for manufacturers? 6. Is it better to use your distributor as your MRH, or an independent third party? 7. What are the specific post-market surveillance requirements you must meet in Mexico? At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative in over 30 markets, including Mexico, to get your product approved and maintain compliance. Contact us to learn how we can accelerate your entry into the LATAM market at info@pureglobal.com or visit us at https://pureglobal.com/.

LATAM MedTech Insights by Pure Global: A Strategic Guide to ANVISA Medical Device Registration in Brazil

Thu, 21 Aug 2025 19:38:02 -0400

Brazil's MedTech market is a massive opportunity, but ANVISA's complex and unique regulatory requirements can be a significant barrier for foreign manufacturers. This episode provides a clear, step-by-step guide to navigating the medical device registration process, breaking down everything from initial classification to post-market responsibilities. We uncover the critical decisions and common pitfalls that can delay your market entry by years and cost you millions. Learn the strategic importance of every step, from selecting a local partner to preparing for rigorous facility audits, and discover how to leverage recent regulatory changes to your advantage. **Featured Case:** Imagine spending two years and hundreds of thousands of dollars to get your innovative medical device approved in Brazil, only to realize your distributor legally owns your registration. When you decide to switch to a better partner, you're forced to start the entire lengthy and expensive process all over again. This episode explains how this common and costly trap occurs and provides a clear strategy to avoid it from day one. **Key Questions Answered:** - Why is choosing your Brazil Registration Holder (BRH) the single most critical decision for market access? - What is the difference between a Cadastro and a Registro submission, and which path does your device need to follow? - Can my existing FDA clearance or CE Mark help fast-track my ANVISA application? - What specific preparations are needed to pass the mandatory Brazilian Good Manufacturing Practice (BGMP) audit? - Is it possible for a foreign company to register a device without a physical office in Brazil? - How do you avoid the common pitfall of losing your device registration when you change local distributors? - What are the latest regulatory updates from ANVISA that can accelerate your approval timeline? - Why must all technical documentation be submitted in Brazilian Portuguese, and what's the best way to manage this? At Pure Global, we offer end-to-end regulatory solutions to streamline your global market access. We act as your independent local representative in Brazil and over 30 other markets, ensuring you always maintain full control of your assets. Our team combines local expertise with advanced AI tools to efficiently manage technical dossiers, navigate complex submissions, and monitor regulatory changes. Don’t let regulatory hurdles block your entry into LATAM's most promising market. Contact us today at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can accelerate your path to market.

Unlocking Brazil's MedTech Market: A Pure Global Deep Dive on ANVISA Medical Device Registration for Your LATAM Strategy

Tue, 19 Aug 2025 19:16:00 -0400

Brazil represents the largest MedTech market in Latin America, but its regulatory landscape, governed by the agency ANVISA, is one of the most demanding in the world. This episode breaks down the essential steps and common pitfalls companies face when seeking medical device approval in this complex market. We provide a clear overview of the multi-layered process, from initial facility certification to final product registration.

We explore the critical requirements that every MedTech manufacturer must meet, including the often-underestimated B-GMP certification, the different registration pathways based on device risk class, and the strategic importance of selecting the right Brazil Registration Holder (BRH). We also share a crucial real-world example: learn about a company that appointed its distributor as its BRH, only to find itself trapped and unable to change commercial partners without losing its hard-won market registration, forcing a complete restart of the entire process.

This episode's key takeaways:

- Why is a B-GMP certificate the first, and often biggest, hurdle to clear before even submitting your device dossier?

- What is the crucial difference between the 'Notificação' and 'Registro' pathways under the new RDC 751/2022 regulation?

- Why is choosing your Brazil Registration Holder one of the most critical strategic decisions you will make?

- What common mistake can lead to a complete loss of control over your product's registration in Brazil?

- How do you prepare a technical dossier that meets ANVISA’s specific and demanding requirements?

- Do you need additional certifications like INMETRO or ANATEL for your device?

- How can you avoid years of delays and unexpected costs when entering the Brazilian market?

Navigating the complexities of the Brazilian market requires local expertise and a robust regulatory strategy. At Pure Global, we offer end-to-end solutions, acting as your local representative and using advanced tools to streamline dossier submissions. Ready to build your LATAM market access strategy? Contact our experts at info@pureglobal.com or visit https://pureglobal.com/.